data_2m2q_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m2q _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.43 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 29.6 p . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.757 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -57.0 130.29 45.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.422 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.53 -16.55 58.75 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.416 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.582 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.1 mttt -63.58 142.68 58.31 Favored 'General case' 0 CA--C 1.512 -0.483 0 CA-C-O 120.965 0.412 . . . . 0.0 111.934 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 p -78.48 139.99 38.64 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.652 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.7 p -156.44 179.21 9.47 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.903 0.382 . . . . 0.0 110.794 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.63 146.76 22.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.301 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.8 mm -59.11 -14.41 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 115.483 -0.781 . . . . 0.0 111.663 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.5 mt -53.3 -28.08 26.35 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.751 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.59 -14.45 65.26 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.196 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.6 p -69.98 -35.54 74.49 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.26 0.553 . . . . 0.0 110.585 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.652 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 15.2 m-20 -125.27 65.93 51.21 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.076 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 95.2 Cg_endo -76.04 -137.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.329 2.019 . . . . 0.0 111.932 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.428 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 83.5 m -138.83 166.81 23.45 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 121.842 -0.536 . . . . 0.0 112.078 -178.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -60.17 153.92 20.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.743 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.84 125.2 14.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.972 0.415 . . . . 0.0 111.264 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.0 -40.37 2.52 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 29.1 m -90.1 158.58 17.22 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -132.51 149.38 52.34 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.452 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.7 t -75.64 113.47 13.11 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.125 -0.943 . . . . 0.0 109.883 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.7 tp -100.37 122.18 50.82 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.089 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -64.43 131.71 30.9 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.704 2.27 . . . . 0.0 113.106 -179.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.18 -17.16 7.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.396 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.83 -133.33 2.7 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.351 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.452 HD13 HG21 ' A' ' 26' ' ' ILE . 19.1 pt -76.5 -35.25 25.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.269 0.557 . . . . 0.0 111.454 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.41 -32.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.74 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.42 152.37 40.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.299 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.16 -160.21 11.7 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.1 -0.572 . . . . 0.0 112.119 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.1 m -144.52 150.46 16.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.228 0.537 . . . . 0.0 110.793 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.582 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 63.5 m -71.8 133.14 45.34 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.966 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.322 -0.611 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.345 179.132 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p . . . . . 0 N--CA 1.456 -0.16 0 CA-C-O 120.728 0.299 . . . . 0.0 111.078 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.68 128.14 35.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.072 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.15 -20.74 37.29 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.966 -179.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.503 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.72 151.25 39.0 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 122.662 0.385 . . . . 0.0 110.807 -179.973 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.5 m -78.72 168.34 19.88 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.714 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.7 p -177.02 174.53 1.69 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.856 0.36 . . . . 0.0 110.547 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.47 143.47 22.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.208 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.422 HG21 ' O ' ' A' ' 9' ' ' ILE . 51.7 mt -54.86 -22.36 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.595 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.0 mt -52.28 -27.67 15.99 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.824 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.7 -6.78 74.12 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.952 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.0 p -72.37 -25.54 61.55 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.542 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.714 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.4 t0 -132.51 66.07 76.03 Favored Pre-proline 0 C--O 1.219 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.978 179.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 60.2 Cg_endo -71.98 -145.3 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 121.623 1.549 . . . . 0.0 111.645 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.45 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.1 m -141.23 154.97 46.07 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.63 -0.669 . . . . 0.0 112.031 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.46 156.55 22.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.17 120.21 5.21 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.08 0.467 . . . . 0.0 111.041 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.84 -39.99 2.33 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.4 m -106.17 151.56 24.59 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.807 0.337 . . . . 0.0 110.279 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -124.89 147.88 48.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.674 0.273 . . . . 0.0 110.36 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.8 t -73.02 109.4 6.53 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.161 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.429 HD21 HG11 ' A' ' 32' ' ' VAL . 34.7 tp -102.61 123.06 43.96 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.389 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.22 130.93 28.53 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.654 2.236 . . . . 0.0 112.822 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.98 -17.83 7.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.571 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.77 -132.68 2.7 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.406 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.412 HD13 HG22 ' A' ' 26' ' ' ILE . 18.7 pt -76.87 -35.0 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 121.22 0.534 . . . . 0.0 111.417 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -147.6 -32.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.931 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.4 154.37 37.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.38 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.468 ' O ' HG11 ' A' ' 30' ' ' VAL . . . -164.66 -158.86 10.61 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 121.371 -0.443 . . . . 0.0 112.022 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.468 HG11 ' O ' ' A' ' 29' ' ' GLY . 17.8 m -147.74 152.52 12.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.189 0.518 . . . . 0.0 110.829 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.503 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 88.9 m -73.43 125.79 28.7 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.506 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.429 HG11 HD21 ' A' ' 22' ' ' LEU . 7.2 p . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.643 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.8 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 121.043 0.449 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.23 135.73 56.53 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.738 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.69 -26.16 20.52 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.844 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.588 ' HZ2' ' HB3' ' A' ' 5' ' ' LYS . 1.6 mtpm? -55.43 132.93 49.48 Favored 'General case' 0 CA--C 1.512 -0.5 0 CA-C-O 120.691 0.281 . . . . 0.0 111.547 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.7 m -76.13 154.54 35.39 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.665 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.1 p -174.51 -158.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.031 0.444 . . . . 0.0 110.632 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.56 153.51 31.54 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.932 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.557 HG22 ' HA ' ' A' ' 27' ' ' VAL . 12.6 tt -53.07 -20.92 2.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 114.448 -1.251 . . . . 0.0 112.565 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.414 ' N ' HG21 ' A' ' 9' ' ' ILE . 26.6 mt -60.63 -17.73 48.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.337 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.38 16.08 80.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.097 -0.573 . . . . 0.0 111.795 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -74.99 -26.44 59.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.825 0.345 . . . . 0.0 110.565 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.665 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 15.5 t0 -126.37 66.06 60.76 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.095 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -71.28 -151.09 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.248 1.965 . . . . 0.0 111.812 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.507 ' SG ' ' HD3' ' A' ' 5' ' ' LYS . 1.5 m -156.08 179.74 8.93 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.011 -0.43 . . . . 0.0 111.984 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -54.46 156.02 3.62 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 124.211 0.944 . . . . 0.0 111.409 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.06 121.37 5.99 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.817 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.51 -40.55 2.51 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.0 m -91.34 142.11 28.05 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -138.06 154.0 49.29 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 120.621 -0.432 . . . . 0.0 111.619 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.56 117.4 18.17 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.768 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.41 124.4 34.63 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.414 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -63.6 130.91 29.58 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 122.626 2.217 . . . . 0.0 112.391 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -101.66 -21.97 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.107 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.02 -134.44 3.33 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.47 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.421 HG13 HG11 ' A' ' 27' ' ' VAL . 19.7 pt -77.68 -35.23 21.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.311 0.576 . . . . 0.0 110.908 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.557 ' HA ' HG22 ' A' ' 9' ' ' ILE . 7.7 p -142.76 -37.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.356 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.55 149.91 49.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.069 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.79 -170.99 28.43 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 121.081 -0.581 . . . . 0.0 111.89 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.7 m -148.22 149.9 14.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.933 0.397 . . . . 0.0 110.693 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -67.88 139.41 56.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.593 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 C--N 1.321 -0.648 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.147 178.945 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.8 p . . . . . 0 N--CA 1.455 -0.186 0 CA-C-O 120.536 0.208 . . . . 0.0 111.185 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.44 135.57 56.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.729 0.3 . . . . 0.0 111.511 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 -22.48 39.27 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.86 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 33.6 mtpt -57.7 143.08 42.98 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -74.72 143.22 44.24 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.771 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 17.5 p -163.52 -176.4 4.69 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.559 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.1 OUTLIER -156.67 152.17 26.77 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.617 0.722 . . . . 0.0 112.223 178.449 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.587 HG23 ' HA ' ' A' ' 27' ' ' VAL . 8.2 tt -61.38 -9.95 3.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 113.854 -1.521 . . . . 0.0 112.876 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -60.25 -18.75 50.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.955 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.478 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.41 -22.78 22.05 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.633 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.1 p -69.62 -33.22 72.35 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.045 0.45 . . . . 0.0 110.537 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.771 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 1.9 m-20 -121.6 66.29 18.86 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.794 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.6 Cg_endo -76.05 -138.93 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.576 0 C-N-CA 122.225 1.95 . . . . 0.0 111.117 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.426 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 94.9 m -140.3 159.65 41.72 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 121.778 -0.576 . . . . 0.0 112.081 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -62.86 152.24 36.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.163 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.75 124.83 11.82 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 123.433 0.458 . . . . 0.0 111.28 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.84 2.4 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -178.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -101.47 146.9 27.02 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.034 0.445 . . . . 0.0 110.738 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 36.2 p90 -112.79 146.83 38.13 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.2 t -82.68 109.3 16.74 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 36.9 tp -102.79 122.05 47.22 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.553 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.4 129.01 20.41 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.534 2.156 . . . . 0.0 112.543 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.52 -20.95 5.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.549 0.69 . . . . 0.0 109.516 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.76 -133.93 3.23 Favored Glycine 0 N--CA 1.444 -0.81 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.981 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 21.8 pt -79.03 -40.4 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.037 0.446 . . . . 0.0 111.087 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.587 ' HA ' HG23 ' A' ' 9' ' ' ILE . 15.9 m -135.21 -34.67 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.26 149.44 44.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.153 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.19 -163.59 17.51 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.078 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -149.48 153.14 11.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.033 0.444 . . . . 0.0 110.747 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 90.4 m -70.13 143.32 52.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.846 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.443 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 53.1 t . . . . . 0 C--N 1.315 -0.894 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.249 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.5 p . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 120.51 0.195 . . . . 0.0 111.36 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.3 131.92 52.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.705 0.288 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 100.17 -19.8 51.44 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.307 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 66.0 mttt -62.2 146.31 51.11 Favored 'General case' 0 C--O 1.219 -0.517 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -82.56 144.74 30.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.668 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.9 p -157.34 -179.31 8.06 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.899 0.381 . . . . 0.0 110.853 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 146.0 21.66 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.279 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.471 ' O ' HG23 ' A' ' 9' ' ' ILE . 41.3 mm -59.25 -13.15 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.621 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -53.96 -27.17 29.66 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.688 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.428 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.48 -16.61 60.28 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.28 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.4 p -69.54 -35.59 75.59 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.27 0.557 . . . . 0.0 110.563 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.668 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.8 m-20 -125.08 66.78 52.26 Favored Pre-proline 0 N--CA 1.449 -0.513 0 CA-C-N 115.069 -0.969 . . . . 0.0 111.023 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.428 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 88.1 Cg_endo -74.81 -137.17 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.639 0 C-N-CA 122.358 2.039 . . . . 0.0 111.822 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.42 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.9 m -142.0 157.11 45.32 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 121.709 -0.62 . . . . 0.0 112.527 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 4.7 m-20 -60.67 153.37 24.11 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.6 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.4 127.09 18.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 111.225 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.05 -42.7 1.9 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 65.4 m -98.74 147.58 24.74 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -118.46 147.79 43.24 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.329 179.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 43.2 t -73.89 111.44 9.04 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.004 -179.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.414 ' HB2' HG12 ' A' ' 32' ' ' VAL . 35.5 tp -102.53 122.92 44.58 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.185 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.36 131.32 26.16 Favored 'Trans proline' 0 N--CA 1.465 -0.195 0 C-N-CA 122.59 2.193 . . . . 0.0 113.045 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.57 -17.13 7.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.403 179.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 -132.48 2.67 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.443 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.2 pt -76.12 -34.85 27.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.294 0.569 . . . . 0.0 111.44 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.4 p -149.05 -32.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.728 -179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.32 151.71 41.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.287 179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.413 ' O ' HG13 ' A' ' 30' ' ' VAL . . . -165.04 -159.57 11.49 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.033 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 29' ' ' GLY . 18.7 m -145.79 153.04 13.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.235 0.541 . . . . 0.0 110.674 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.6 m -74.3 128.18 34.87 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.934 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 22' ' ' LEU . 7.0 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.678 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.7 p . . . . . 0 N--CA 1.456 -0.154 0 CA-C-O 120.831 0.348 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -58.94 125.93 25.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.942 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 110.4 -24.79 17.05 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.951 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.539 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -61.72 148.49 42.7 Favored 'General case' 0 C--O 1.22 -0.494 0 C-N-CA 122.227 0.211 . . . . 0.0 110.518 179.87 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.404 ' O ' ' HB3' ' A' ' 7' ' ' CYS . 11.9 m -79.73 169.78 17.46 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.729 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 4.5 p 179.86 179.13 0.54 Allowed 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.72 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.411 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.48 150.83 25.45 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.383 178.677 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 27' ' ' VAL . 67.4 mt -54.02 -24.37 10.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.379 -1.282 . . . . 0.0 111.895 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.5 mt -52.15 -25.78 9.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.201 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.462 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.62 -4.26 85.94 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.556 -0.83 . . . . 0.0 111.817 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.0 p -72.72 -26.59 61.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.04 0.448 . . . . 0.0 110.486 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.729 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 26.2 t0 -127.58 65.32 66.45 Favored Pre-proline 0 C--O 1.219 -0.51 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.948 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 59.7 Cg_endo -71.3 -145.39 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 121.72 1.614 . . . . 0.0 112.028 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 67.7 m -140.93 168.83 18.84 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.654 -0.654 . . . . 0.0 112.141 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.38 155.63 6.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.98 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -54.27 119.68 5.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.926 0.393 . . . . 0.0 110.641 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.78 -37.89 3.59 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 27.5 m -89.49 157.95 17.89 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 30.8 p90 -136.44 149.02 48.05 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.24 -0.584 . . . . 0.0 111.59 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.9 t -73.67 111.85 9.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.76 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 39.0 tp -100.02 119.79 58.55 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.555 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.02 131.9 30.32 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.856 2.37 . . . . 0.0 112.677 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -107.11 -19.2 6.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.962 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.51 -134.3 3.0 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.693 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.2 pt -75.82 -34.32 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.269 0.556 . . . . 0.0 111.139 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.465 ' HA ' HD13 ' A' ' 9' ' ' ILE . 7.8 p -147.1 -35.67 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.316 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.15 150.27 47.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.893 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.23 -163.87 18.19 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.9 m -146.73 152.69 13.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.159 0.504 . . . . 0.0 110.875 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.539 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 40.6 m -71.71 131.97 43.88 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.777 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.321 -0.637 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.191 178.91 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.461 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.9 p . . . . . 0 N--CA 1.456 -0.126 0 CA-C-O 120.634 0.254 . . . . 0.0 111.307 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.66 128.79 38.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.771 0.319 . . . . 0.0 111.272 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.02 -20.45 40.79 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.052 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.82 150.59 41.21 Favored 'General case' 0 C--O 1.219 -0.549 0 C-N-CA 122.611 0.364 . . . . 0.0 110.925 179.999 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.3 m -78.01 167.76 20.95 Favored 'General case' 0 C--N 1.314 -0.942 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 178.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.701 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.8 p -176.83 173.1 1.96 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.024 0.44 . . . . 0.0 110.793 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.34 141.26 20.21 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.925 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.428 ' O ' HG22 ' A' ' 9' ' ' ILE . 46.7 mm -56.4 -19.32 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.579 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.624 ' HG ' HG21 ' A' ' 27' ' ' VAL . 75.7 mt -52.82 -28.11 21.21 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.544 179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.456 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 96.93 -9.26 65.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.781 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.8 p -71.94 -26.49 62.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.651 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.701 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 22.8 t0 -134.39 66.36 70.31 Favored Pre-proline 0 C--O 1.219 -0.536 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.131 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 61.6 Cg_endo -72.6 -144.62 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 121.605 1.537 . . . . 0.0 111.53 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.446 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 74.0 m -140.68 155.3 46.53 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 121.485 -0.759 . . . . 0.0 112.297 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -62.84 156.57 23.69 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.285 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.58 123.45 9.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.061 0.458 . . . . 0.0 111.026 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.83 -40.62 2.41 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 73.7 m -103.79 150.57 23.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.895 0.379 . . . . 0.0 110.342 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -123.99 148.11 47.24 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.376 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 t -73.58 107.39 5.82 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.096 -179.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.574 HD22 HG12 ' A' ' 32' ' ' VAL . 35.5 tp -99.42 123.29 48.85 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.257 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.17 130.74 24.89 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.583 2.189 . . . . 0.0 112.893 -179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -102.82 -17.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.516 -0.766 . . . . 0.0 109.36 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.53 -132.26 2.67 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.408 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.433 HD12 HG22 ' A' ' 26' ' ' ILE . 19.0 pt -76.34 -34.78 25.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.168 0.508 . . . . 0.0 111.447 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.624 HG21 ' HG ' ' A' ' 10' ' ' LEU . 13.6 p -149.23 -31.98 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.865 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.26 152.9 39.61 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.96 -157.35 9.62 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 121.307 -0.473 . . . . 0.0 112.101 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.1 m -147.38 152.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.163 0.506 . . . . 0.0 110.758 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.494 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 91.7 m -73.27 125.58 28.12 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.548 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.574 HG12 HD22 ' A' ' 22' ' ' LEU . 7.3 p . . . . . 0 C--N 1.321 -0.663 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.63 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 N--CA 1.451 -0.384 0 CA-C-O 120.878 0.37 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -62.5 134.53 56.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.968 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.88 -19.19 47.73 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.337 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 73.9 mttt -59.79 137.17 58.13 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.206 0.526 . . . . 0.0 111.621 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 p -80.13 137.73 36.78 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.719 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.1 p -163.26 -160.24 0.59 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.681 0.277 . . . . 0.0 110.698 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.8 156.64 35.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.33 0.586 . . . . 0.0 111.708 179.473 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.503 HG21 ' HA ' ' A' ' 27' ' ' VAL . 11.7 tt -55.88 -16.48 2.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.298 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.99 -21.03 27.29 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.76 -6.41 65.96 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.442 179.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.9 p -71.91 -24.07 61.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.308 0.575 . . . . 0.0 110.275 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -118.72 63.09 5.6 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.177 -178.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 72.6 Cg_endo -73.37 -143.74 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.348 2.032 . . . . 0.0 110.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.405 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 0.7 OUTLIER -154.86 -171.08 3.71 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.443 -0.786 . . . . 0.0 113.067 179.85 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.01 148.37 26.32 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 113.915 -1.493 . . . . 0.0 109.929 -179.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.85 118.18 2.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.07 0.462 . . . . 0.0 111.325 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.65 -35.59 4.44 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.546 -179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 31.1 m -100.77 147.79 25.65 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -132.67 155.89 47.96 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.976 0.417 . . . . 0.0 111.623 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -76.48 118.85 19.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.893 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.453 ' HB2' HG12 ' A' ' 32' ' ' VAL . 28.0 tp -109.05 124.66 33.48 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.402 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 22' ' ' LEU . 25.4 Cg_exo -62.68 131.89 35.35 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.797 2.331 . . . . 0.0 112.499 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.22 -21.57 5.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.375 0.607 . . . . 0.0 110.137 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.51 -135.35 3.35 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.477 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.448 HD12 HG22 ' A' ' 26' ' ' ILE . 20.4 pt -77.35 -35.65 22.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.43 0.633 . . . . 0.0 110.911 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.503 ' HA ' HG21 ' A' ' 9' ' ' ILE . 6.8 p -141.84 -38.18 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.133 179.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.417 ' N ' HG13 ' A' ' 27' ' ' VAL . . . -66.03 149.11 50.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -160.62 -176.14 32.4 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.952 -0.642 . . . . 0.0 111.972 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 10.5 m -142.68 147.7 20.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.016 0.436 . . . . 0.0 110.501 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 36.2 m -68.5 138.82 55.51 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.751 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.453 HG12 ' HB2' ' A' ' 22' ' ' LEU . 14.6 p . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.252 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p . . . . . 0 N--CA 1.454 -0.255 0 CA-C-O 120.505 0.193 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.01 135.83 57.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.92 -21.73 44.49 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.649 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 56.8 mttt -58.02 150.21 21.39 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 m -80.87 144.35 32.05 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.8 p -160.27 178.5 9.56 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.954 0.407 . . . . 0.0 110.794 -178.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.423 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.57 146.5 23.51 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.409 179.527 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.485 ' O ' HG23 ' A' ' 9' ' ' ILE . 41.5 mm -59.37 -14.77 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.558 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.0 -28.17 22.76 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.878 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.434 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.93 -16.45 60.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.085 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.4 p -69.83 -36.5 75.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.247 0.546 . . . . 0.0 110.527 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.584 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.2 m-20 -126.39 65.7 59.74 Favored Pre-proline 0 N--CA 1.448 -0.53 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.89 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.447 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 86.7 Cg_endo -77.22 -134.84 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.566 0 C-N-CA 122.214 1.943 . . . . 0.0 111.645 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.447 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 72.4 m -139.96 158.78 43.52 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.918 -0.488 . . . . 0.0 112.091 -178.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.44 ' CG ' ' HZ2' ' A' ' 5' ' ' LYS . 6.8 m-20 -61.79 151.05 35.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.48 179.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.75 120.47 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.039 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.22 -39.93 2.32 Favored Glycine 0 N--CA 1.448 -0.541 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.5 m -101.96 145.42 29.28 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.931 0.396 . . . . 0.0 110.865 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -107.16 148.79 28.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -84.51 112.54 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.9 tp -102.75 123.23 43.16 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.424 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.03 131.14 24.55 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.583 2.189 . . . . 0.0 112.822 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -101.41 -17.97 6.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.482 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.95 -132.5 2.75 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.311 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.3 pt -76.2 -34.7 26.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.234 0.54 . . . . 0.0 111.383 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.438 HG23 ' HB ' ' A' ' 9' ' ' ILE . 12.9 p -148.97 -32.5 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.794 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.431 ' N ' HG13 ' A' ' 27' ' ' VAL . . . -73.17 150.48 42.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.214 179.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.435 ' O ' HG11 ' A' ' 30' ' ' VAL . . . -165.91 -158.61 11.0 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.108 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 29' ' ' GLY . 18.6 m -146.18 151.94 14.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.154 0.502 . . . . 0.0 110.893 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 96.1 m -71.91 144.24 49.04 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.169 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.434 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 44.9 t . . . . . 0 C--N 1.317 -0.831 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.211 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.3 p . . . . . 0 N--CA 1.452 -0.355 0 CA-C-O 120.625 0.25 . . . . 0.0 110.989 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.95 141.6 57.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.393 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.37 -18.38 57.58 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.395 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.0 mttp -63.32 166.76 5.95 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.345 0.593 . . . . 0.0 111.988 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -93.57 145.94 24.16 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.626 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.66 -177.29 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.686 0.279 . . . . 0.0 110.447 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.443 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.13 147.82 26.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.273 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.649 HG23 ' HA ' ' A' ' 27' ' ' VAL . 13.5 tt -61.21 -14.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.354 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.1 mt -57.52 -25.18 59.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.217 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.472 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.15 -13.09 64.33 Favored Glycine 0 C--N 1.33 0.199 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.905 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -68.88 -35.63 77.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.327 0.584 . . . . 0.0 110.35 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.626 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 17.9 m-20 -124.82 67.28 51.15 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.75 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.0 Cg_endo -73.72 -138.08 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.344 2.029 . . . . 0.0 112.15 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.468 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 69.2 m -138.18 161.98 35.43 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.724 -0.61 . . . . 0.0 112.126 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.598 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 0.4 OUTLIER -59.38 148.89 30.86 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.333 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.55 120.7 5.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.183 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.92 -39.54 2.45 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.383 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.477 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 31.4 m -101.53 149.19 24.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.831 0.348 . . . . 0.0 110.972 179.313 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.6 p90 -109.94 150.8 27.93 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.365 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -85.84 119.71 26.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.405 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 33.6 tp -111.88 122.54 36.78 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-O 120.551 0.215 . . . . 0.0 110.477 -179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.92 130.33 25.67 Favored 'Trans proline' 0 CA--C 1.528 0.214 0 C-N-CA 122.625 2.217 . . . . 0.0 112.655 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.3 p -99.79 -20.74 5.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.537 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.71 -133.17 3.1 Favored Glycine 0 N--CA 1.445 -0.737 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.978 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 21.4 pt -78.9 -40.5 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.015 0.436 . . . . 0.0 111.141 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.649 ' HA ' HG23 ' A' ' 9' ' ' ILE . 16.0 m -136.18 -33.89 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.011 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.5 153.8 37.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.02 -161.74 14.61 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.3 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -144.68 153.76 14.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.148 0.499 . . . . 0.0 110.544 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 89.4 m -74.1 144.64 44.86 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.372 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.437 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 46.4 t . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.276 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.561 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 2.9 p . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 120.538 0.209 . . . . 0.0 110.958 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.67 137.68 58.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.477 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.18 -21.73 44.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.523 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.561 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 31.0 mtmt -65.14 166.92 8.84 Favored 'General case' 0 C--O 1.216 -0.664 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 m -91.32 151.46 20.86 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.256 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.54 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 15.2 p -163.86 178.71 7.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.323 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.407 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.87 147.69 24.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.931 0.396 . . . . 0.0 110.694 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.2 mt -57.51 -19.3 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.445 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.449 ' HG ' HG21 ' A' ' 27' ' ' VAL . 80.6 mt -51.72 -28.77 16.05 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 112.028 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.444 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.85 -13.42 66.86 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.145 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -70.25 -36.1 74.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.293 0.568 . . . . 0.0 110.432 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.54 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.9 m-20 -126.46 64.93 57.84 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.91 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.1 Cg_endo -77.76 -139.54 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.557 0 C-N-CA 122.087 1.858 . . . . 0.0 111.626 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.409 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 66.6 m -135.97 154.74 51.0 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 121.84 -0.537 . . . . 0.0 111.606 -179.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.502 ' CG ' ' HZ1' ' A' ' 5' ' ' LYS . 1.4 m-20 -62.32 153.43 30.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.06 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.78 123.24 8.62 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.405 0.441 . . . . 0.0 111.148 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.5 -40.67 2.32 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.415 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.0 m -102.78 147.05 27.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.928 0.394 . . . . 0.0 110.753 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 37.2 p90 -111.95 149.98 31.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.27 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.2 t -83.97 114.97 22.08 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.506 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -104.86 122.29 43.84 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.451 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.77 131.06 27.96 Favored 'Trans proline' 0 CA--C 1.527 0.165 0 C-N-CA 122.784 2.323 . . . . 0.0 112.555 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -104.71 -18.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.404 0.621 . . . . 0.0 109.788 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.2 -133.25 2.73 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.569 -0.741 . . . . 0.0 112.496 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -76.11 -35.16 28.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.296 0.57 . . . . 0.0 111.411 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.449 HG21 ' HG ' ' A' ' 10' ' ' LEU . 12.7 p -147.85 -32.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.715 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.433 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -73.87 152.48 40.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.447 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.8 -160.01 11.32 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.096 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.71 152.56 16.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.005 0.431 . . . . 0.0 110.835 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 86.5 m -74.39 143.3 44.87 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.746 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.423 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 48.9 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.346 -179.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 6.1 p . . . . . 0 N--CA 1.453 -0.281 0 CA-C-O 120.736 0.303 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.47 126.84 28.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.642 0.258 . . . . 0.0 110.791 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.99 -13.32 52.73 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.734 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.581 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 20.3 mmtp -64.05 170.15 3.82 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-O 121.525 0.679 . . . . 0.0 111.038 179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -105.62 148.3 27.49 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.219 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.551 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 12.9 p -162.79 178.27 8.59 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.069 0.462 . . . . 0.0 110.862 -178.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.06 147.53 25.04 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.5 mt -56.36 -18.62 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.674 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.403 ' HG ' HG23 ' A' ' 27' ' ' VAL . 77.8 mt -52.7 -27.77 18.97 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.99 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.448 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 90.14 -14.88 61.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.233 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.6 p -68.75 -35.9 77.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.411 0.624 . . . . 0.0 110.449 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.551 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.3 m-20 -124.74 67.97 52.12 Favored Pre-proline 0 N--CA 1.448 -0.56 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.8 -178.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 71.9 Cg_endo -72.87 -133.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 122.423 2.082 . . . . 0.0 111.949 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.42 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 93.0 m -139.09 157.1 46.56 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -178.549 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.754 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.7 m-20 -62.47 149.75 41.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.209 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.29 119.9 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 123.319 0.387 . . . . 0.0 111.206 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 125.72 -38.45 2.26 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 111.434 -0.667 . . . . 0.0 111.434 -179.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 88.2 m -112.3 154.41 25.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.726 0.298 . . . . 0.0 110.583 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -114.69 150.7 34.82 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.724 0.297 . . . . 0.0 110.425 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.7 t -75.23 115.11 14.52 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.44 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.441 HD22 HG12 ' A' ' 32' ' ' VAL . 31.2 tp -109.17 122.02 41.0 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.027 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.37 132.17 32.65 Favored 'Trans proline' 0 CA--C 1.528 0.183 0 C-N-CA 122.734 2.289 . . . . 0.0 112.888 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.4 p -104.96 -17.97 7.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.577 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.59 -132.63 2.71 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.524 -0.762 . . . . 0.0 112.436 -179.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.4 pt -76.63 -34.72 24.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.197 0.523 . . . . 0.0 111.383 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.403 HG23 ' HG ' ' A' ' 10' ' ' LEU . 11.8 p -148.28 -32.88 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.818 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.82 153.22 38.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.503 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.33 -162.74 15.87 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.14 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.96 156.14 22.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.442 0.639 . . . . 0.0 110.448 179.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.581 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 89.3 m -80.15 128.1 33.11 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.994 -179.537 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.441 HG12 HD22 ' A' ' 22' ' ' LEU . 7.4 p . . . . . 0 C--N 1.323 -0.583 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.101 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 19' ' ' CYS . 2.9 p . . . . . 0 N--CA 1.455 -0.204 0 CA-C-O 120.556 0.217 . . . . 0.0 111.011 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.78 136.78 58.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.108 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -19.55 54.14 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.515 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.47 ' HZ3' ' CG ' ' A' ' 16' ' ' ASP . 66.6 mttt -60.47 157.31 14.31 Favored 'General case' 0 C--O 1.218 -0.596 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 m -86.87 147.31 25.85 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.684 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.49 -175.15 4.05 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.68 150.26 28.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.859 0.361 . . . . 0.0 110.379 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.418 HG21 ' HA ' ' A' ' 27' ' ' VAL . 10.2 tp -59.58 -17.11 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.014 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.2 mt -57.64 -24.8 58.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.706 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 85.42 -7.86 74.17 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.512 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.0 p -70.04 -33.77 72.38 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.59 0.71 . . . . 0.0 109.961 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.684 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 18.6 m-20 -124.23 67.02 44.33 Favored Pre-proline 0 C--O 1.217 -0.614 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.289 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 72.4 Cg_endo -73.78 -139.4 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.276 1.984 . . . . 0.0 112.058 -179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.444 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 62.3 m -139.04 162.18 35.57 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.762 -0.586 . . . . 0.0 111.993 -178.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.47 ' CG ' ' HZ3' ' A' ' 5' ' ' LYS . 7.5 m-20 -60.59 150.14 32.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.488 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.67 120.05 4.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.052 0.453 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.08 -39.58 2.42 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 111.307 -0.717 . . . . 0.0 111.307 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.2 m -102.2 146.83 27.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.983 0.42 . . . . 0.0 110.846 179.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -110.21 149.26 30.37 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.324 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 t -84.57 118.14 24.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.342 179.274 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.1 tp -111.97 123.65 34.03 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.729 -0.214 . . . . 0.0 110.576 -179.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -62.66 130.75 30.75 Favored 'Trans proline' 0 CA--C 1.529 0.228 0 C-N-CA 122.607 2.204 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.416 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 4.5 p -102.27 -19.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.08 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.51 -133.63 3.05 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.619 -0.719 . . . . 0.0 112.535 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.436 HG21 HD11 ' A' ' 26' ' ' ILE . 18.6 pt -79.77 -34.03 15.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.162 0.506 . . . . 0.0 111.388 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 28' ' ' ALA . 7.6 p -143.07 -35.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.813 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.43 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -75.25 154.94 37.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.835 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.416 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -161.82 -163.91 15.68 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 121.263 -0.494 . . . . 0.0 111.948 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.4 m -145.92 152.29 14.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.218 0.532 . . . . 0.0 110.788 179.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.444 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 85.4 m -72.91 143.95 47.54 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.035 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.423 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 47.5 t . . . . . 0 C--N 1.316 -0.872 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.222 -179.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.535 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 1.9 p . . . . . 0 N--CA 1.455 -0.197 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.66 141.43 57.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.64 -26.5 22.88 Favored Glycine 0 CA--C 1.52 0.37 0 C-N-CA 120.558 -0.829 . . . . 0.0 113.005 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mptm? -53.22 143.41 18.34 Favored 'General case' 0 C--O 1.217 -0.642 0 C-N-CA 122.87 0.468 . . . . 0.0 112.176 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 m -76.82 143.18 39.95 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.609 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.6 p -158.6 179.13 9.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -178.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.43 147.78 23.83 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.621 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.455 ' O ' HG23 ' A' ' 9' ' ' ILE . 33.6 mt -57.7 -16.74 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.653 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.8 mt -52.41 -27.36 15.54 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.07 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.471 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.89 -17.33 57.0 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.184 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.8 p -69.81 -36.13 75.39 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.199 0.523 . . . . 0.0 110.455 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.609 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 2.6 m-20 -123.67 66.5 37.0 Favored Pre-proline 0 C--O 1.218 -0.575 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.52 -179.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.471 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 89.3 Cg_endo -75.8 -130.71 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.166 1.911 . . . . 0.0 111.712 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.2 m -142.02 160.08 40.94 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.535 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.1 m-20 -61.59 147.75 44.63 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.977 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.65 114.92 1.71 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.973 0.416 . . . . 0.0 111.087 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.82 -37.44 2.23 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.436 -179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.503 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 37.3 m -107.82 149.75 27.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.057 0.456 . . . . 0.0 111.135 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.465 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.1 p90 -105.8 149.28 26.62 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.353 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.8 t -84.42 114.41 21.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -105.97 122.59 41.91 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-O 120.629 0.252 . . . . 0.0 110.581 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.07 131.54 27.28 Favored 'Trans proline' 0 N--CA 1.464 -0.211 0 C-N-CA 122.68 2.253 . . . . 0.0 112.77 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -101.21 -18.3 6.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.447 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.38 -132.49 2.79 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.372 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.0 pt -76.72 -34.9 24.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.186 0.517 . . . . 0.0 111.421 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.428 HG11 ' N ' ' A' ' 28' ' ' ALA . 11.9 p -147.9 -32.83 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.799 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.428 ' N ' HG11 ' A' ' 27' ' ' VAL . . . -73.7 150.71 41.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.393 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.51 -159.56 12.45 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 121.201 -0.523 . . . . 0.0 112.002 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.62 151.44 13.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.297 0.57 . . . . 0.0 110.919 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 75.2 m -69.98 144.86 52.2 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.399 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.465 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 45.1 t . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.204 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.511 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 30.3 p . . . . . 0 N--CA 1.451 -0.383 0 CA-C-O 120.667 0.27 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -55.97 132.5 50.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.425 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.58 -17.36 58.7 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.651 -0.785 . . . . 0.0 113.036 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 9.2 mttp -57.35 144.58 35.5 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 120.653 0.264 . . . . 0.0 111.505 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.9 m -77.0 141.83 40.19 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.567 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 16.7 p -161.32 177.38 10.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.128 0.489 . . . . 0.0 111.073 -178.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.91 146.18 23.86 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.234 179.508 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.4 HG21 ' O ' ' A' ' 9' ' ' ILE . 39.4 mm -60.0 -13.26 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.52 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.653 ' HG ' HG22 ' A' ' 27' ' ' VAL . 81.4 mt -53.42 -28.02 27.64 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.757 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 94.92 -17.85 58.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.116 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -69.53 -37.04 76.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.313 0.577 . . . . 0.0 110.58 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.567 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 13.3 m-20 -126.7 66.14 63.73 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.856 -178.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 83.1 Cg_endo -77.09 -128.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.506 0 C-N-CA 122.187 1.925 . . . . 0.0 111.764 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 80.0 m -141.41 168.19 20.37 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -178.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -59.5 145.89 42.37 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.872 178.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.02 122.71 7.04 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.803 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.19 -37.76 3.65 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.823 -0.626 . . . . 0.0 112.211 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -91.79 154.61 18.81 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.576 0.227 . . . . 0.0 110.518 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 47.2 p90 -112.65 151.2 30.43 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -178.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 34.6 t -90.73 115.01 27.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.078 -0.965 . . . . 0.0 108.951 178.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.1 tp -101.15 122.21 49.31 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.479 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.47 131.5 24.84 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.575 2.183 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -100.61 -18.07 6.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.413 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.44 -132.2 2.76 Favored Glycine 0 N--CA 1.445 -0.725 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.395 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 pt -76.23 -34.76 26.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.179 0.514 . . . . 0.0 111.401 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.653 HG22 ' HG ' ' A' ' 10' ' ' LEU . 14.0 p -149.14 -32.35 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.828 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.43 149.79 42.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.119 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -167.43 -158.34 11.61 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.015 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 28.4 m -145.7 151.37 14.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.314 0.578 . . . . 0.0 110.928 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.471 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 99.2 m -71.78 148.03 46.69 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.744 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.434 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 40.3 t . . . . . 0 C--N 1.318 -0.796 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.997 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.529 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.9 p . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 120.687 0.28 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.3 135.16 55.94 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.21 -15.33 63.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.328 -179.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 0.0 OUTLIER -55.41 145.04 23.49 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 120.87 0.367 . . . . 0.0 111.074 179.954 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.528 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 9.5 m -84.24 147.65 27.14 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.474 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.7 p -167.03 -161.07 0.41 Allowed 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.039 0.447 . . . . 0.0 111.008 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -157.92 158.96 36.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.112 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.466 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.9 mt -53.08 -27.18 13.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.841 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.6 mt -54.07 -24.14 16.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.736 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.98 15.75 81.39 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.0 p -79.05 -19.54 51.13 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.733 0.301 . . . . 0.0 110.721 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.474 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 9.3 t0 -127.94 61.88 54.0 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.242 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.61 -154.83 0.04 OUTLIER 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 121.889 1.726 . . . . 0.0 112.208 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 8.1 m -153.84 157.51 39.43 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.585 0.231 . . . . 0.0 111.065 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -57.05 162.52 2.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.722 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.77 124.6 10.04 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.164 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.2 -40.66 2.38 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -178.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.468 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 58.5 m -104.94 137.77 42.19 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.919 0.39 . . . . 0.0 110.136 178.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 36.4 p90 -128.76 143.75 51.0 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.585 -178.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.401 ' HA ' ' HA ' ' A' ' 31' ' ' CYS . 13.3 t -77.98 114.3 16.72 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 178.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 28.0 tp -111.9 129.29 24.36 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.653 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HG3' HG12 ' A' ' 9' ' ' ILE . 32.1 Cg_exo -59.45 130.52 36.07 Favored 'Trans proline' 0 CA--C 1.528 0.209 0 C-N-CA 122.833 2.355 . . . . 0.0 112.26 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.425 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.9 p -105.7 -21.57 5.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.188 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.18 -138.26 3.63 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.44 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.2 pt -77.0 -38.23 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.985 0.421 . . . . 0.0 111.188 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.61 -32.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.58 154.22 38.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.216 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.425 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -159.51 -175.79 30.85 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 121.196 -0.526 . . . . 0.0 111.834 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.9 m -147.28 147.52 17.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.171 0.51 . . . . 0.0 110.829 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 35.0 m -70.64 147.23 49.4 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.556 179.037 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 21.8 t . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.986 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.559 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.8 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.708 0.289 . . . . 0.0 111.101 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.96 134.11 53.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.719 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.29 -17.65 58.89 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.306 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.559 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.7 ttpt -55.61 144.29 27.07 Favored 'General case' 0 C--O 1.217 -0.655 0 C-N-CA 122.563 0.345 . . . . 0.0 111.599 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.6 m -81.67 147.66 29.41 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.4 p -165.15 -160.86 0.5 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.859 0.362 . . . . 0.0 110.738 -179.32 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -161.26 154.28 21.06 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.231 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.463 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.0 mt -52.69 -26.76 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 O-C-N 124.471 1.107 . . . . 0.0 111.752 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt -53.56 -22.47 8.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.801 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.444 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 78.82 12.53 84.08 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.767 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -72.78 -32.2 65.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.859 0.362 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.89 63.04 46.27 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.963 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.7 Cg_endo -73.58 -154.43 0.04 OUTLIER 'Trans proline' 0 CA--C 1.532 0.38 0 C-N-CA 121.813 1.676 . . . . 0.0 111.946 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 11.9 m -152.18 152.97 32.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.652 0.263 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.63 166.56 3.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.645 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.77 123.75 9.66 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.004 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.29 -37.38 3.18 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 57.0 m -115.88 138.13 51.45 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.966 0.412 . . . . 0.0 110.377 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.41 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.8 p90 -126.46 143.32 51.23 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.324 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.6 t -77.67 112.79 14.87 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.8 tp -106.72 127.17 28.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.681 -178.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.463 ' HG3' HG12 ' A' ' 9' ' ' ILE . 25.6 Cg_exo -62.64 133.08 40.59 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.932 2.421 . . . . 0.0 112.4 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.74 -19.95 6.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.259 0.552 . . . . 0.0 110.301 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.75 -135.46 3.13 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.651 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 20.0 pt -75.82 -34.85 28.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.375 0.607 . . . . 0.0 111.163 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.432 ' HA ' HD11 ' A' ' 9' ' ' ILE . 7.2 p -145.34 -36.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.108 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.423 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -67.09 149.67 50.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.87 -171.29 27.77 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 15.7 m -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.049 0.452 . . . . 0.0 111.029 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 23.7 m -71.2 145.49 49.65 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.128 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 33.3 t . . . . . 0 C--N 1.315 -0.903 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.153 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.594 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.0 p . . . . . 0 N--CA 1.455 -0.19 0 CA-C-O 120.624 0.25 . . . . 0.0 111.105 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.69 133.19 53.15 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.627 0.251 . . . . 0.0 110.705 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.41 -16.23 61.13 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.46 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.594 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 1.7 ttpp -55.89 139.53 45.65 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 122.434 0.294 . . . . 0.0 111.676 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.7 m -74.6 147.45 41.64 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.1 p -163.84 -168.1 1.54 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.823 0.344 . . . . 0.0 110.936 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.535 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -162.77 156.63 20.56 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.181 179.861 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.716 HD12 ' HB3' ' A' ' 23' ' ' PRO . 47.1 mm -53.19 -26.32 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.782 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.7 mt -52.97 -25.18 11.18 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.768 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 79.11 12.86 83.6 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.186 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 p -78.0 -26.35 48.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.891 0.377 . . . . 0.0 110.655 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.39 60.15 50.49 Favored Pre-proline 0 C--O 1.223 -0.317 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.76 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -79.5 -153.8 0.05 OUTLIER 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 121.777 1.651 . . . . 0.0 112.374 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 22.3 m -152.43 148.1 27.05 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -68.79 -176.73 0.87 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.679 -178.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.03 125.7 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.926 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.33 -34.0 4.46 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.474 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 68.9 m -129.28 139.91 51.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.055 0.455 . . . . 0.0 110.764 179.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -124.98 142.79 51.25 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.184 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.7 t -76.82 114.24 15.37 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 31.4 tp -108.22 126.02 30.62 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.503 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.716 ' HB3' HD12 ' A' ' 9' ' ' ILE . 32.9 Cg_endo -64.77 133.36 36.08 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.678 2.252 . . . . 0.0 112.861 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 p -107.04 -18.94 6.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.614 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.16 -135.09 3.12 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.283 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 20.9 pt -76.77 -36.13 25.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.373 0.606 . . . . 0.0 111.056 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.535 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.1 p -143.07 -36.37 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.165 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.475 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -67.31 148.13 52.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.436 ' O ' HG13 ' A' ' 30' ' ' VAL . . . -165.45 -167.64 26.37 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.436 HG13 ' O ' ' A' ' 29' ' ' GLY . 16.0 m -147.31 147.84 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.096 0.475 . . . . 0.0 111.018 179.636 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -70.75 146.52 49.78 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.213 178.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 29.1 t . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.211 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 25.9 p . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 120.782 0.325 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.7 129.6 42.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.017 -179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.23 -25.42 27.81 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.52 -0.848 . . . . 0.0 112.789 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.465 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -56.98 150.86 15.98 Favored 'General case' 0 C--O 1.216 -0.684 0 C-N-CA 122.554 0.341 . . . . 0.0 110.525 179.792 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.8 m -75.2 165.99 24.34 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 178.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.712 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 6.1 p -178.1 172.83 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.886 0.374 . . . . 0.0 110.571 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.474 ' HB2' HG21 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.92 149.33 23.23 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.522 178.965 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.86 HD12 ' HG3' ' A' ' 23' ' ' PRO . 49.7 mm -53.88 -23.21 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 114.334 -1.303 . . . . 0.0 111.756 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.8 mt -51.57 -24.49 5.41 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.194 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.07 -8.42 76.59 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.842 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.7 t -74.29 -21.09 59.9 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.712 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.9 t0 -135.88 63.9 53.81 Favored Pre-proline 0 C--O 1.217 -0.611 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.102 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 74.9 Cg_endo -75.89 -142.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.532 0 C-N-CA 121.327 1.351 . . . . 0.0 111.265 179.393 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.428 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 61.6 m -139.34 164.34 30.09 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 121.802 -0.561 . . . . 0.0 111.624 -178.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.42 158.28 9.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.239 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.81 122.17 9.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.906 0.384 . . . . 0.0 110.943 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.97 -34.05 6.09 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.557 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 32.1 m -89.1 151.01 22.47 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.411 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.1 p90 -124.89 145.88 49.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 10.5 t -83.22 107.22 15.61 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.044 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 34.9 tp -93.82 123.55 59.3 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.557 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.86 ' HG3' HD12 ' A' ' 9' ' ' ILE . 13.7 Cg_exo -68.19 131.15 22.87 Favored 'Trans proline' 0 N--CA 1.464 -0.222 0 C-N-CA 122.662 2.241 . . . . 0.0 112.561 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -105.45 -18.35 7.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.398 0.618 . . . . 0.0 109.551 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.32 -135.11 2.96 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.275 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.421 HD11 HG22 ' A' ' 26' ' ' ILE . 21.0 pt -77.23 -36.41 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.237 0.542 . . . . 0.0 111.262 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.474 HG21 ' HB2' ' A' ' 8' ' ' ASN . 7.2 p -142.4 -35.36 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.312 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.447 ' N ' HG13 ' A' ' 27' ' ' VAL . . . -70.49 148.81 47.85 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.438 ' O ' HG13 ' A' ' 30' ' ' VAL . . . -165.15 -162.42 16.23 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.438 HG13 ' O ' ' A' ' 29' ' ' GLY . 29.2 m -146.69 149.4 15.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.235 0.54 . . . . 0.0 111.082 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.465 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 39.2 m -69.56 142.8 53.54 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.932 179.142 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.411 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 59.7 t . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.059 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.487 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 5.9 p . . . . . 0 N--CA 1.453 -0.296 0 CA-C-O 120.699 0.285 . . . . 0.0 110.936 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.37 132.79 55.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.36 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.68 -21.43 36.63 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.29 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -61.14 144.07 54.3 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 t -88.52 151.23 22.65 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.695 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 28.3 p -167.16 -166.23 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 O-C-N 123.23 0.331 . . . . 0.0 110.233 -179.114 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.31 153.22 31.29 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.405 0.622 . . . . 0.0 111.7 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 9' ' ' ILE . 7.8 tp -58.33 -11.73 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.148 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -59.09 -20.77 56.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.501 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.69 -20.01 30.08 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.611 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 m -66.34 -26.88 67.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.942 0.401 . . . . 0.0 110.498 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.695 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 25.2 m-20 -118.46 66.28 6.6 Favored Pre-proline 0 C--O 1.221 -0.44 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.445 -179.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 56.6 Cg_endo -70.05 -146.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.254 1.969 . . . . 0.0 111.829 179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 70.3 m -143.31 165.29 27.88 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 121.593 -0.692 . . . . 0.0 111.727 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.9 m-20 -62.81 154.34 30.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.691 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.381 0.426 . . . . 0.0 111.197 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.94 -39.56 2.81 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 64.1 m -105.88 148.74 27.25 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.801 0.334 . . . . 0.0 110.595 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -123.54 147.08 47.6 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.222 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.6 t -73.47 109.37 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.016 -179.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.531 HD23 HG13 ' A' ' 32' ' ' VAL . 31.8 tp -105.49 124.7 35.5 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.582 -179.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.68 131.29 28.93 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.59 2.193 . . . . 0.0 112.304 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -102.89 -20.57 5.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.983 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.66 -134.39 3.24 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.451 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -77.85 -34.78 20.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.359 0.599 . . . . 0.0 111.021 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -143.34 -37.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.381 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.73 149.14 50.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.955 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -158.36 -169.4 21.83 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.079 -0.581 . . . . 0.0 112.057 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.4 m -146.97 151.03 14.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.092 0.472 . . . . 0.0 111.062 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 94.2 m -72.96 124.61 25.79 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.359 179.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.531 HG13 HD23 ' A' ' 22' ' ' LEU . 8.0 p . . . . . 0 C--N 1.321 -0.666 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.722 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.403 0 N-CA-C 111.98 -0.448 . . . . 0.0 111.98 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.43 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 29.6 p -80.61 -38.76 28.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.763 0.316 . . . . 0.0 110.757 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -57.0 130.29 45.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.422 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.53 -16.55 58.75 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.416 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.582 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.1 mttt -63.58 142.68 58.31 Favored 'General case' 0 CA--C 1.512 -0.483 0 CA-C-O 120.965 0.412 . . . . 0.0 111.934 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 p -78.48 139.99 38.64 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.652 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.7 p -156.44 179.21 9.47 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.903 0.382 . . . . 0.0 110.794 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.63 146.76 22.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.301 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.8 mm -59.11 -14.41 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 115.483 -0.781 . . . . 0.0 111.663 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.5 mt -53.3 -28.08 26.35 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.751 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.59 -14.45 65.26 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.196 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.6 p -69.98 -35.54 74.49 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.26 0.553 . . . . 0.0 110.585 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.652 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 15.2 m-20 -125.27 65.93 51.21 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.076 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 95.2 Cg_endo -76.04 -137.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.329 2.019 . . . . 0.0 111.932 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.428 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 83.5 m -138.83 166.81 23.45 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 121.842 -0.536 . . . . 0.0 112.078 -178.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -60.17 153.92 20.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.743 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.84 125.2 14.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.972 0.415 . . . . 0.0 111.264 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.0 -40.37 2.52 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 29.1 m -90.1 158.58 17.22 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -132.51 149.38 52.34 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.452 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.7 t -75.64 113.47 13.11 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.125 -0.943 . . . . 0.0 109.883 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.7 tp -100.37 122.18 50.82 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.089 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -64.43 131.71 30.9 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.704 2.27 . . . . 0.0 113.106 -179.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.18 -17.16 7.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.396 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.83 -133.33 2.7 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.351 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.452 HD13 HG21 ' A' ' 26' ' ' ILE . 19.1 pt -76.5 -35.25 25.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.269 0.557 . . . . 0.0 111.454 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.41 -32.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.74 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.42 152.37 40.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.299 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.16 -160.21 11.7 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.1 -0.572 . . . . 0.0 112.119 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.1 m -144.52 150.46 16.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.228 0.537 . . . . 0.0 110.793 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.582 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 63.5 m -71.8 133.14 45.34 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.966 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.322 -0.611 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.345 179.132 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 N-CA-C 111.993 -0.443 . . . . 0.0 111.993 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p -70.65 -37.11 73.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.728 0.299 . . . . 0.0 111.078 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.68 128.14 35.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.072 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.15 -20.74 37.29 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.966 -179.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.503 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.72 151.25 39.0 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 122.662 0.385 . . . . 0.0 110.807 -179.973 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.5 m -78.72 168.34 19.88 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.714 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.7 p -177.02 174.53 1.69 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.856 0.36 . . . . 0.0 110.547 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.47 143.47 22.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.208 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.422 HG21 ' O ' ' A' ' 9' ' ' ILE . 51.7 mt -54.86 -22.36 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.595 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.0 mt -52.28 -27.67 15.99 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.824 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.7 -6.78 74.12 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.952 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.0 p -72.37 -25.54 61.55 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.542 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.714 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.4 t0 -132.51 66.07 76.03 Favored Pre-proline 0 C--O 1.219 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.978 179.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 60.2 Cg_endo -71.98 -145.3 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 121.623 1.549 . . . . 0.0 111.645 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.45 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.1 m -141.23 154.97 46.07 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.63 -0.669 . . . . 0.0 112.031 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.46 156.55 22.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.17 120.21 5.21 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.08 0.467 . . . . 0.0 111.041 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.84 -39.99 2.33 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.4 m -106.17 151.56 24.59 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.807 0.337 . . . . 0.0 110.279 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -124.89 147.88 48.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.674 0.273 . . . . 0.0 110.36 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.8 t -73.02 109.4 6.53 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.161 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.429 HD21 HG11 ' A' ' 32' ' ' VAL . 34.7 tp -102.61 123.06 43.96 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.389 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.22 130.93 28.53 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.654 2.236 . . . . 0.0 112.822 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.98 -17.83 7.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.571 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.77 -132.68 2.7 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.406 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.412 HD13 HG22 ' A' ' 26' ' ' ILE . 18.7 pt -76.87 -35.0 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 121.22 0.534 . . . . 0.0 111.417 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.1 p -147.6 -32.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.931 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.4 154.37 37.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.38 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.468 ' O ' HG11 ' A' ' 30' ' ' VAL . . . -164.66 -158.86 10.61 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 121.371 -0.443 . . . . 0.0 112.022 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.468 HG11 ' O ' ' A' ' 29' ' ' GLY . 17.8 m -147.74 152.52 12.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.189 0.518 . . . . 0.0 110.829 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.503 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 88.9 m -73.43 125.79 28.7 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.506 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.429 HG11 HD21 ' A' ' 22' ' ' LEU . 7.2 p . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.643 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.38 0 N-CA-C 112.038 -0.425 . . . . 0.0 112.038 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.8 p -70.91 -46.57 62.29 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.043 0.449 . . . . 0.0 110.274 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.23 135.73 56.53 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.738 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.69 -26.16 20.52 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.844 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.588 ' HZ2' ' HB3' ' A' ' 5' ' ' LYS . 1.6 mtpm? -55.43 132.93 49.48 Favored 'General case' 0 CA--C 1.512 -0.5 0 CA-C-O 120.691 0.281 . . . . 0.0 111.547 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.7 m -76.13 154.54 35.39 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.665 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.1 p -174.51 -158.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.031 0.444 . . . . 0.0 110.632 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.56 153.51 31.54 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.932 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.557 HG22 ' HA ' ' A' ' 27' ' ' VAL . 12.6 tt -53.07 -20.92 2.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 114.448 -1.251 . . . . 0.0 112.565 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.414 ' N ' HG21 ' A' ' 9' ' ' ILE . 26.6 mt -60.63 -17.73 48.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.337 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.38 16.08 80.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.097 -0.573 . . . . 0.0 111.795 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -74.99 -26.44 59.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.825 0.345 . . . . 0.0 110.565 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.665 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 15.5 t0 -126.37 66.06 60.76 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.095 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -71.28 -151.09 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.248 1.965 . . . . 0.0 111.812 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.507 ' SG ' ' HD3' ' A' ' 5' ' ' LYS . 1.5 m -156.08 179.74 8.93 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.011 -0.43 . . . . 0.0 111.984 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -54.46 156.02 3.62 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 124.211 0.944 . . . . 0.0 111.409 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.06 121.37 5.99 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.817 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.51 -40.55 2.51 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 12.0 m -91.34 142.11 28.05 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -138.06 154.0 49.29 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 120.621 -0.432 . . . . 0.0 111.619 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.56 117.4 18.17 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.768 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.41 124.4 34.63 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.414 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -63.6 130.91 29.58 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 122.626 2.217 . . . . 0.0 112.391 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -101.66 -21.97 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.107 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.02 -134.44 3.33 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.47 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.421 HG13 HG11 ' A' ' 27' ' ' VAL . 19.7 pt -77.68 -35.23 21.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.311 0.576 . . . . 0.0 110.908 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.557 ' HA ' HG22 ' A' ' 9' ' ' ILE . 7.7 p -142.76 -37.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.356 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.55 149.91 49.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.069 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.79 -170.99 28.43 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 121.081 -0.581 . . . . 0.0 111.89 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.7 m -148.22 149.9 14.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.933 0.397 . . . . 0.0 110.693 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -67.88 139.41 56.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.593 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 C--N 1.321 -0.648 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.147 178.945 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.461 0 N-CA-C 112.061 -0.415 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.8 p -75.64 -40.8 55.65 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.536 0.208 . . . . 0.0 111.185 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.44 135.57 56.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.729 0.3 . . . . 0.0 111.511 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 -22.48 39.27 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.86 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 33.6 mtpt -57.7 143.08 42.98 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -74.72 143.22 44.24 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.771 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 17.5 p -163.52 -176.4 4.69 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.559 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.1 OUTLIER -156.67 152.17 26.77 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.617 0.722 . . . . 0.0 112.223 178.449 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.587 HG23 ' HA ' ' A' ' 27' ' ' VAL . 8.2 tt -61.38 -9.95 3.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 113.854 -1.521 . . . . 0.0 112.876 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -60.25 -18.75 50.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.955 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.41 -22.78 22.05 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.633 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.1 p -69.62 -33.22 72.35 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.045 0.45 . . . . 0.0 110.537 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.771 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 1.9 m-20 -121.6 66.29 18.86 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.794 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.6 Cg_endo -76.05 -138.93 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.576 0 C-N-CA 122.225 1.95 . . . . 0.0 111.117 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.426 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 94.9 m -140.3 159.65 41.72 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 121.778 -0.576 . . . . 0.0 112.081 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -62.86 152.24 36.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.163 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.75 124.83 11.82 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 123.433 0.458 . . . . 0.0 111.28 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.84 2.4 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -178.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -101.47 146.9 27.02 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.034 0.445 . . . . 0.0 110.738 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 36.2 p90 -112.79 146.83 38.13 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.2 t -82.68 109.3 16.74 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 36.9 tp -102.79 122.05 47.22 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.553 -179.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.4 129.01 20.41 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.534 2.156 . . . . 0.0 112.543 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.52 -20.95 5.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.549 0.69 . . . . 0.0 109.516 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.76 -133.93 3.23 Favored Glycine 0 N--CA 1.444 -0.81 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.981 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 21.8 pt -79.03 -40.4 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.037 0.446 . . . . 0.0 111.087 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.587 ' HA ' HG23 ' A' ' 9' ' ' ILE . 15.9 m -135.21 -34.67 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.26 149.44 44.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.153 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.19 -163.59 17.51 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.078 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -149.48 153.14 11.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.033 0.444 . . . . 0.0 110.747 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 90.4 m -70.13 143.32 52.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.846 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.443 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 53.1 t . . . . . 0 C--N 1.315 -0.894 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.249 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.422 0 N-CA-C 111.941 -0.463 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.5 p -80.26 -44.63 19.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.51 0.195 . . . . 0.0 111.36 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.3 131.92 52.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.705 0.288 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 100.17 -19.8 51.44 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.307 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 66.0 mttt -62.2 146.31 51.11 Favored 'General case' 0 C--O 1.219 -0.517 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -82.56 144.74 30.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.668 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.9 p -157.34 -179.31 8.06 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.899 0.381 . . . . 0.0 110.853 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 146.0 21.66 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.279 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.471 ' O ' HG23 ' A' ' 9' ' ' ILE . 41.3 mm -59.25 -13.15 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.621 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -53.96 -27.17 29.66 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.688 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.428 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.48 -16.61 60.28 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.28 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.4 p -69.54 -35.59 75.59 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.27 0.557 . . . . 0.0 110.563 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.668 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.8 m-20 -125.08 66.78 52.26 Favored Pre-proline 0 N--CA 1.449 -0.513 0 CA-C-N 115.069 -0.969 . . . . 0.0 111.023 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.428 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 88.1 Cg_endo -74.81 -137.17 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.639 0 C-N-CA 122.358 2.039 . . . . 0.0 111.822 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.42 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.9 m -142.0 157.11 45.32 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 121.709 -0.62 . . . . 0.0 112.527 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 4.7 m-20 -60.67 153.37 24.11 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.6 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.4 127.09 18.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 111.225 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.05 -42.7 1.9 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 65.4 m -98.74 147.58 24.74 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -118.46 147.79 43.24 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.329 179.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 43.2 t -73.89 111.44 9.04 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.004 -179.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.414 ' HB2' HG12 ' A' ' 32' ' ' VAL . 35.5 tp -102.53 122.92 44.58 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.185 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.36 131.32 26.16 Favored 'Trans proline' 0 N--CA 1.465 -0.195 0 C-N-CA 122.59 2.193 . . . . 0.0 113.045 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.57 -17.13 7.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.403 179.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 -132.48 2.67 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.443 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.2 pt -76.12 -34.85 27.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.294 0.569 . . . . 0.0 111.44 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.4 p -149.05 -32.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.728 -179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.32 151.71 41.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.287 179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.413 ' O ' HG13 ' A' ' 30' ' ' VAL . . . -165.04 -159.57 11.49 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.033 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 29' ' ' GLY . 18.7 m -145.79 153.04 13.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.235 0.541 . . . . 0.0 110.674 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.6 m -74.3 128.18 34.87 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.934 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 22' ' ' LEU . 7.0 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.678 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.094 -0.402 . . . . 0.0 112.094 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.7 p -68.54 -38.45 80.84 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.831 0.348 . . . . 0.0 110.659 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -58.94 125.93 25.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.942 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 110.4 -24.79 17.05 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.951 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.539 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -61.72 148.49 42.7 Favored 'General case' 0 C--O 1.22 -0.494 0 C-N-CA 122.227 0.211 . . . . 0.0 110.518 179.87 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.404 ' O ' ' HB3' ' A' ' 7' ' ' CYS . 11.9 m -79.73 169.78 17.46 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.729 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 4.5 p 179.86 179.13 0.54 Allowed 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.72 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.411 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.48 150.83 25.45 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.383 178.677 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 27' ' ' VAL . 67.4 mt -54.02 -24.37 10.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.379 -1.282 . . . . 0.0 111.895 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.5 mt -52.15 -25.78 9.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.201 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.462 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.62 -4.26 85.94 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.556 -0.83 . . . . 0.0 111.817 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.0 p -72.72 -26.59 61.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.04 0.448 . . . . 0.0 110.486 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.729 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 26.2 t0 -127.58 65.32 66.45 Favored Pre-proline 0 C--O 1.219 -0.51 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.948 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 59.7 Cg_endo -71.3 -145.39 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 121.72 1.614 . . . . 0.0 112.028 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 67.7 m -140.93 168.83 18.84 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.654 -0.654 . . . . 0.0 112.141 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.38 155.63 6.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.98 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -54.27 119.68 5.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.926 0.393 . . . . 0.0 110.641 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.78 -37.89 3.59 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 27.5 m -89.49 157.95 17.89 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 30.8 p90 -136.44 149.02 48.05 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.24 -0.584 . . . . 0.0 111.59 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.9 t -73.67 111.85 9.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.76 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 39.0 tp -100.02 119.79 58.55 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.555 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.02 131.9 30.32 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.856 2.37 . . . . 0.0 112.677 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -107.11 -19.2 6.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.962 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.51 -134.3 3.0 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.693 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.2 pt -75.82 -34.32 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.269 0.556 . . . . 0.0 111.139 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.465 ' HA ' HD13 ' A' ' 9' ' ' ILE . 7.8 p -147.1 -35.67 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.316 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.15 150.27 47.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.893 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.23 -163.87 18.19 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.9 m -146.73 152.69 13.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.159 0.504 . . . . 0.0 110.875 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.539 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 40.6 m -71.71 131.97 43.88 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.777 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.321 -0.637 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.191 178.91 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.508 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.461 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.9 p -70.02 -36.52 75.14 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.634 0.254 . . . . 0.0 111.307 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.66 128.79 38.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.771 0.319 . . . . 0.0 111.272 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.02 -20.45 40.79 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.052 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.82 150.59 41.21 Favored 'General case' 0 C--O 1.219 -0.549 0 C-N-CA 122.611 0.364 . . . . 0.0 110.925 179.999 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.3 m -78.01 167.76 20.95 Favored 'General case' 0 C--N 1.314 -0.942 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 178.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.701 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.8 p -176.83 173.1 1.96 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.024 0.44 . . . . 0.0 110.793 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.34 141.26 20.21 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.925 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.428 ' O ' HG22 ' A' ' 9' ' ' ILE . 46.7 mm -56.4 -19.32 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.579 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.624 ' HG ' HG21 ' A' ' 27' ' ' VAL . 75.7 mt -52.82 -28.11 21.21 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.544 179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.456 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 96.93 -9.26 65.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.781 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.8 p -71.94 -26.49 62.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.651 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.701 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 22.8 t0 -134.39 66.36 70.31 Favored Pre-proline 0 C--O 1.219 -0.536 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.131 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 61.6 Cg_endo -72.6 -144.62 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 121.605 1.537 . . . . 0.0 111.53 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.446 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 74.0 m -140.68 155.3 46.53 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 121.485 -0.759 . . . . 0.0 112.297 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -62.84 156.57 23.69 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.285 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.58 123.45 9.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.061 0.458 . . . . 0.0 111.026 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.83 -40.62 2.41 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 73.7 m -103.79 150.57 23.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.895 0.379 . . . . 0.0 110.342 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -123.99 148.11 47.24 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.376 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 t -73.58 107.39 5.82 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.096 -179.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.574 HD22 HG12 ' A' ' 32' ' ' VAL . 35.5 tp -99.42 123.29 48.85 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.257 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.17 130.74 24.89 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.583 2.189 . . . . 0.0 112.893 -179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -102.82 -17.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.516 -0.766 . . . . 0.0 109.36 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.53 -132.26 2.67 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.408 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.433 HD12 HG22 ' A' ' 26' ' ' ILE . 19.0 pt -76.34 -34.78 25.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.168 0.508 . . . . 0.0 111.447 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.624 HG21 ' HG ' ' A' ' 10' ' ' LEU . 13.6 p -149.23 -31.98 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.865 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.26 152.9 39.61 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.96 -157.35 9.62 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 121.307 -0.473 . . . . 0.0 112.101 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.1 m -147.38 152.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.163 0.506 . . . . 0.0 110.758 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.494 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 91.7 m -73.27 125.58 28.12 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.548 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.574 HG12 HD22 ' A' ' 22' ' ' LEU . 7.3 p . . . . . 0 C--N 1.321 -0.663 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.63 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 111.954 -0.458 . . . . 0.0 111.954 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.6 p -80.35 -43.17 21.61 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.878 0.37 . . . . 0.0 110.673 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -62.5 134.53 56.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.968 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.88 -19.19 47.73 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.337 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 73.9 mttt -59.79 137.17 58.13 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.206 0.526 . . . . 0.0 111.621 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 p -80.13 137.73 36.78 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.719 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.1 p -163.26 -160.24 0.59 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.681 0.277 . . . . 0.0 110.698 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.8 156.64 35.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.33 0.586 . . . . 0.0 111.708 179.473 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.503 HG21 ' HA ' ' A' ' 27' ' ' VAL . 11.7 tt -55.88 -16.48 2.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.298 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.99 -21.03 27.29 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.76 -6.41 65.96 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.442 179.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.9 p -71.91 -24.07 61.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.308 0.575 . . . . 0.0 110.275 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -118.72 63.09 5.6 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.177 -178.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 72.6 Cg_endo -73.37 -143.74 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.348 2.032 . . . . 0.0 110.963 178.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.405 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 0.7 OUTLIER -154.86 -171.08 3.71 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.443 -0.786 . . . . 0.0 113.067 179.85 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.01 148.37 26.32 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 113.915 -1.493 . . . . 0.0 109.929 -179.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.85 118.18 2.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.07 0.462 . . . . 0.0 111.325 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.65 -35.59 4.44 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.546 -179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 31.1 m -100.77 147.79 25.65 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -132.67 155.89 47.96 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.976 0.417 . . . . 0.0 111.623 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -76.48 118.85 19.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.893 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.453 ' HB2' HG12 ' A' ' 32' ' ' VAL . 28.0 tp -109.05 124.66 33.48 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.402 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 22' ' ' LEU . 25.4 Cg_exo -62.68 131.89 35.35 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.797 2.331 . . . . 0.0 112.499 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.22 -21.57 5.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.375 0.607 . . . . 0.0 110.137 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.51 -135.35 3.35 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.477 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.448 HD12 HG22 ' A' ' 26' ' ' ILE . 20.4 pt -77.35 -35.65 22.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.43 0.633 . . . . 0.0 110.911 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.503 ' HA ' HG21 ' A' ' 9' ' ' ILE . 6.8 p -141.84 -38.18 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.133 179.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.417 ' N ' HG13 ' A' ' 27' ' ' VAL . . . -66.03 149.11 50.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -160.62 -176.14 32.4 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.952 -0.642 . . . . 0.0 111.972 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 10.5 m -142.68 147.7 20.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.016 0.436 . . . . 0.0 110.501 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 36.2 m -68.5 138.82 55.51 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.751 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.453 HG12 ' HB2' ' A' ' 22' ' ' LEU . 14.6 p . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.252 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.589 0 N-CA-C 112.023 -0.431 . . . . 0.0 112.023 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p -79.22 -42.91 24.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.505 0.193 . . . . 0.0 111.143 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.01 135.83 57.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.92 -21.73 44.49 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.649 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 56.8 mttt -58.02 150.21 21.39 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 m -80.87 144.35 32.05 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.8 p -160.27 178.5 9.56 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.954 0.407 . . . . 0.0 110.794 -178.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.423 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.57 146.5 23.51 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.409 179.527 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.485 ' O ' HG23 ' A' ' 9' ' ' ILE . 41.5 mm -59.37 -14.77 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.558 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.0 -28.17 22.76 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.878 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.434 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.93 -16.45 60.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.085 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.4 p -69.83 -36.5 75.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.247 0.546 . . . . 0.0 110.527 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.584 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.2 m-20 -126.39 65.7 59.74 Favored Pre-proline 0 N--CA 1.448 -0.53 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.89 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.447 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 86.7 Cg_endo -77.22 -134.84 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.566 0 C-N-CA 122.214 1.943 . . . . 0.0 111.645 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.447 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 72.4 m -139.96 158.78 43.52 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.918 -0.488 . . . . 0.0 112.091 -178.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.44 ' CG ' ' HZ2' ' A' ' 5' ' ' LYS . 6.8 m-20 -61.79 151.05 35.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.48 179.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.75 120.47 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.039 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.22 -39.93 2.32 Favored Glycine 0 N--CA 1.448 -0.541 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.5 m -101.96 145.42 29.28 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.931 0.396 . . . . 0.0 110.865 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -107.16 148.79 28.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -84.51 112.54 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.9 tp -102.75 123.23 43.16 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.424 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -67.03 131.14 24.55 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.583 2.189 . . . . 0.0 112.822 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -101.41 -17.97 6.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.482 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.95 -132.5 2.75 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.311 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.3 pt -76.2 -34.7 26.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.234 0.54 . . . . 0.0 111.383 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.438 HG23 ' HB ' ' A' ' 9' ' ' ILE . 12.9 p -148.97 -32.5 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.794 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.431 ' N ' HG13 ' A' ' 27' ' ' VAL . . . -73.17 150.48 42.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.214 179.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.435 ' O ' HG11 ' A' ' 30' ' ' VAL . . . -165.91 -158.61 11.0 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.108 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 29' ' ' GLY . 18.6 m -146.18 151.94 14.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.154 0.502 . . . . 0.0 110.893 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 96.1 m -71.91 144.24 49.04 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.169 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.434 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 44.9 t . . . . . 0 C--N 1.317 -0.831 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.211 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.448 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.598 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.3 p -80.84 -49.22 11.35 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.625 0.25 . . . . 0.0 110.989 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.95 141.6 57.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.393 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.37 -18.38 57.58 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.395 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.0 mttp -63.32 166.76 5.95 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.345 0.593 . . . . 0.0 111.988 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -93.57 145.94 24.16 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.626 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.66 -177.29 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.686 0.279 . . . . 0.0 110.447 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.443 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.13 147.82 26.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.273 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.649 HG23 ' HA ' ' A' ' 27' ' ' VAL . 13.5 tt -61.21 -14.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.354 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.1 mt -57.52 -25.18 59.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.217 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.472 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.15 -13.09 64.33 Favored Glycine 0 C--N 1.33 0.199 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.905 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -68.88 -35.63 77.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.327 0.584 . . . . 0.0 110.35 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.626 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 17.9 m-20 -124.82 67.28 51.15 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.75 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.0 Cg_endo -73.72 -138.08 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.344 2.029 . . . . 0.0 112.15 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.468 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 69.2 m -138.18 161.98 35.43 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.724 -0.61 . . . . 0.0 112.126 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.598 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 0.4 OUTLIER -59.38 148.89 30.86 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.333 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.55 120.7 5.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.183 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.92 -39.54 2.45 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.383 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.477 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 31.4 m -101.53 149.19 24.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.831 0.348 . . . . 0.0 110.972 179.313 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.6 p90 -109.94 150.8 27.93 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.365 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -85.84 119.71 26.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.405 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 33.6 tp -111.88 122.54 36.78 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-O 120.551 0.215 . . . . 0.0 110.477 -179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.92 130.33 25.67 Favored 'Trans proline' 0 CA--C 1.528 0.214 0 C-N-CA 122.625 2.217 . . . . 0.0 112.655 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.3 p -99.79 -20.74 5.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.537 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.71 -133.17 3.1 Favored Glycine 0 N--CA 1.445 -0.737 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.978 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 21.4 pt -78.9 -40.5 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.015 0.436 . . . . 0.0 111.141 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.649 ' HA ' HG23 ' A' ' 9' ' ' ILE . 16.0 m -136.18 -33.89 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.011 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.5 153.8 37.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.02 -161.74 14.61 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.3 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -144.68 153.76 14.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.148 0.499 . . . . 0.0 110.544 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 89.4 m -74.1 144.64 44.86 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.372 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.437 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 46.4 t . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.276 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.443 0 N-CA-C 111.98 -0.448 . . . . 0.0 111.98 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.561 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 2.9 p -77.95 -47.71 17.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.538 0.209 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.67 137.68 58.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.477 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.18 -21.73 44.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.523 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.561 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 31.0 mtmt -65.14 166.92 8.84 Favored 'General case' 0 C--O 1.216 -0.664 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 m -91.32 151.46 20.86 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.256 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.54 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 15.2 p -163.86 178.71 7.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.323 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.407 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.87 147.69 24.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.931 0.396 . . . . 0.0 110.694 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.2 mt -57.51 -19.3 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.445 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.449 ' HG ' HG21 ' A' ' 27' ' ' VAL . 80.6 mt -51.72 -28.77 16.05 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 112.028 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.444 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.85 -13.42 66.86 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.145 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -70.25 -36.1 74.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.293 0.568 . . . . 0.0 110.432 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.54 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.9 m-20 -126.46 64.93 57.84 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.91 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.1 Cg_endo -77.76 -139.54 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.557 0 C-N-CA 122.087 1.858 . . . . 0.0 111.626 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.409 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 66.6 m -135.97 154.74 51.0 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 121.84 -0.537 . . . . 0.0 111.606 -179.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.502 ' CG ' ' HZ1' ' A' ' 5' ' ' LYS . 1.4 m-20 -62.32 153.43 30.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.06 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.78 123.24 8.62 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.405 0.441 . . . . 0.0 111.148 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.5 -40.67 2.32 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.415 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.0 m -102.78 147.05 27.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.928 0.394 . . . . 0.0 110.753 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 37.2 p90 -111.95 149.98 31.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.27 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.2 t -83.97 114.97 22.08 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.506 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -104.86 122.29 43.84 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.451 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.77 131.06 27.96 Favored 'Trans proline' 0 CA--C 1.527 0.165 0 C-N-CA 122.784 2.323 . . . . 0.0 112.555 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -104.71 -18.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.404 0.621 . . . . 0.0 109.788 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.2 -133.25 2.73 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.569 -0.741 . . . . 0.0 112.496 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -76.11 -35.16 28.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.296 0.57 . . . . 0.0 111.411 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.449 HG21 ' HG ' ' A' ' 10' ' ' LEU . 12.7 p -147.85 -32.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.715 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.433 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -73.87 152.48 40.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.447 179.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.8 -160.01 11.32 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.096 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.71 152.56 16.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.005 0.431 . . . . 0.0 110.835 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 86.5 m -74.39 143.3 44.87 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.746 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.423 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 48.9 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.346 -179.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 6.1 p -79.99 -38.17 32.69 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.736 0.303 . . . . 0.0 111.07 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.47 126.84 28.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.642 0.258 . . . . 0.0 110.791 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.99 -13.32 52.73 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.734 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.581 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 20.3 mmtp -64.05 170.15 3.82 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-O 121.525 0.679 . . . . 0.0 111.038 179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -105.62 148.3 27.49 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.219 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.551 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 12.9 p -162.79 178.27 8.59 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.069 0.462 . . . . 0.0 110.862 -178.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.06 147.53 25.04 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.5 mt -56.36 -18.62 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.674 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.403 ' HG ' HG23 ' A' ' 27' ' ' VAL . 77.8 mt -52.7 -27.77 18.97 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.99 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.448 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 90.14 -14.88 61.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.233 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.6 p -68.75 -35.9 77.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.411 0.624 . . . . 0.0 110.449 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.551 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.3 m-20 -124.74 67.97 52.12 Favored Pre-proline 0 N--CA 1.448 -0.56 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.8 -178.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 71.9 Cg_endo -72.87 -133.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 122.423 2.082 . . . . 0.0 111.949 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.42 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 93.0 m -139.09 157.1 46.56 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -178.549 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.754 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.7 m-20 -62.47 149.75 41.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.209 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.29 119.9 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 123.319 0.387 . . . . 0.0 111.206 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 125.72 -38.45 2.26 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 111.434 -0.667 . . . . 0.0 111.434 -179.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 88.2 m -112.3 154.41 25.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.726 0.298 . . . . 0.0 110.583 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -114.69 150.7 34.82 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.724 0.297 . . . . 0.0 110.425 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.7 t -75.23 115.11 14.52 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.44 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.441 HD22 HG12 ' A' ' 32' ' ' VAL . 31.2 tp -109.17 122.02 41.0 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.027 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.37 132.17 32.65 Favored 'Trans proline' 0 CA--C 1.528 0.183 0 C-N-CA 122.734 2.289 . . . . 0.0 112.888 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.4 p -104.96 -17.97 7.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.577 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.59 -132.63 2.71 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.524 -0.762 . . . . 0.0 112.436 -179.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.4 pt -76.63 -34.72 24.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.197 0.523 . . . . 0.0 111.383 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.403 HG23 ' HG ' ' A' ' 10' ' ' LEU . 11.8 p -148.28 -32.88 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.818 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.82 153.22 38.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.503 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.33 -162.74 15.87 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.14 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.96 156.14 22.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.442 0.639 . . . . 0.0 110.448 179.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.581 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 89.3 m -80.15 128.1 33.11 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.994 -179.537 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.441 HG12 HD22 ' A' ' 22' ' ' LEU . 7.4 p . . . . . 0 C--N 1.323 -0.583 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.101 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 19' ' ' CYS . 2.9 p -77.57 -42.69 34.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.556 0.217 . . . . 0.0 111.011 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.78 136.78 58.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.108 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -19.55 54.14 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.515 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.47 ' HZ3' ' CG ' ' A' ' 16' ' ' ASP . 66.6 mttt -60.47 157.31 14.31 Favored 'General case' 0 C--O 1.218 -0.596 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 m -86.87 147.31 25.85 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.684 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.49 -175.15 4.05 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.68 150.26 28.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.859 0.361 . . . . 0.0 110.379 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.418 HG21 ' HA ' ' A' ' 27' ' ' VAL . 10.2 tp -59.58 -17.11 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.014 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.2 mt -57.64 -24.8 58.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.706 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 85.42 -7.86 74.17 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.512 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.0 p -70.04 -33.77 72.38 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.59 0.71 . . . . 0.0 109.961 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.684 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 18.6 m-20 -124.23 67.02 44.33 Favored Pre-proline 0 C--O 1.217 -0.614 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.289 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 72.4 Cg_endo -73.78 -139.4 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.276 1.984 . . . . 0.0 112.058 -179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.444 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 62.3 m -139.04 162.18 35.57 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.762 -0.586 . . . . 0.0 111.993 -178.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.47 ' CG ' ' HZ3' ' A' ' 5' ' ' LYS . 7.5 m-20 -60.59 150.14 32.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.488 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.67 120.05 4.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.052 0.453 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.08 -39.58 2.42 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 111.307 -0.717 . . . . 0.0 111.307 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.2 m -102.2 146.83 27.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.983 0.42 . . . . 0.0 110.846 179.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -110.21 149.26 30.37 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.324 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 t -84.57 118.14 24.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.342 179.274 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.1 tp -111.97 123.65 34.03 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.729 -0.214 . . . . 0.0 110.576 -179.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -62.66 130.75 30.75 Favored 'Trans proline' 0 CA--C 1.529 0.228 0 C-N-CA 122.607 2.204 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.416 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 4.5 p -102.27 -19.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.08 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.51 -133.63 3.05 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.619 -0.719 . . . . 0.0 112.535 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.436 HG21 HD11 ' A' ' 26' ' ' ILE . 18.6 pt -79.77 -34.03 15.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.162 0.506 . . . . 0.0 111.388 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 28' ' ' ALA . 7.6 p -143.07 -35.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.813 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.43 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -75.25 154.94 37.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.835 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.416 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -161.82 -163.91 15.68 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 121.263 -0.494 . . . . 0.0 111.948 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.4 m -145.92 152.29 14.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.218 0.532 . . . . 0.0 110.788 179.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.444 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 85.4 m -72.91 143.95 47.54 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.035 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.423 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 47.5 t . . . . . 0 C--N 1.316 -0.872 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.222 -179.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.408 0 N-CA-C 112.036 -0.425 . . . . 0.0 112.036 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.535 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 1.9 p -79.63 -37.69 35.52 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.66 141.43 57.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.64 -26.5 22.88 Favored Glycine 0 CA--C 1.52 0.37 0 C-N-CA 120.558 -0.829 . . . . 0.0 113.005 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mptm? -53.22 143.41 18.34 Favored 'General case' 0 C--O 1.217 -0.642 0 C-N-CA 122.87 0.468 . . . . 0.0 112.176 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 m -76.82 143.18 39.95 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.609 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.6 p -158.6 179.13 9.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -178.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.43 147.78 23.83 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.621 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.455 ' O ' HG23 ' A' ' 9' ' ' ILE . 33.6 mt -57.7 -16.74 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.653 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.8 mt -52.41 -27.36 15.54 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.07 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.471 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.89 -17.33 57.0 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.184 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.8 p -69.81 -36.13 75.39 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.199 0.523 . . . . 0.0 110.455 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.609 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 2.6 m-20 -123.67 66.5 37.0 Favored Pre-proline 0 C--O 1.218 -0.575 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.52 -179.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.471 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 89.3 Cg_endo -75.8 -130.71 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.166 1.911 . . . . 0.0 111.712 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 71.2 m -142.02 160.08 40.94 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.535 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.1 m-20 -61.59 147.75 44.63 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.977 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.65 114.92 1.71 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.973 0.416 . . . . 0.0 111.087 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.82 -37.44 2.23 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.436 -179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.503 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 37.3 m -107.82 149.75 27.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.057 0.456 . . . . 0.0 111.135 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.465 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.1 p90 -105.8 149.28 26.62 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.353 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.8 t -84.42 114.41 21.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -105.97 122.59 41.91 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-O 120.629 0.252 . . . . 0.0 110.581 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.07 131.54 27.28 Favored 'Trans proline' 0 N--CA 1.464 -0.211 0 C-N-CA 122.68 2.253 . . . . 0.0 112.77 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -101.21 -18.3 6.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.447 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.38 -132.49 2.79 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.372 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.0 pt -76.72 -34.9 24.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.186 0.517 . . . . 0.0 111.421 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.428 HG11 ' N ' ' A' ' 28' ' ' ALA . 11.9 p -147.9 -32.83 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.799 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.428 ' N ' HG11 ' A' ' 27' ' ' VAL . . . -73.7 150.71 41.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.393 179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.51 -159.56 12.45 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 121.201 -0.523 . . . . 0.0 112.002 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.62 151.44 13.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.297 0.57 . . . . 0.0 110.919 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 75.2 m -69.98 144.86 52.2 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.399 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.465 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 45.1 t . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.204 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.402 0 N-CA-C 112.005 -0.438 . . . . 0.0 112.005 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.511 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 30.3 p -81.69 -44.68 16.79 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.667 0.27 . . . . 0.0 110.946 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -55.97 132.5 50.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.425 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.58 -17.36 58.7 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.651 -0.785 . . . . 0.0 113.036 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 9.2 mttp -57.35 144.58 35.5 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 120.653 0.264 . . . . 0.0 111.505 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.9 m -77.0 141.83 40.19 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.567 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 16.7 p -161.32 177.38 10.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.128 0.489 . . . . 0.0 111.073 -178.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.91 146.18 23.86 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.234 179.508 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.4 HG21 ' O ' ' A' ' 9' ' ' ILE . 39.4 mm -60.0 -13.26 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.52 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.653 ' HG ' HG22 ' A' ' 27' ' ' VAL . 81.4 mt -53.42 -28.02 27.64 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.757 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 94.92 -17.85 58.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.116 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -69.53 -37.04 76.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.313 0.577 . . . . 0.0 110.58 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.567 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 13.3 m-20 -126.7 66.14 63.73 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.856 -178.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 83.1 Cg_endo -77.09 -128.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.506 0 C-N-CA 122.187 1.925 . . . . 0.0 111.764 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 80.0 m -141.41 168.19 20.37 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -178.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -59.5 145.89 42.37 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.872 178.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.02 122.71 7.04 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.803 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.19 -37.76 3.65 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.823 -0.626 . . . . 0.0 112.211 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -91.79 154.61 18.81 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.576 0.227 . . . . 0.0 110.518 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 47.2 p90 -112.65 151.2 30.43 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -178.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 34.6 t -90.73 115.01 27.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.078 -0.965 . . . . 0.0 108.951 178.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.1 tp -101.15 122.21 49.31 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.479 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -67.47 131.5 24.84 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.575 2.183 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -100.61 -18.07 6.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.413 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.44 -132.2 2.76 Favored Glycine 0 N--CA 1.445 -0.725 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.395 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 pt -76.23 -34.76 26.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.179 0.514 . . . . 0.0 111.401 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.653 HG22 ' HG ' ' A' ' 10' ' ' LEU . 14.0 p -149.14 -32.35 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.828 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.43 149.79 42.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.119 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -167.43 -158.34 11.61 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.015 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 28.4 m -145.7 151.37 14.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.314 0.578 . . . . 0.0 110.928 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.471 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 99.2 m -71.78 148.03 46.69 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.744 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.434 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 40.3 t . . . . . 0 C--N 1.318 -0.796 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.997 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.053 -0.419 . . . . 0.0 112.053 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.529 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.9 p -76.6 -41.43 46.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.687 0.28 . . . . 0.0 110.905 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.3 135.16 55.94 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.21 -15.33 63.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.328 -179.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 0.0 OUTLIER -55.41 145.04 23.49 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 120.87 0.367 . . . . 0.0 111.074 179.954 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.528 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 9.5 m -84.24 147.65 27.14 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.474 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.7 p -167.03 -161.07 0.41 Allowed 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.039 0.447 . . . . 0.0 111.008 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -157.92 158.96 36.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.112 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.466 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.9 mt -53.08 -27.18 13.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.841 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.6 mt -54.07 -24.14 16.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.736 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.98 15.75 81.39 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.0 p -79.05 -19.54 51.13 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.733 0.301 . . . . 0.0 110.721 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.474 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 9.3 t0 -127.94 61.88 54.0 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.242 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.61 -154.83 0.04 OUTLIER 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 121.889 1.726 . . . . 0.0 112.208 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 8.1 m -153.84 157.51 39.43 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.585 0.231 . . . . 0.0 111.065 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -57.05 162.52 2.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.722 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.77 124.6 10.04 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.164 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.2 -40.66 2.38 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -178.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.468 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 58.5 m -104.94 137.77 42.19 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.919 0.39 . . . . 0.0 110.136 178.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 36.4 p90 -128.76 143.75 51.0 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.585 -178.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.401 ' HA ' ' HA ' ' A' ' 31' ' ' CYS . 13.3 t -77.98 114.3 16.72 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 178.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 28.0 tp -111.9 129.29 24.36 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.653 -178.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HG3' HG12 ' A' ' 9' ' ' ILE . 32.1 Cg_exo -59.45 130.52 36.07 Favored 'Trans proline' 0 CA--C 1.528 0.209 0 C-N-CA 122.833 2.355 . . . . 0.0 112.26 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.425 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.9 p -105.7 -21.57 5.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.188 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.18 -138.26 3.63 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.44 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.2 pt -77.0 -38.23 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.985 0.421 . . . . 0.0 111.188 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.61 -32.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.58 154.22 38.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.216 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.425 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -159.51 -175.79 30.85 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 121.196 -0.526 . . . . 0.0 111.834 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.9 m -147.28 147.52 17.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.171 0.51 . . . . 0.0 110.829 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 35.0 m -70.64 147.23 49.4 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.556 179.037 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 21.8 t . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.986 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.559 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.8 p -76.78 -37.15 56.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.708 0.289 . . . . 0.0 111.101 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.96 134.11 53.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.719 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.29 -17.65 58.89 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.306 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.559 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.7 ttpt -55.61 144.29 27.07 Favored 'General case' 0 C--O 1.217 -0.655 0 C-N-CA 122.563 0.345 . . . . 0.0 111.599 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.6 m -81.67 147.66 29.41 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.4 p -165.15 -160.86 0.5 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.859 0.362 . . . . 0.0 110.738 -179.32 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -161.26 154.28 21.06 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.231 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.463 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.0 mt -52.69 -26.76 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 O-C-N 124.471 1.107 . . . . 0.0 111.752 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt -53.56 -22.47 8.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.801 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.444 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 78.82 12.53 84.08 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.767 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -72.78 -32.2 65.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.859 0.362 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.89 63.04 46.27 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.963 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.7 Cg_endo -73.58 -154.43 0.04 OUTLIER 'Trans proline' 0 CA--C 1.532 0.38 0 C-N-CA 121.813 1.676 . . . . 0.0 111.946 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 11.9 m -152.18 152.97 32.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.652 0.263 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.63 166.56 3.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.645 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.77 123.75 9.66 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.004 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.29 -37.38 3.18 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 57.0 m -115.88 138.13 51.45 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.966 0.412 . . . . 0.0 110.377 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.41 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.8 p90 -126.46 143.32 51.23 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.324 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.6 t -77.67 112.79 14.87 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.8 tp -106.72 127.17 28.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.681 -178.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.463 ' HG3' HG12 ' A' ' 9' ' ' ILE . 25.6 Cg_exo -62.64 133.08 40.59 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.932 2.421 . . . . 0.0 112.4 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.74 -19.95 6.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.259 0.552 . . . . 0.0 110.301 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.75 -135.46 3.13 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.651 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 20.0 pt -75.82 -34.85 28.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.375 0.607 . . . . 0.0 111.163 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.432 ' HA ' HD11 ' A' ' 9' ' ' ILE . 7.2 p -145.34 -36.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.108 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.423 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -67.09 149.67 50.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.87 -171.29 27.77 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 15.7 m -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.049 0.452 . . . . 0.0 111.029 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 23.7 m -71.2 145.49 49.65 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.128 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 33.3 t . . . . . 0 C--N 1.315 -0.903 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.153 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.594 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.0 p -77.27 -36.59 54.23 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.624 0.25 . . . . 0.0 111.105 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.69 133.19 53.15 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.627 0.251 . . . . 0.0 110.705 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.41 -16.23 61.13 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.46 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.594 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 1.7 ttpp -55.89 139.53 45.65 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 122.434 0.294 . . . . 0.0 111.676 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.7 m -74.6 147.45 41.64 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.1 p -163.84 -168.1 1.54 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.823 0.344 . . . . 0.0 110.936 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.535 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -162.77 156.63 20.56 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.181 179.861 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.716 HD12 ' HB3' ' A' ' 23' ' ' PRO . 47.1 mm -53.19 -26.32 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.782 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.7 mt -52.97 -25.18 11.18 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.768 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 79.11 12.86 83.6 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.186 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 p -78.0 -26.35 48.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.891 0.377 . . . . 0.0 110.655 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.39 60.15 50.49 Favored Pre-proline 0 C--O 1.223 -0.317 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.76 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -79.5 -153.8 0.05 OUTLIER 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 121.777 1.651 . . . . 0.0 112.374 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 22.3 m -152.43 148.1 27.05 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -68.79 -176.73 0.87 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.679 -178.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.03 125.7 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.926 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.33 -34.0 4.46 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.474 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 68.9 m -129.28 139.91 51.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.055 0.455 . . . . 0.0 110.764 179.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -124.98 142.79 51.25 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.184 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.7 t -76.82 114.24 15.37 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 31.4 tp -108.22 126.02 30.62 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.503 -179.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.716 ' HB3' HD12 ' A' ' 9' ' ' ILE . 32.9 Cg_endo -64.77 133.36 36.08 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.678 2.252 . . . . 0.0 112.861 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 p -107.04 -18.94 6.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.614 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.16 -135.09 3.12 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.283 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 20.9 pt -76.77 -36.13 25.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.373 0.606 . . . . 0.0 111.056 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.535 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.1 p -143.07 -36.37 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.165 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.475 ' N ' HG12 ' A' ' 27' ' ' VAL . . . -67.31 148.13 52.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.436 ' O ' HG13 ' A' ' 30' ' ' VAL . . . -165.45 -167.64 26.37 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.436 HG13 ' O ' ' A' ' 29' ' ' GLY . 16.0 m -147.31 147.84 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.096 0.475 . . . . 0.0 111.018 179.636 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -70.75 146.52 49.78 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.213 178.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 29.1 t . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.211 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.506 0 N-CA-C 111.995 -0.442 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 25.9 p -69.81 -38.16 76.5 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.782 0.325 . . . . 0.0 110.895 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.7 129.6 42.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.017 -179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.23 -25.42 27.81 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.52 -0.848 . . . . 0.0 112.789 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.465 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -56.98 150.86 15.98 Favored 'General case' 0 C--O 1.216 -0.684 0 C-N-CA 122.554 0.341 . . . . 0.0 110.525 179.792 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.8 m -75.2 165.99 24.34 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 178.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.712 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 6.1 p -178.1 172.83 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.886 0.374 . . . . 0.0 110.571 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.474 ' HB2' HG21 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.92 149.33 23.23 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.522 178.965 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.86 HD12 ' HG3' ' A' ' 23' ' ' PRO . 49.7 mm -53.88 -23.21 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 114.334 -1.303 . . . . 0.0 111.756 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.8 mt -51.57 -24.49 5.41 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.194 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.07 -8.42 76.59 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.842 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.7 t -74.29 -21.09 59.9 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.712 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.9 t0 -135.88 63.9 53.81 Favored Pre-proline 0 C--O 1.217 -0.611 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.102 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 74.9 Cg_endo -75.89 -142.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.532 0 C-N-CA 121.327 1.351 . . . . 0.0 111.265 179.393 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.428 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 61.6 m -139.34 164.34 30.09 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 121.802 -0.561 . . . . 0.0 111.624 -178.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.42 158.28 9.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.239 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.81 122.17 9.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.906 0.384 . . . . 0.0 110.943 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.97 -34.05 6.09 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.557 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 32.1 m -89.1 151.01 22.47 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.411 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.1 p90 -124.89 145.88 49.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 10.5 t -83.22 107.22 15.61 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.044 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 34.9 tp -93.82 123.55 59.3 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.557 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.86 ' HG3' HD12 ' A' ' 9' ' ' ILE . 13.7 Cg_exo -68.19 131.15 22.87 Favored 'Trans proline' 0 N--CA 1.464 -0.222 0 C-N-CA 122.662 2.241 . . . . 0.0 112.561 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -105.45 -18.35 7.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.398 0.618 . . . . 0.0 109.551 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.32 -135.11 2.96 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.275 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.421 HD11 HG22 ' A' ' 26' ' ' ILE . 21.0 pt -77.23 -36.41 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.237 0.542 . . . . 0.0 111.262 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.474 HG21 ' HB2' ' A' ' 8' ' ' ASN . 7.2 p -142.4 -35.36 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.312 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.447 ' N ' HG13 ' A' ' 27' ' ' VAL . . . -70.49 148.81 47.85 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.886 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.438 ' O ' HG13 ' A' ' 30' ' ' VAL . . . -165.15 -162.42 16.23 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.438 HG13 ' O ' ' A' ' 29' ' ' GLY . 29.2 m -146.69 149.4 15.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.235 0.54 . . . . 0.0 111.082 179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.465 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 39.2 m -69.56 142.8 53.54 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.932 179.142 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.411 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 59.7 t . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.059 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 111.939 -0.464 . . . . 0.0 111.939 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.487 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 5.9 p -80.13 -43.77 21.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.699 0.285 . . . . 0.0 110.936 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.37 132.79 55.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.36 -179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.68 -21.43 36.63 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.29 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -61.14 144.07 54.3 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 t -88.52 151.23 22.65 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.695 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 28.3 p -167.16 -166.23 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 O-C-N 123.23 0.331 . . . . 0.0 110.233 -179.114 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.31 153.22 31.29 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.405 0.622 . . . . 0.0 111.7 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 9' ' ' ILE . 7.8 tp -58.33 -11.73 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.148 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -59.09 -20.77 56.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.501 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.69 -20.01 30.08 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.611 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 m -66.34 -26.88 67.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.942 0.401 . . . . 0.0 110.498 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.695 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 25.2 m-20 -118.46 66.28 6.6 Favored Pre-proline 0 C--O 1.221 -0.44 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.445 -179.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 56.6 Cg_endo -70.05 -146.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.254 1.969 . . . . 0.0 111.829 179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 70.3 m -143.31 165.29 27.88 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 121.593 -0.692 . . . . 0.0 111.727 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.9 m-20 -62.81 154.34 30.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.691 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.381 0.426 . . . . 0.0 111.197 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.94 -39.56 2.81 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 64.1 m -105.88 148.74 27.25 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.801 0.334 . . . . 0.0 110.595 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -123.54 147.08 47.6 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.222 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.6 t -73.47 109.37 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.016 -179.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.531 HD23 HG13 ' A' ' 32' ' ' VAL . 31.8 tp -105.49 124.7 35.5 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.582 -179.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.68 131.29 28.93 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.59 2.193 . . . . 0.0 112.304 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -102.89 -20.57 5.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.983 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.66 -134.39 3.24 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.451 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -77.85 -34.78 20.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.359 0.599 . . . . 0.0 111.021 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 7.2 p -143.34 -37.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.381 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.73 149.14 50.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.955 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -158.36 -169.4 21.83 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.079 -0.581 . . . . 0.0 112.057 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.4 m -146.97 151.03 14.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.092 0.472 . . . . 0.0 111.062 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 94.2 m -72.96 124.61 25.79 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.359 179.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.531 HG13 HD23 ' A' ' 22' ' ' LEU . 8.0 p . . . . . 0 C--N 1.321 -0.666 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.722 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 29.6 p . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.757 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -57.0 130.29 45.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.422 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.53 -16.55 58.75 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.416 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.1 mttt -63.58 142.68 58.31 Favored 'General case' 0 CA--C 1.512 -0.483 0 CA-C-O 120.965 0.412 . . . . 0.0 111.934 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 p -78.48 139.99 38.64 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.673 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.7 p -156.44 179.21 9.47 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.903 0.382 . . . . 0.0 110.794 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.63 146.76 22.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.301 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.8 mm -59.11 -14.41 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 115.483 -0.781 . . . . 0.0 111.663 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.5 mt -53.3 -28.08 26.35 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.751 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.59 -14.45 65.26 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.196 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.6 p -69.98 -35.54 74.49 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.26 0.553 . . . . 0.0 110.585 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.673 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 15.2 m-20 -125.27 65.93 51.21 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.076 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 95.2 Cg_endo -76.04 -137.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.329 2.019 . . . . 0.0 111.932 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -138.83 166.81 23.45 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 121.842 -0.536 . . . . 0.0 112.078 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -60.17 153.92 20.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.743 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.84 125.2 14.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.972 0.415 . . . . 0.0 111.264 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.0 -40.37 2.52 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 29.1 m -90.1 158.58 17.22 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -132.51 149.38 52.34 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.452 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.7 t -75.64 113.47 13.11 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.125 -0.943 . . . . 0.0 109.883 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.599 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.7 tp -100.37 122.18 50.82 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.089 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HD2' HD12 ' A' ' 22' ' ' LEU . 31.5 Cg_endo -64.43 131.71 30.9 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.704 2.27 . . . . 0.0 113.106 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.18 -17.16 7.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.396 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.83 -133.33 2.7 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.351 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -76.5 -35.25 25.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.269 0.557 . . . . 0.0 111.454 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.41 -32.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.74 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.42 152.37 40.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.299 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.16 -160.21 11.7 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.1 -0.572 . . . . 0.0 112.119 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.1 m -144.52 150.46 16.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.228 0.537 . . . . 0.0 110.793 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 63.5 m -71.8 133.14 45.34 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.966 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.322 -0.611 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.345 179.132 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p . . . . . 0 N--CA 1.456 -0.16 0 CA-C-O 120.728 0.299 . . . . 0.0 111.078 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.68 128.14 35.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.072 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.15 -20.74 37.29 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.966 -179.553 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.72 151.25 39.0 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 122.662 0.385 . . . . 0.0 110.807 -179.973 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.5 m -78.72 168.34 19.88 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.7 p -177.02 174.53 1.69 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.856 0.36 . . . . 0.0 110.547 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.47 143.47 22.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.208 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.564 HD11 ' HB3' ' A' ' 23' ' ' PRO . 51.7 mt -54.86 -22.36 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.595 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.0 mt -52.28 -27.67 15.99 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.824 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.486 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.7 -6.78 74.12 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.952 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.0 p -72.37 -25.54 61.55 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.542 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.4 t0 -132.51 66.07 76.03 Favored Pre-proline 0 C--O 1.219 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.978 179.578 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 60.2 Cg_endo -71.98 -145.3 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 121.623 1.549 . . . . 0.0 111.645 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.1 m -141.23 154.97 46.07 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.63 -0.669 . . . . 0.0 112.031 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.46 156.55 22.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.17 120.21 5.21 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.08 0.467 . . . . 0.0 111.041 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.84 -39.99 2.33 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.4 m -106.17 151.56 24.59 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.807 0.337 . . . . 0.0 110.279 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -124.89 147.88 48.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.674 0.273 . . . . 0.0 110.36 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.8 t -73.02 109.4 6.53 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.161 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.7 tp -102.61 123.06 43.96 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.389 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.2 Cg_endo -64.22 130.93 28.53 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.654 2.236 . . . . 0.0 112.822 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.98 -17.83 7.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.571 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.77 -132.68 2.7 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.406 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 18.7 pt -76.87 -35.0 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 121.22 0.534 . . . . 0.0 111.417 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 12.1 p -147.6 -32.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.931 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.4 154.37 37.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.38 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.66 -158.86 10.61 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 121.371 -0.443 . . . . 0.0 112.022 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.8 m -147.74 152.52 12.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.189 0.518 . . . . 0.0 110.829 179.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.505 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 88.9 m -73.43 125.79 28.7 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.506 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.532 HG11 HD22 ' A' ' 22' ' ' LEU . 7.2 p . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.643 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.8 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 121.043 0.449 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.23 135.73 56.53 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.738 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.69 -26.16 20.52 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.844 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HD3' ' SG ' ' A' ' 15' ' ' CYS . 1.6 mtpm? -55.43 132.93 49.48 Favored 'General case' 0 CA--C 1.512 -0.5 0 CA-C-O 120.691 0.281 . . . . 0.0 111.547 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' HG12 ' A' ' 30' ' ' VAL . 9.7 m -76.13 154.54 35.39 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.671 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.1 p -174.51 -158.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.031 0.444 . . . . 0.0 110.632 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -154.56 153.51 31.54 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.932 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 12.6 tt -53.07 -20.92 2.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 114.448 -1.251 . . . . 0.0 112.565 -179.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 26.6 mt -60.63 -17.73 48.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.337 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.38 16.08 80.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.097 -0.573 . . . . 0.0 111.795 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -74.99 -26.44 59.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.825 0.345 . . . . 0.0 110.565 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.671 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 15.5 t0 -126.37 66.06 60.76 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.095 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -71.28 -151.09 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.248 1.965 . . . . 0.0 111.812 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.51 ' SG ' ' HD3' ' A' ' 5' ' ' LYS . 1.5 m -156.08 179.74 8.93 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.011 -0.43 . . . . 0.0 111.984 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -54.46 156.02 3.62 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 124.211 0.944 . . . . 0.0 111.409 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.06 121.37 5.99 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.817 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.51 -40.55 2.51 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.422 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 12.0 m -91.34 142.11 28.05 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -138.06 154.0 49.29 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 120.621 -0.432 . . . . 0.0 111.619 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.56 117.4 18.17 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.768 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.635 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.3 tp -108.41 124.4 34.63 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.414 -179.441 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.635 ' HD2' HD12 ' A' ' 22' ' ' LEU . 29.0 Cg_endo -63.6 130.91 29.58 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 122.626 2.217 . . . . 0.0 112.391 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -101.66 -21.97 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.107 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.02 -134.44 3.33 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.47 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.493 HG13 HG12 ' A' ' 27' ' ' VAL . 19.7 pt -77.68 -35.23 21.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.311 0.576 . . . . 0.0 110.908 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.493 HG12 HG13 ' A' ' 26' ' ' ILE . 7.7 p -142.76 -37.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.356 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.55 149.91 49.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.069 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.79 -170.99 28.43 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 121.081 -0.581 . . . . 0.0 111.89 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 6' ' ' SER . 13.7 m -148.22 149.9 14.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.933 0.397 . . . . 0.0 110.693 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -67.88 139.41 56.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.593 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 C--N 1.321 -0.648 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.147 178.945 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.8 p . . . . . 0 N--CA 1.455 -0.186 0 CA-C-O 120.536 0.208 . . . . 0.0 111.185 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.44 135.57 56.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.729 0.3 . . . . 0.0 111.511 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 -22.48 39.27 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.86 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 33.6 mtpt -57.7 143.08 42.98 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -74.72 143.22 44.24 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.782 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 17.5 p -163.52 -176.4 4.69 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.546 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.1 OUTLIER -156.67 152.17 26.77 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.617 0.722 . . . . 0.0 112.223 178.449 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.2 tt -61.38 -9.95 3.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 113.854 -1.521 . . . . 0.0 112.876 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -60.25 -18.75 50.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.955 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.41 -22.78 22.05 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.633 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.1 p -69.62 -33.22 72.35 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.045 0.45 . . . . 0.0 110.537 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.782 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 1.9 m-20 -121.6 66.29 18.86 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.794 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.6 Cg_endo -76.05 -138.93 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.576 0 C-N-CA 122.225 1.95 . . . . 0.0 111.117 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.9 m -140.3 159.65 41.72 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 121.778 -0.576 . . . . 0.0 112.081 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -62.86 152.24 36.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.163 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.75 124.83 11.82 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 123.433 0.458 . . . . 0.0 111.28 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.84 2.4 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -178.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -101.47 146.9 27.02 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.034 0.445 . . . . 0.0 110.738 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 36.2 p90 -112.79 146.83 38.13 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.2 t -82.68 109.3 16.74 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 36.9 tp -102.79 122.05 47.22 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.553 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.7 Cg_endo -66.4 129.01 20.41 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.534 2.156 . . . . 0.0 112.543 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.46 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 8.4 p -95.52 -20.95 5.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.549 0.69 . . . . 0.0 109.516 179.324 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.76 -133.93 3.23 Favored Glycine 0 N--CA 1.444 -0.81 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.981 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.498 HG13 HG22 ' A' ' 27' ' ' VAL . 21.8 pt -79.03 -40.4 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.037 0.446 . . . . 0.0 111.087 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.498 HG22 HG13 ' A' ' 26' ' ' ILE . 15.9 m -135.21 -34.67 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.26 149.44 44.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.153 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.46 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -164.19 -163.59 17.51 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.078 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -149.48 153.14 11.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.033 0.444 . . . . 0.0 110.747 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.429 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 90.4 m -70.13 143.32 52.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.846 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.463 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 53.1 t . . . . . 0 C--N 1.315 -0.894 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.249 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.5 p . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 120.51 0.195 . . . . 0.0 111.36 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.3 131.92 52.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.705 0.288 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 100.17 -19.8 51.44 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.307 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 66.0 mttt -62.2 146.31 51.11 Favored 'General case' 0 C--O 1.219 -0.517 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -82.56 144.74 30.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.685 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.9 p -157.34 -179.31 8.06 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.899 0.381 . . . . 0.0 110.853 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 146.0 21.66 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.279 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 41.3 mm -59.25 -13.15 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.621 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -53.96 -27.17 29.66 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.688 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.48 -16.61 60.28 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.28 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.4 p -69.54 -35.59 75.59 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.27 0.557 . . . . 0.0 110.563 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.685 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.8 m-20 -125.08 66.78 52.26 Favored Pre-proline 0 N--CA 1.449 -0.513 0 CA-C-N 115.069 -0.969 . . . . 0.0 111.023 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 88.1 Cg_endo -74.81 -137.17 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.639 0 C-N-CA 122.358 2.039 . . . . 0.0 111.822 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.407 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.9 m -142.0 157.11 45.32 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 121.709 -0.62 . . . . 0.0 112.527 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 4.7 m-20 -60.67 153.37 24.11 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.6 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.4 127.09 18.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 111.225 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.05 -42.7 1.9 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.423 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 65.4 m -98.74 147.58 24.74 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -118.46 147.79 43.24 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.329 179.361 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 43.2 t -73.89 111.44 9.04 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.004 -179.302 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.627 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -102.53 122.92 44.58 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.185 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.627 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.0 Cg_endo -66.36 131.32 26.16 Favored 'Trans proline' 0 N--CA 1.465 -0.195 0 C-N-CA 122.59 2.193 . . . . 0.0 113.045 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.57 -17.13 7.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.403 179.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 -132.48 2.67 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.443 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -76.12 -34.85 27.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.294 0.569 . . . . 0.0 111.44 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 26' ' ' ILE . 12.4 p -149.05 -32.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.728 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.32 151.71 41.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.287 179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.04 -159.57 11.49 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.033 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.79 153.04 13.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.235 0.541 . . . . 0.0 110.674 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 93.6 m -74.3 128.18 34.87 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.934 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.452 HG11 HD22 ' A' ' 22' ' ' LEU . 7.0 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.678 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.7 p . . . . . 0 N--CA 1.456 -0.154 0 CA-C-O 120.831 0.348 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -58.94 125.93 25.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.942 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 110.4 -24.79 17.05 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.951 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.537 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -61.72 148.49 42.7 Favored 'General case' 0 C--O 1.22 -0.494 0 C-N-CA 122.227 0.211 . . . . 0.0 110.518 179.87 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' A' ' 7' ' ' CYS . 11.9 m -79.73 169.78 17.46 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 4.5 p 179.86 179.13 0.54 Allowed 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.72 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.598 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.48 150.83 25.45 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.383 178.677 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.4 mt -54.02 -24.37 10.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.379 -1.282 . . . . 0.0 111.895 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.5 mt -52.15 -25.78 9.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.201 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.62 -4.26 85.94 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.556 -0.83 . . . . 0.0 111.817 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.0 p -72.72 -26.59 61.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.04 0.448 . . . . 0.0 110.486 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.756 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 26.2 t0 -127.58 65.32 66.45 Favored Pre-proline 0 C--O 1.219 -0.51 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.948 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 59.7 Cg_endo -71.3 -145.39 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 121.72 1.614 . . . . 0.0 112.028 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.405 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.7 m -140.93 168.83 18.84 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.654 -0.654 . . . . 0.0 112.141 -178.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.38 155.63 6.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.98 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -54.27 119.68 5.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.926 0.393 . . . . 0.0 110.641 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.78 -37.89 3.59 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 27.5 m -89.49 157.95 17.89 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 30.8 p90 -136.44 149.02 48.05 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.24 -0.584 . . . . 0.0 111.59 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.9 t -73.67 111.85 9.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.76 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 39.0 tp -100.02 119.79 58.55 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.555 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.02 131.9 30.32 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.856 2.37 . . . . 0.0 112.677 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -107.11 -19.2 6.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.962 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.51 -134.3 3.0 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.693 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -75.82 -34.32 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.269 0.556 . . . . 0.0 111.139 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.598 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.8 p -147.1 -35.67 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.316 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.15 150.27 47.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.893 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.23 -163.87 18.19 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.9 m -146.73 152.69 13.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.159 0.504 . . . . 0.0 110.875 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.537 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 40.6 m -71.71 131.97 43.88 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.777 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.321 -0.637 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.191 178.91 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.474 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.9 p . . . . . 0 N--CA 1.456 -0.126 0 CA-C-O 120.634 0.254 . . . . 0.0 111.307 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.66 128.79 38.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.771 0.319 . . . . 0.0 111.272 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.02 -20.45 40.79 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.052 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.82 150.59 41.21 Favored 'General case' 0 C--O 1.219 -0.549 0 C-N-CA 122.611 0.364 . . . . 0.0 110.925 179.999 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.3 m -78.01 167.76 20.95 Favored 'General case' 0 C--N 1.314 -0.942 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 178.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.723 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.8 p -176.83 173.1 1.96 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.024 0.44 . . . . 0.0 110.793 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.34 141.26 20.21 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.925 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.408 ' HB ' HG23 ' A' ' 27' ' ' VAL . 46.7 mm -56.4 -19.32 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.579 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.7 mt -52.82 -28.11 21.21 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.544 179.252 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 96.93 -9.26 65.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.781 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.8 p -71.94 -26.49 62.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.651 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.723 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 22.8 t0 -134.39 66.36 70.31 Favored Pre-proline 0 C--O 1.219 -0.536 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.131 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 61.6 Cg_endo -72.6 -144.62 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 121.605 1.537 . . . . 0.0 111.53 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.413 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 74.0 m -140.68 155.3 46.53 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 121.485 -0.759 . . . . 0.0 112.297 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -62.84 156.57 23.69 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.285 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.58 123.45 9.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.061 0.458 . . . . 0.0 111.026 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.83 -40.62 2.41 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 73.7 m -103.79 150.57 23.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.895 0.379 . . . . 0.0 110.342 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -123.99 148.11 47.24 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.376 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 t -73.58 107.39 5.82 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.096 -179.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.623 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -99.42 123.29 48.85 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.257 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.623 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.2 Cg_endo -66.17 130.74 24.89 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.583 2.189 . . . . 0.0 112.893 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -102.82 -17.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.516 -0.766 . . . . 0.0 109.36 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.53 -132.26 2.67 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.408 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.0 pt -76.34 -34.78 25.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.168 0.508 . . . . 0.0 111.447 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 9' ' ' ILE . 13.6 p -149.23 -31.98 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.865 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.26 152.9 39.61 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.96 -157.35 9.62 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 121.307 -0.473 . . . . 0.0 112.101 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.1 m -147.38 152.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.163 0.506 . . . . 0.0 110.758 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.494 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 91.7 m -73.27 125.58 28.12 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.548 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 22' ' ' LEU . 7.3 p . . . . . 0 C--N 1.321 -0.663 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.63 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 N--CA 1.451 -0.384 0 CA-C-O 120.878 0.37 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.43 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -62.5 134.53 56.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.968 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.88 -19.19 47.73 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.337 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 73.9 mttt -59.79 137.17 58.13 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.206 0.526 . . . . 0.0 111.621 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 p -80.13 137.73 36.78 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.719 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.1 p -163.26 -160.24 0.59 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.681 0.277 . . . . 0.0 110.698 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.8 156.64 35.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.33 0.586 . . . . 0.0 111.708 179.473 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.438 HG22 HG23 ' A' ' 27' ' ' VAL . 11.7 tt -55.88 -16.48 2.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.298 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.99 -21.03 27.29 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.76 -6.41 65.96 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.442 179.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.9 p -71.91 -24.07 61.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.308 0.575 . . . . 0.0 110.275 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -118.72 63.09 5.6 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.177 -178.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.37 -143.74 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.348 2.032 . . . . 0.0 110.963 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -154.86 -171.08 3.71 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.443 -0.786 . . . . 0.0 113.067 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.01 148.37 26.32 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 113.915 -1.493 . . . . 0.0 109.929 -179.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.85 118.18 2.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.07 0.462 . . . . 0.0 111.325 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.65 -35.59 4.44 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.546 -179.075 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 31.1 m -100.77 147.79 25.65 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -132.67 155.89 47.96 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.976 0.417 . . . . 0.0 111.623 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -76.48 118.85 19.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.893 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.425 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -109.05 124.66 33.48 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.402 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 22' ' ' LEU . 25.4 Cg_exo -62.68 131.89 35.35 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.797 2.331 . . . . 0.0 112.499 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.22 -21.57 5.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.375 0.607 . . . . 0.0 110.137 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.51 -135.35 3.35 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.477 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.508 HG13 HG12 ' A' ' 27' ' ' VAL . 20.4 pt -77.35 -35.65 22.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.43 0.633 . . . . 0.0 110.911 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 26' ' ' ILE . 6.8 p -141.84 -38.18 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.133 179.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.03 149.11 50.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -160.62 -176.14 32.4 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.952 -0.642 . . . . 0.0 111.972 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 10.5 m -142.68 147.7 20.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.016 0.436 . . . . 0.0 110.501 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 36.2 m -68.5 138.82 55.51 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.751 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.252 179.242 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p . . . . . 0 N--CA 1.454 -0.255 0 CA-C-O 120.505 0.193 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.01 135.83 57.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.92 -21.73 44.49 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.649 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 56.8 mttt -58.02 150.21 21.39 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 m -80.87 144.35 32.05 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.603 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.8 p -160.27 178.5 9.56 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.954 0.407 . . . . 0.0 110.794 -178.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.405 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.57 146.5 23.51 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.409 179.527 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HB ' HG23 ' A' ' 27' ' ' VAL . 41.5 mm -59.37 -14.77 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.558 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.0 -28.17 22.76 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.878 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.93 -16.45 60.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.085 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.4 p -69.83 -36.5 75.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.247 0.546 . . . . 0.0 110.527 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.603 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.2 m-20 -126.39 65.7 59.74 Favored Pre-proline 0 N--CA 1.448 -0.53 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.89 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 86.7 Cg_endo -77.22 -134.84 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.566 0 C-N-CA 122.214 1.943 . . . . 0.0 111.645 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.4 m -139.96 158.78 43.52 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.918 -0.488 . . . . 0.0 112.091 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -61.79 151.05 35.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.48 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.75 120.47 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.039 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.22 -39.93 2.32 Favored Glycine 0 N--CA 1.448 -0.541 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.5 m -101.96 145.42 29.28 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.931 0.396 . . . . 0.0 110.865 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -107.16 148.79 28.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -84.51 112.54 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.669 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.9 tp -102.75 123.23 43.16 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.424 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.669 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.8 Cg_endo -67.03 131.14 24.55 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.583 2.189 . . . . 0.0 112.822 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -101.41 -17.97 6.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.482 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.95 -132.5 2.75 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.311 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.3 pt -76.2 -34.7 26.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.234 0.54 . . . . 0.0 111.383 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 9' ' ' ILE . 12.9 p -148.97 -32.5 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.794 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.17 150.48 42.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.214 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.91 -158.61 11.0 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.108 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.6 m -146.18 151.94 14.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.154 0.502 . . . . 0.0 110.893 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 96.1 m -71.91 144.24 49.04 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.169 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 44.9 t . . . . . 0 C--N 1.317 -0.831 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.211 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.613 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.3 p . . . . . 0 N--CA 1.452 -0.355 0 CA-C-O 120.625 0.25 . . . . 0.0 110.989 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.95 141.6 57.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.393 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.37 -18.38 57.58 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.395 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.0 mttp -63.32 166.76 5.95 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.345 0.593 . . . . 0.0 111.988 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -93.57 145.94 24.16 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.646 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.66 -177.29 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.686 0.279 . . . . 0.0 110.447 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.13 147.82 26.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.273 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 13.5 tt -61.21 -14.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.354 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.1 mt -57.52 -25.18 59.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.217 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.15 -13.09 64.33 Favored Glycine 0 C--N 1.33 0.199 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.905 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -68.88 -35.63 77.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.327 0.584 . . . . 0.0 110.35 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.646 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 17.9 m-20 -124.82 67.28 51.15 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.75 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.0 Cg_endo -73.72 -138.08 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.344 2.029 . . . . 0.0 112.15 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 69.2 m -138.18 161.98 35.43 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.724 -0.61 . . . . 0.0 112.126 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.613 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 0.4 OUTLIER -59.38 148.89 30.86 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.333 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.55 120.7 5.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.183 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.92 -39.54 2.45 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.383 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 31.4 m -101.53 149.19 24.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.831 0.348 . . . . 0.0 110.972 179.313 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.456 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.6 p90 -109.94 150.8 27.93 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.365 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -85.84 119.71 26.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.405 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.651 HD12 ' HD2' ' A' ' 23' ' ' PRO . 33.6 tp -111.88 122.54 36.78 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-O 120.551 0.215 . . . . 0.0 110.477 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.651 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.92 130.33 25.67 Favored 'Trans proline' 0 CA--C 1.528 0.214 0 C-N-CA 122.625 2.217 . . . . 0.0 112.655 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.414 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 5.3 p -99.79 -20.74 5.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.537 179.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.71 -133.17 3.1 Favored Glycine 0 N--CA 1.445 -0.737 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.978 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.513 HG13 HG22 ' A' ' 27' ' ' VAL . 21.4 pt -78.9 -40.5 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.015 0.436 . . . . 0.0 111.141 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.513 HG22 HG13 ' A' ' 26' ' ' ILE . 16.0 m -136.18 -33.89 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.011 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.5 153.8 37.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.414 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -165.02 -161.74 14.61 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.3 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -144.68 153.76 14.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.148 0.499 . . . . 0.0 110.544 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 89.4 m -74.1 144.64 44.86 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.372 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.456 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 46.4 t . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.276 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.59 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 2.9 p . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 120.538 0.209 . . . . 0.0 110.958 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.67 137.68 58.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.477 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.18 -21.73 44.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.523 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.59 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 31.0 mtmt -65.14 166.92 8.84 Favored 'General case' 0 C--O 1.216 -0.664 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 m -91.32 151.46 20.86 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.256 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.56 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 15.2 p -163.86 178.71 7.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.323 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.87 147.69 24.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.931 0.396 . . . . 0.0 110.694 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.2 mt -57.51 -19.3 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.445 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -51.72 -28.77 16.05 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 112.028 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.85 -13.42 66.86 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.145 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -70.25 -36.1 74.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.293 0.568 . . . . 0.0 110.432 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.56 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.9 m-20 -126.46 64.93 57.84 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.91 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.1 Cg_endo -77.76 -139.54 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.557 0 C-N-CA 122.087 1.858 . . . . 0.0 111.626 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.6 m -135.97 154.74 51.0 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 121.84 -0.537 . . . . 0.0 111.606 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -62.32 153.43 30.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.06 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.78 123.24 8.62 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.405 0.441 . . . . 0.0 111.148 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.5 -40.67 2.32 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.0 m -102.78 147.05 27.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.928 0.394 . . . . 0.0 110.753 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 37.2 p90 -111.95 149.98 31.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.27 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.2 t -83.97 114.97 22.08 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.506 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -104.86 122.29 43.84 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.451 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.77 131.06 27.96 Favored 'Trans proline' 0 CA--C 1.527 0.165 0 C-N-CA 122.784 2.323 . . . . 0.0 112.555 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -104.71 -18.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.404 0.621 . . . . 0.0 109.788 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.2 -133.25 2.73 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.569 -0.741 . . . . 0.0 112.496 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -76.11 -35.16 28.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.296 0.57 . . . . 0.0 111.411 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.7 p -147.85 -32.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.715 -179.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.87 152.48 40.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.8 -160.01 11.32 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.096 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.71 152.56 16.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.005 0.431 . . . . 0.0 110.835 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 86.5 m -74.39 143.3 44.87 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.746 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.443 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 48.9 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.346 -179.535 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.769 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 6.1 p . . . . . 0 N--CA 1.453 -0.281 0 CA-C-O 120.736 0.303 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.47 126.84 28.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.642 0.258 . . . . 0.0 110.791 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.99 -13.32 52.73 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.734 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 20.3 mmtp -64.05 170.15 3.82 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-O 121.525 0.679 . . . . 0.0 111.038 179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -105.62 148.3 27.49 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.219 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 12.9 p -162.79 178.27 8.59 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.069 0.462 . . . . 0.0 110.862 -178.726 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.06 147.53 25.04 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.503 HD11 ' HB3' ' A' ' 23' ' ' PRO . 42.5 mt -56.36 -18.62 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.674 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 77.8 mt -52.7 -27.77 18.97 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.99 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 90.14 -14.88 61.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.233 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.6 p -68.75 -35.9 77.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.411 0.624 . . . . 0.0 110.449 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.571 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.3 m-20 -124.74 67.97 52.12 Favored Pre-proline 0 N--CA 1.448 -0.56 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.8 -178.666 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 71.9 Cg_endo -72.87 -133.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 122.423 2.082 . . . . 0.0 111.949 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.432 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 93.0 m -139.09 157.1 46.56 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -178.549 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.769 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.7 m-20 -62.47 149.75 41.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.209 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.29 119.9 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 123.319 0.387 . . . . 0.0 111.206 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 125.72 -38.45 2.26 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 111.434 -0.667 . . . . 0.0 111.434 -179.161 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.469 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 88.2 m -112.3 154.41 25.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.726 0.298 . . . . 0.0 110.583 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -114.69 150.7 34.82 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.724 0.297 . . . . 0.0 110.425 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.7 t -75.23 115.11 14.52 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.44 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.2 tp -109.17 122.02 41.0 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.027 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.4 Cg_endo -64.37 132.17 32.65 Favored 'Trans proline' 0 CA--C 1.528 0.183 0 C-N-CA 122.734 2.289 . . . . 0.0 112.888 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.4 p -104.96 -17.97 7.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.577 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.59 -132.63 2.71 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.524 -0.762 . . . . 0.0 112.436 -179.703 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.412 HG13 HG12 ' A' ' 27' ' ' VAL . 18.4 pt -76.63 -34.72 24.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.197 0.523 . . . . 0.0 111.383 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.412 HG12 HG13 ' A' ' 26' ' ' ILE . 11.8 p -148.28 -32.88 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.818 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.82 153.22 38.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.503 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.33 -162.74 15.87 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.14 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.96 156.14 22.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.442 0.639 . . . . 0.0 110.448 179.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 89.3 m -80.15 128.1 33.11 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.994 -179.537 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.446 HG11 HD22 ' A' ' 22' ' ' LEU . 7.4 p . . . . . 0 C--N 1.323 -0.583 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.101 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 19' ' ' CYS . 2.9 p . . . . . 0 N--CA 1.455 -0.204 0 CA-C-O 120.556 0.217 . . . . 0.0 111.011 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.78 136.78 58.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.108 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -19.55 54.14 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.515 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.6 mttt -60.47 157.31 14.31 Favored 'General case' 0 C--O 1.218 -0.596 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 m -86.87 147.31 25.85 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.709 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.49 -175.15 4.05 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.68 150.26 28.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.859 0.361 . . . . 0.0 110.379 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.47 HG22 HG23 ' A' ' 27' ' ' VAL . 10.2 tp -59.58 -17.11 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.014 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.2 mt -57.64 -24.8 58.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.706 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 85.42 -7.86 74.17 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.512 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.0 p -70.04 -33.77 72.38 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.59 0.71 . . . . 0.0 109.961 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.709 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 18.6 m-20 -124.23 67.02 44.33 Favored Pre-proline 0 C--O 1.217 -0.614 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.289 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 72.4 Cg_endo -73.78 -139.4 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.276 1.984 . . . . 0.0 112.058 -179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.417 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 62.3 m -139.04 162.18 35.57 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.762 -0.586 . . . . 0.0 111.993 -178.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.5 m-20 -60.59 150.14 32.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.488 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.67 120.05 4.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.052 0.453 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.08 -39.58 2.42 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 111.307 -0.717 . . . . 0.0 111.307 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.2 m -102.2 146.83 27.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.983 0.42 . . . . 0.0 110.846 179.396 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -110.21 149.26 30.37 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.324 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 t -84.57 118.14 24.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.342 179.274 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.1 tp -111.97 123.65 34.03 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.729 -0.214 . . . . 0.0 110.576 -179.293 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' A' ' 22' ' ' LEU . 26.7 Cg_endo -62.66 130.75 30.75 Favored 'Trans proline' 0 CA--C 1.529 0.228 0 C-N-CA 122.607 2.204 . . . . 0.0 112.388 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.479 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 4.5 p -102.27 -19.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.08 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.51 -133.63 3.05 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.619 -0.719 . . . . 0.0 112.535 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.511 HG13 HG12 ' A' ' 27' ' ' VAL . 18.6 pt -79.77 -34.03 15.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.162 0.506 . . . . 0.0 111.388 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.511 HG12 HG13 ' A' ' 26' ' ' ILE . 7.6 p -143.07 -35.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.813 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.25 154.94 37.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.835 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -161.82 -163.91 15.68 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 121.263 -0.494 . . . . 0.0 111.948 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.4 m -145.92 152.29 14.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.218 0.532 . . . . 0.0 110.788 179.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 85.4 m -72.91 143.95 47.54 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.035 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.442 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 47.5 t . . . . . 0 C--N 1.316 -0.872 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.222 -179.546 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.552 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 1.9 p . . . . . 0 N--CA 1.455 -0.197 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.66 141.43 57.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.64 -26.5 22.88 Favored Glycine 0 CA--C 1.52 0.37 0 C-N-CA 120.558 -0.829 . . . . 0.0 113.005 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mptm? -53.22 143.41 18.34 Favored 'General case' 0 C--O 1.217 -0.642 0 C-N-CA 122.87 0.468 . . . . 0.0 112.176 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 m -76.82 143.18 39.95 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.632 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.6 p -158.6 179.13 9.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -178.428 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.43 147.78 23.83 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.621 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.524 HD11 ' HB3' ' A' ' 23' ' ' PRO . 33.6 mt -57.7 -16.74 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.653 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.8 mt -52.41 -27.36 15.54 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.07 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.89 -17.33 57.0 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.184 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.8 p -69.81 -36.13 75.39 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.199 0.523 . . . . 0.0 110.455 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.632 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 2.6 m-20 -123.67 66.5 37.0 Favored Pre-proline 0 C--O 1.218 -0.575 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.52 -179.296 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 89.3 Cg_endo -75.8 -130.71 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.166 1.911 . . . . 0.0 111.712 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.2 m -142.02 160.08 40.94 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.713 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.552 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.1 m-20 -61.59 147.75 44.63 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.977 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.65 114.92 1.71 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.973 0.416 . . . . 0.0 111.087 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.82 -37.44 2.23 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.436 -179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 37.3 m -107.82 149.75 27.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.057 0.456 . . . . 0.0 111.135 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.486 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.1 p90 -105.8 149.28 26.62 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.353 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.8 t -84.42 114.41 21.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.667 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.2 tp -105.97 122.59 41.91 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-O 120.629 0.252 . . . . 0.0 110.581 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.667 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.3 Cg_endo -66.07 131.54 27.28 Favored 'Trans proline' 0 N--CA 1.464 -0.211 0 C-N-CA 122.68 2.253 . . . . 0.0 112.77 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -101.21 -18.3 6.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.447 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.38 -132.49 2.79 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.372 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.0 pt -76.72 -34.9 24.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.186 0.517 . . . . 0.0 111.421 -179.665 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.9 -32.83 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.799 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.7 150.71 41.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.393 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.51 -159.56 12.45 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 121.201 -0.523 . . . . 0.0 112.002 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.62 151.44 13.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.297 0.57 . . . . 0.0 110.919 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 75.2 m -69.98 144.86 52.2 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.399 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 45.1 t . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.204 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.51 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 30.3 p . . . . . 0 N--CA 1.451 -0.383 0 CA-C-O 120.667 0.27 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -55.97 132.5 50.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.425 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.58 -17.36 58.7 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.651 -0.785 . . . . 0.0 113.036 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 9.2 mttp -57.35 144.58 35.5 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 120.653 0.264 . . . . 0.0 111.505 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.9 m -77.0 141.83 40.19 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.59 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 16.7 p -161.32 177.38 10.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.128 0.489 . . . . 0.0 111.073 -178.499 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.41 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.91 146.18 23.86 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.234 179.508 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.411 ' HB ' HG23 ' A' ' 27' ' ' VAL . 39.4 mm -60.0 -13.26 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.52 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.4 mt -53.42 -28.02 27.64 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.757 179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 94.92 -17.85 58.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.116 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -69.53 -37.04 76.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.313 0.577 . . . . 0.0 110.58 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.59 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 13.3 m-20 -126.7 66.14 63.73 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.856 -178.441 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 83.1 Cg_endo -77.09 -128.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.506 0 C-N-CA 122.187 1.925 . . . . 0.0 111.764 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.441 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 80.0 m -141.41 168.19 20.37 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -59.5 145.89 42.37 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.872 178.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.02 122.71 7.04 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.803 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.19 -37.76 3.65 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.823 -0.626 . . . . 0.0 112.211 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -91.79 154.61 18.81 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.576 0.227 . . . . 0.0 110.518 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 47.2 p90 -112.65 151.2 30.43 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -178.078 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 34.6 t -90.73 115.01 27.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.078 -0.965 . . . . 0.0 108.951 178.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.1 tp -101.15 122.21 49.31 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.479 -179.167 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 38.7 Cg_endo -67.47 131.5 24.84 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.575 2.183 . . . . 0.0 112.839 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -100.61 -18.07 6.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.413 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.44 -132.2 2.76 Favored Glycine 0 N--CA 1.445 -0.725 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.395 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 pt -76.23 -34.76 26.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.179 0.514 . . . . 0.0 111.401 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.411 HG23 ' HB ' ' A' ' 9' ' ' ILE . 14.0 p -149.14 -32.35 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.828 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.43 149.79 42.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.119 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -167.43 -158.34 11.61 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.015 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 28.4 m -145.7 151.37 14.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.314 0.578 . . . . 0.0 110.928 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.489 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 99.2 m -71.78 148.03 46.69 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.744 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 40.3 t . . . . . 0 C--N 1.318 -0.796 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.997 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.536 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.9 p . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 120.687 0.28 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.3 135.16 55.94 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.21 -15.33 63.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.328 -179.38 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' HE2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -55.41 145.04 23.49 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 120.87 0.367 . . . . 0.0 111.074 179.954 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.552 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 9.5 m -84.24 147.65 27.14 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.48 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.7 p -167.03 -161.07 0.41 Allowed 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.039 0.447 . . . . 0.0 111.008 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -157.92 158.96 36.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.112 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.484 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.9 mt -53.08 -27.18 13.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.841 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.6 mt -54.07 -24.14 16.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.736 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.98 15.75 81.39 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.0 p -79.05 -19.54 51.13 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.733 0.301 . . . . 0.0 110.721 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.48 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 9.3 t0 -127.94 61.88 54.0 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.242 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.61 -154.83 0.04 OUTLIER 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 121.889 1.726 . . . . 0.0 112.208 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 8.1 m -153.84 157.51 39.43 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.585 0.231 . . . . 0.0 111.065 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -57.05 162.52 2.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.722 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.77 124.6 10.04 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.164 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.2 -40.66 2.38 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -178.534 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 58.5 m -104.94 137.77 42.19 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.919 0.39 . . . . 0.0 110.136 178.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.436 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 36.4 p90 -128.76 143.75 51.0 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.585 -178.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 13.3 t -77.98 114.3 16.72 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 178.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -111.9 129.29 24.36 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.653 -178.75 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.484 ' HG3' HG12 ' A' ' 9' ' ' ILE . 32.1 Cg_exo -59.45 130.52 36.07 Favored 'Trans proline' 0 CA--C 1.528 0.209 0 C-N-CA 122.833 2.355 . . . . 0.0 112.26 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.477 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.9 p -105.7 -21.57 5.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.188 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.18 -138.26 3.63 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.44 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 27' ' ' VAL . 23.2 pt -77.0 -38.23 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.985 0.421 . . . . 0.0 111.188 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 26' ' ' ILE . 15.5 m -136.61 -32.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.847 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.58 154.22 38.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.216 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.477 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -159.51 -175.79 30.85 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 121.196 -0.526 . . . . 0.0 111.834 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.9 m -147.28 147.52 17.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.171 0.51 . . . . 0.0 110.829 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 35.0 m -70.64 147.23 49.4 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.556 179.037 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 21.8 t . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.986 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.571 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.8 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.708 0.289 . . . . 0.0 111.101 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.96 134.11 53.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.719 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.29 -17.65 58.89 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.306 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.7 ttpt -55.61 144.29 27.07 Favored 'General case' 0 C--O 1.217 -0.655 0 C-N-CA 122.563 0.345 . . . . 0.0 111.599 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.6 m -81.67 147.66 29.41 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.067 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.4 p -165.15 -160.86 0.5 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.859 0.362 . . . . 0.0 110.738 -179.32 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -161.26 154.28 21.06 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.231 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.476 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.0 mt -52.69 -26.76 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 O-C-N 124.471 1.107 . . . . 0.0 111.752 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt -53.56 -22.47 8.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.801 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.446 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 78.82 12.53 84.08 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.767 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -72.78 -32.2 65.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.859 0.362 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.89 63.04 46.27 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.963 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.7 Cg_endo -73.58 -154.43 0.04 OUTLIER 'Trans proline' 0 CA--C 1.532 0.38 0 C-N-CA 121.813 1.676 . . . . 0.0 111.946 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 11.9 m -152.18 152.97 32.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.652 0.263 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.63 166.56 3.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.645 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.77 123.75 9.66 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.004 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.29 -37.38 3.18 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 57.0 m -115.88 138.13 51.45 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.966 0.412 . . . . 0.0 110.377 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.418 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.8 p90 -126.46 143.32 51.23 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.324 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.6 t -77.67 112.79 14.87 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.8 tp -106.72 127.17 28.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.681 -178.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.476 ' HG3' HG12 ' A' ' 9' ' ' ILE . 25.6 Cg_exo -62.64 133.08 40.59 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.932 2.421 . . . . 0.0 112.4 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.74 -19.95 6.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.259 0.552 . . . . 0.0 110.301 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.75 -135.46 3.13 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.651 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.451 HG13 HG12 ' A' ' 27' ' ' VAL . 20.0 pt -75.82 -34.85 28.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.375 0.607 . . . . 0.0 111.163 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.451 HG12 HG13 ' A' ' 26' ' ' ILE . 7.2 p -145.34 -36.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.108 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.09 149.67 50.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.87 -171.29 27.77 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.7 m -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.049 0.452 . . . . 0.0 111.029 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.418 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 23.7 m -71.2 145.49 49.65 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.128 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 33.3 t . . . . . 0 C--N 1.315 -0.903 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.153 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.0 p . . . . . 0 N--CA 1.455 -0.19 0 CA-C-O 120.624 0.25 . . . . 0.0 111.105 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.69 133.19 53.15 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.627 0.251 . . . . 0.0 110.705 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.41 -16.23 61.13 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.46 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.606 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 1.7 ttpp -55.89 139.53 45.65 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 122.434 0.294 . . . . 0.0 111.676 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.7 m -74.6 147.45 41.64 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.1 p -163.84 -168.1 1.54 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.823 0.344 . . . . 0.0 110.936 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.597 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -162.77 156.63 20.56 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.181 179.861 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.678 HD11 ' HB3' ' A' ' 23' ' ' PRO . 47.1 mm -53.19 -26.32 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.782 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.7 mt -52.97 -25.18 11.18 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.768 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 79.11 12.86 83.6 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.186 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 p -78.0 -26.35 48.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.891 0.377 . . . . 0.0 110.655 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.39 60.15 50.49 Favored Pre-proline 0 C--O 1.223 -0.317 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.76 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -79.5 -153.8 0.05 OUTLIER 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 121.777 1.651 . . . . 0.0 112.374 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 22.3 m -152.43 148.1 27.05 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -68.79 -176.73 0.87 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.679 -178.603 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.03 125.7 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.926 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.33 -34.0 4.46 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 68.9 m -129.28 139.91 51.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.055 0.455 . . . . 0.0 110.764 179.619 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.9 p90 -124.98 142.79 51.25 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.184 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.7 t -76.82 114.24 15.37 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.676 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.4 tp -108.22 126.02 30.62 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.503 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.678 ' HB3' HD11 ' A' ' 9' ' ' ILE . 32.9 Cg_endo -64.77 133.36 36.08 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.678 2.252 . . . . 0.0 112.861 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 p -107.04 -18.94 6.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.614 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.16 -135.09 3.12 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.283 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.434 HG13 HG12 ' A' ' 27' ' ' VAL . 20.9 pt -76.77 -36.13 25.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.373 0.606 . . . . 0.0 111.056 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.597 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.1 p -143.07 -36.37 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.165 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.31 148.13 52.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.45 -167.64 26.37 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -147.31 147.84 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.096 0.475 . . . . 0.0 111.018 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 22.3 m -70.75 146.52 49.78 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.213 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 29.1 t . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.211 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 25.9 p . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 120.782 0.325 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.7 129.6 42.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.017 -179.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.23 -25.42 27.81 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.52 -0.848 . . . . 0.0 112.789 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.464 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -56.98 150.86 15.98 Favored 'General case' 0 C--O 1.216 -0.684 0 C-N-CA 122.554 0.341 . . . . 0.0 110.525 179.792 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.8 m -75.2 165.99 24.34 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 178.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 6.1 p -178.1 172.83 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.886 0.374 . . . . 0.0 110.571 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.528 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.92 149.33 23.23 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.522 178.965 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.892 HD11 ' HG3' ' A' ' 23' ' ' PRO . 49.7 mm -53.88 -23.21 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 114.334 -1.303 . . . . 0.0 111.756 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.8 mt -51.57 -24.49 5.41 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.194 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.07 -8.42 76.59 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.842 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.7 t -74.29 -21.09 59.9 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.9 t0 -135.88 63.9 53.81 Favored Pre-proline 0 C--O 1.217 -0.611 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.102 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 74.9 Cg_endo -75.89 -142.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.532 0 C-N-CA 121.327 1.351 . . . . 0.0 111.265 179.393 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 61.6 m -139.34 164.34 30.09 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 121.802 -0.561 . . . . 0.0 111.624 -178.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.42 158.28 9.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.239 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.81 122.17 9.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.906 0.384 . . . . 0.0 110.943 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.97 -34.05 6.09 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.557 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 32.1 m -89.1 151.01 22.47 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.1 p90 -124.89 145.88 49.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 10.5 t -83.22 107.22 15.61 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.044 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 34.9 tp -93.82 123.55 59.3 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.557 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.892 ' HG3' HD11 ' A' ' 9' ' ' ILE . 13.7 Cg_exo -68.19 131.15 22.87 Favored 'Trans proline' 0 N--CA 1.464 -0.222 0 C-N-CA 122.662 2.241 . . . . 0.0 112.561 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -105.45 -18.35 7.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.398 0.618 . . . . 0.0 109.551 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.32 -135.11 2.96 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.275 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.427 HG13 HG12 ' A' ' 27' ' ' VAL . 21.0 pt -77.23 -36.41 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.237 0.542 . . . . 0.0 111.262 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.528 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.2 p -142.4 -35.36 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.312 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.49 148.81 47.85 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.886 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.15 -162.42 16.23 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.2 m -146.69 149.4 15.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.235 0.54 . . . . 0.0 111.082 179.289 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.464 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 39.2 m -69.56 142.8 53.54 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.932 179.142 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.432 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 59.7 t . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.059 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.498 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 5.9 p . . . . . 0 N--CA 1.453 -0.296 0 CA-C-O 120.699 0.285 . . . . 0.0 110.936 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -60.37 132.79 55.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.36 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.68 -21.43 36.63 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.29 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -61.14 144.07 54.3 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 t -88.52 151.23 22.65 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.443 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.717 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 28.3 p -167.16 -166.23 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 O-C-N 123.23 0.331 . . . . 0.0 110.233 -179.114 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.31 153.22 31.29 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.405 0.622 . . . . 0.0 111.7 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.592 HG22 HG23 ' A' ' 27' ' ' VAL . 7.8 tp -58.33 -11.73 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.148 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -59.09 -20.77 56.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.495 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.69 -20.01 30.08 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.611 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 m -66.34 -26.88 67.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.942 0.401 . . . . 0.0 110.498 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.717 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 25.2 m-20 -118.46 66.28 6.6 Favored Pre-proline 0 C--O 1.221 -0.44 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.445 -179.278 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 56.6 Cg_endo -70.05 -146.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.254 1.969 . . . . 0.0 111.829 179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 70.3 m -143.31 165.29 27.88 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 121.593 -0.692 . . . . 0.0 111.727 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.9 m-20 -62.81 154.34 30.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.691 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.381 0.426 . . . . 0.0 111.197 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.94 -39.56 2.81 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 64.1 m -105.88 148.74 27.25 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.801 0.334 . . . . 0.0 110.595 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -123.54 147.08 47.6 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.222 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.6 t -73.47 109.37 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.016 -179.351 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.638 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.8 tp -105.49 124.7 35.5 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.582 -179.443 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.68 131.29 28.93 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.59 2.193 . . . . 0.0 112.304 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.417 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.0 p -102.89 -20.57 5.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.983 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.66 -134.39 3.24 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.451 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.503 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -77.85 -34.78 20.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.359 0.599 . . . . 0.0 111.021 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.592 HG23 HG22 ' A' ' 9' ' ' ILE . 7.2 p -143.34 -37.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.381 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.73 149.14 50.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.955 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.417 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -158.36 -169.4 21.83 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.079 -0.581 . . . . 0.0 112.057 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.4 m -146.97 151.03 14.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.092 0.472 . . . . 0.0 111.062 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 94.2 m -72.96 124.61 25.79 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.359 179.442 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--N 1.321 -0.666 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.722 179.209 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.403 0 N-CA-C 111.98 -0.448 . . . . 0.0 111.98 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 29.6 p -80.61 -38.76 28.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.763 0.316 . . . . 0.0 110.757 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -57.0 130.29 45.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.422 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.53 -16.55 58.75 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.416 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.1 mttt -63.58 142.68 58.31 Favored 'General case' 0 CA--C 1.512 -0.483 0 CA-C-O 120.965 0.412 . . . . 0.0 111.934 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 p -78.48 139.99 38.64 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.673 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.7 p -156.44 179.21 9.47 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.903 0.382 . . . . 0.0 110.794 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.63 146.76 22.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.301 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.8 mm -59.11 -14.41 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 115.483 -0.781 . . . . 0.0 111.663 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.5 mt -53.3 -28.08 26.35 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.751 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.59 -14.45 65.26 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.196 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.6 p -69.98 -35.54 74.49 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.26 0.553 . . . . 0.0 110.585 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.673 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 15.2 m-20 -125.27 65.93 51.21 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.076 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 95.2 Cg_endo -76.04 -137.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.329 2.019 . . . . 0.0 111.932 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -138.83 166.81 23.45 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 121.842 -0.536 . . . . 0.0 112.078 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -60.17 153.92 20.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.743 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.84 125.2 14.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.972 0.415 . . . . 0.0 111.264 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.0 -40.37 2.52 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 29.1 m -90.1 158.58 17.22 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -132.51 149.38 52.34 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.452 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.7 t -75.64 113.47 13.11 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.125 -0.943 . . . . 0.0 109.883 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.599 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.7 tp -100.37 122.18 50.82 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.089 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HD2' HD12 ' A' ' 22' ' ' LEU . 31.5 Cg_endo -64.43 131.71 30.9 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.704 2.27 . . . . 0.0 113.106 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.18 -17.16 7.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.396 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.83 -133.33 2.7 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.351 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -76.5 -35.25 25.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.269 0.557 . . . . 0.0 111.454 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.41 -32.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.74 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.42 152.37 40.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.299 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.16 -160.21 11.7 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.1 -0.572 . . . . 0.0 112.119 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.1 m -144.52 150.46 16.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.228 0.537 . . . . 0.0 110.793 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 63.5 m -71.8 133.14 45.34 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.966 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.322 -0.611 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.345 179.132 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 N-CA-C 111.993 -0.443 . . . . 0.0 111.993 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p -70.65 -37.11 73.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.728 0.299 . . . . 0.0 111.078 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.68 128.14 35.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.072 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.15 -20.74 37.29 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.966 -179.553 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.72 151.25 39.0 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 122.662 0.385 . . . . 0.0 110.807 -179.973 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.5 m -78.72 168.34 19.88 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.7 p -177.02 174.53 1.69 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.856 0.36 . . . . 0.0 110.547 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.47 143.47 22.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.208 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.564 HD11 ' HB3' ' A' ' 23' ' ' PRO . 51.7 mt -54.86 -22.36 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.595 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.0 mt -52.28 -27.67 15.99 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.824 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.486 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.7 -6.78 74.12 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.952 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.0 p -72.37 -25.54 61.55 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.542 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.4 t0 -132.51 66.07 76.03 Favored Pre-proline 0 C--O 1.219 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.978 179.578 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 60.2 Cg_endo -71.98 -145.3 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 121.623 1.549 . . . . 0.0 111.645 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.1 m -141.23 154.97 46.07 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.63 -0.669 . . . . 0.0 112.031 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.46 156.55 22.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.17 120.21 5.21 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.08 0.467 . . . . 0.0 111.041 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.84 -39.99 2.33 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.4 m -106.17 151.56 24.59 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.807 0.337 . . . . 0.0 110.279 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -124.89 147.88 48.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.674 0.273 . . . . 0.0 110.36 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.8 t -73.02 109.4 6.53 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.161 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.7 tp -102.61 123.06 43.96 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.389 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.2 Cg_endo -64.22 130.93 28.53 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.654 2.236 . . . . 0.0 112.822 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.98 -17.83 7.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.571 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.77 -132.68 2.7 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.406 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 18.7 pt -76.87 -35.0 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 121.22 0.534 . . . . 0.0 111.417 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 12.1 p -147.6 -32.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.931 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.4 154.37 37.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.38 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.66 -158.86 10.61 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 121.371 -0.443 . . . . 0.0 112.022 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.8 m -147.74 152.52 12.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.189 0.518 . . . . 0.0 110.829 179.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.505 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 88.9 m -73.43 125.79 28.7 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.506 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.532 HG11 HD22 ' A' ' 22' ' ' LEU . 7.2 p . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.643 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.38 0 N-CA-C 112.038 -0.425 . . . . 0.0 112.038 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.8 p -70.91 -46.57 62.29 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.043 0.449 . . . . 0.0 110.274 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.23 135.73 56.53 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.738 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.69 -26.16 20.52 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.844 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HD3' ' SG ' ' A' ' 15' ' ' CYS . 1.6 mtpm? -55.43 132.93 49.48 Favored 'General case' 0 CA--C 1.512 -0.5 0 CA-C-O 120.691 0.281 . . . . 0.0 111.547 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' HG12 ' A' ' 30' ' ' VAL . 9.7 m -76.13 154.54 35.39 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.671 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.1 p -174.51 -158.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.031 0.444 . . . . 0.0 110.632 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -154.56 153.51 31.54 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.932 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 12.6 tt -53.07 -20.92 2.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 114.448 -1.251 . . . . 0.0 112.565 -179.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 26.6 mt -60.63 -17.73 48.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.337 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.38 16.08 80.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.097 -0.573 . . . . 0.0 111.795 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -74.99 -26.44 59.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.825 0.345 . . . . 0.0 110.565 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.671 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 15.5 t0 -126.37 66.06 60.76 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.095 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -71.28 -151.09 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.248 1.965 . . . . 0.0 111.812 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.51 ' SG ' ' HD3' ' A' ' 5' ' ' LYS . 1.5 m -156.08 179.74 8.93 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.011 -0.43 . . . . 0.0 111.984 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -54.46 156.02 3.62 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 124.211 0.944 . . . . 0.0 111.409 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.06 121.37 5.99 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.817 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.51 -40.55 2.51 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.422 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 12.0 m -91.34 142.11 28.05 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -138.06 154.0 49.29 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 120.621 -0.432 . . . . 0.0 111.619 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.56 117.4 18.17 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.768 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.635 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.3 tp -108.41 124.4 34.63 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.414 -179.441 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.635 ' HD2' HD12 ' A' ' 22' ' ' LEU . 29.0 Cg_endo -63.6 130.91 29.58 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 122.626 2.217 . . . . 0.0 112.391 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -101.66 -21.97 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.107 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.02 -134.44 3.33 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.47 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.493 HG13 HG12 ' A' ' 27' ' ' VAL . 19.7 pt -77.68 -35.23 21.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.311 0.576 . . . . 0.0 110.908 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.493 HG12 HG13 ' A' ' 26' ' ' ILE . 7.7 p -142.76 -37.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.356 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.55 149.91 49.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.069 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.79 -170.99 28.43 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 121.081 -0.581 . . . . 0.0 111.89 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 6' ' ' SER . 13.7 m -148.22 149.9 14.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.933 0.397 . . . . 0.0 110.693 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -67.88 139.41 56.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.593 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 C--N 1.321 -0.648 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.147 178.945 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.461 0 N-CA-C 112.061 -0.415 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.8 p -75.64 -40.8 55.65 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.536 0.208 . . . . 0.0 111.185 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.44 135.57 56.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.729 0.3 . . . . 0.0 111.511 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 -22.48 39.27 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.86 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 33.6 mtpt -57.7 143.08 42.98 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -74.72 143.22 44.24 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.782 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 17.5 p -163.52 -176.4 4.69 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.546 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.1 OUTLIER -156.67 152.17 26.77 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.617 0.722 . . . . 0.0 112.223 178.449 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.2 tt -61.38 -9.95 3.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 113.854 -1.521 . . . . 0.0 112.876 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -60.25 -18.75 50.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.955 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.41 -22.78 22.05 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.633 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.1 p -69.62 -33.22 72.35 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.045 0.45 . . . . 0.0 110.537 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.782 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 1.9 m-20 -121.6 66.29 18.86 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.794 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.6 Cg_endo -76.05 -138.93 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.576 0 C-N-CA 122.225 1.95 . . . . 0.0 111.117 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.9 m -140.3 159.65 41.72 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 121.778 -0.576 . . . . 0.0 112.081 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -62.86 152.24 36.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.163 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.75 124.83 11.82 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 123.433 0.458 . . . . 0.0 111.28 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.84 2.4 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -178.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -101.47 146.9 27.02 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.034 0.445 . . . . 0.0 110.738 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 36.2 p90 -112.79 146.83 38.13 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.2 t -82.68 109.3 16.74 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 36.9 tp -102.79 122.05 47.22 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.553 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.7 Cg_endo -66.4 129.01 20.41 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.534 2.156 . . . . 0.0 112.543 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.46 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 8.4 p -95.52 -20.95 5.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.549 0.69 . . . . 0.0 109.516 179.324 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.76 -133.93 3.23 Favored Glycine 0 N--CA 1.444 -0.81 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.981 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.498 HG13 HG22 ' A' ' 27' ' ' VAL . 21.8 pt -79.03 -40.4 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.037 0.446 . . . . 0.0 111.087 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.498 HG22 HG13 ' A' ' 26' ' ' ILE . 15.9 m -135.21 -34.67 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.26 149.44 44.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.153 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.46 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -164.19 -163.59 17.51 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.078 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -149.48 153.14 11.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.033 0.444 . . . . 0.0 110.747 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.429 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 90.4 m -70.13 143.32 52.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.846 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.463 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 53.1 t . . . . . 0 C--N 1.315 -0.894 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.249 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.422 0 N-CA-C 111.941 -0.463 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.5 p -80.26 -44.63 19.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.51 0.195 . . . . 0.0 111.36 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.3 131.92 52.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.705 0.288 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 100.17 -19.8 51.44 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.307 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 66.0 mttt -62.2 146.31 51.11 Favored 'General case' 0 C--O 1.219 -0.517 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -82.56 144.74 30.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.685 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.9 p -157.34 -179.31 8.06 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.899 0.381 . . . . 0.0 110.853 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 146.0 21.66 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.279 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 41.3 mm -59.25 -13.15 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.621 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -53.96 -27.17 29.66 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.688 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.48 -16.61 60.28 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.28 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.4 p -69.54 -35.59 75.59 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.27 0.557 . . . . 0.0 110.563 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.685 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.8 m-20 -125.08 66.78 52.26 Favored Pre-proline 0 N--CA 1.449 -0.513 0 CA-C-N 115.069 -0.969 . . . . 0.0 111.023 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 88.1 Cg_endo -74.81 -137.17 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.639 0 C-N-CA 122.358 2.039 . . . . 0.0 111.822 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.407 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.9 m -142.0 157.11 45.32 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 121.709 -0.62 . . . . 0.0 112.527 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 4.7 m-20 -60.67 153.37 24.11 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.6 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.4 127.09 18.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 111.225 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.05 -42.7 1.9 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.423 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 65.4 m -98.74 147.58 24.74 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -118.46 147.79 43.24 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.329 179.361 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 43.2 t -73.89 111.44 9.04 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.004 -179.302 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.627 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -102.53 122.92 44.58 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.185 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.627 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.0 Cg_endo -66.36 131.32 26.16 Favored 'Trans proline' 0 N--CA 1.465 -0.195 0 C-N-CA 122.59 2.193 . . . . 0.0 113.045 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.57 -17.13 7.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.403 179.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 -132.48 2.67 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.443 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -76.12 -34.85 27.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.294 0.569 . . . . 0.0 111.44 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 26' ' ' ILE . 12.4 p -149.05 -32.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.728 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.32 151.71 41.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.287 179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.04 -159.57 11.49 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.033 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.79 153.04 13.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.235 0.541 . . . . 0.0 110.674 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 93.6 m -74.3 128.18 34.87 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.934 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.452 HG11 HD22 ' A' ' 22' ' ' LEU . 7.0 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.678 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.094 -0.402 . . . . 0.0 112.094 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.7 p -68.54 -38.45 80.84 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.831 0.348 . . . . 0.0 110.659 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -58.94 125.93 25.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.942 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 110.4 -24.79 17.05 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.951 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.537 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -61.72 148.49 42.7 Favored 'General case' 0 C--O 1.22 -0.494 0 C-N-CA 122.227 0.211 . . . . 0.0 110.518 179.87 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' A' ' 7' ' ' CYS . 11.9 m -79.73 169.78 17.46 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 4.5 p 179.86 179.13 0.54 Allowed 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.72 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.598 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.48 150.83 25.45 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.383 178.677 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.4 mt -54.02 -24.37 10.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.379 -1.282 . . . . 0.0 111.895 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.5 mt -52.15 -25.78 9.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.201 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.62 -4.26 85.94 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.556 -0.83 . . . . 0.0 111.817 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.0 p -72.72 -26.59 61.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.04 0.448 . . . . 0.0 110.486 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.756 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 26.2 t0 -127.58 65.32 66.45 Favored Pre-proline 0 C--O 1.219 -0.51 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.948 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 59.7 Cg_endo -71.3 -145.39 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 121.72 1.614 . . . . 0.0 112.028 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.405 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.7 m -140.93 168.83 18.84 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.654 -0.654 . . . . 0.0 112.141 -178.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.38 155.63 6.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.98 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -54.27 119.68 5.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.926 0.393 . . . . 0.0 110.641 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.78 -37.89 3.59 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 27.5 m -89.49 157.95 17.89 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 30.8 p90 -136.44 149.02 48.05 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.24 -0.584 . . . . 0.0 111.59 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.9 t -73.67 111.85 9.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.76 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 39.0 tp -100.02 119.79 58.55 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.555 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.02 131.9 30.32 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.856 2.37 . . . . 0.0 112.677 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -107.11 -19.2 6.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.962 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.51 -134.3 3.0 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.693 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -75.82 -34.32 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.269 0.556 . . . . 0.0 111.139 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.598 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.8 p -147.1 -35.67 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.316 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.15 150.27 47.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.893 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.23 -163.87 18.19 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.9 m -146.73 152.69 13.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.159 0.504 . . . . 0.0 110.875 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.537 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 40.6 m -71.71 131.97 43.88 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.777 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.321 -0.637 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.191 178.91 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.508 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.474 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.9 p -70.02 -36.52 75.14 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.634 0.254 . . . . 0.0 111.307 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.66 128.79 38.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.771 0.319 . . . . 0.0 111.272 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.02 -20.45 40.79 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.052 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.82 150.59 41.21 Favored 'General case' 0 C--O 1.219 -0.549 0 C-N-CA 122.611 0.364 . . . . 0.0 110.925 179.999 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.3 m -78.01 167.76 20.95 Favored 'General case' 0 C--N 1.314 -0.942 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 178.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.723 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.8 p -176.83 173.1 1.96 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.024 0.44 . . . . 0.0 110.793 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.34 141.26 20.21 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.925 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.408 ' HB ' HG23 ' A' ' 27' ' ' VAL . 46.7 mm -56.4 -19.32 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.579 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.7 mt -52.82 -28.11 21.21 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.544 179.252 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 96.93 -9.26 65.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.781 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.8 p -71.94 -26.49 62.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.651 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.723 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 22.8 t0 -134.39 66.36 70.31 Favored Pre-proline 0 C--O 1.219 -0.536 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.131 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 61.6 Cg_endo -72.6 -144.62 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 121.605 1.537 . . . . 0.0 111.53 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.413 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 74.0 m -140.68 155.3 46.53 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 121.485 -0.759 . . . . 0.0 112.297 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -62.84 156.57 23.69 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.285 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.58 123.45 9.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.061 0.458 . . . . 0.0 111.026 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.83 -40.62 2.41 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 73.7 m -103.79 150.57 23.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.895 0.379 . . . . 0.0 110.342 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -123.99 148.11 47.24 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.376 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 t -73.58 107.39 5.82 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.096 -179.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.623 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -99.42 123.29 48.85 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.257 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.623 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.2 Cg_endo -66.17 130.74 24.89 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.583 2.189 . . . . 0.0 112.893 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -102.82 -17.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.516 -0.766 . . . . 0.0 109.36 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.53 -132.26 2.67 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.408 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.0 pt -76.34 -34.78 25.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.168 0.508 . . . . 0.0 111.447 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 9' ' ' ILE . 13.6 p -149.23 -31.98 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.865 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.26 152.9 39.61 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.96 -157.35 9.62 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 121.307 -0.473 . . . . 0.0 112.101 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.1 m -147.38 152.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.163 0.506 . . . . 0.0 110.758 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.494 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 91.7 m -73.27 125.58 28.12 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.548 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 22' ' ' LEU . 7.3 p . . . . . 0 C--N 1.321 -0.663 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.63 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 111.954 -0.458 . . . . 0.0 111.954 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.6 p -80.35 -43.17 21.61 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.878 0.37 . . . . 0.0 110.673 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.43 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -62.5 134.53 56.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.968 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.88 -19.19 47.73 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.337 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 73.9 mttt -59.79 137.17 58.13 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.206 0.526 . . . . 0.0 111.621 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 p -80.13 137.73 36.78 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.719 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.1 p -163.26 -160.24 0.59 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.681 0.277 . . . . 0.0 110.698 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.8 156.64 35.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.33 0.586 . . . . 0.0 111.708 179.473 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.438 HG22 HG23 ' A' ' 27' ' ' VAL . 11.7 tt -55.88 -16.48 2.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.298 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.99 -21.03 27.29 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.76 -6.41 65.96 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.442 179.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.9 p -71.91 -24.07 61.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.308 0.575 . . . . 0.0 110.275 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -118.72 63.09 5.6 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.177 -178.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.37 -143.74 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.348 2.032 . . . . 0.0 110.963 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -154.86 -171.08 3.71 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.443 -0.786 . . . . 0.0 113.067 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.01 148.37 26.32 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 113.915 -1.493 . . . . 0.0 109.929 -179.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.85 118.18 2.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.07 0.462 . . . . 0.0 111.325 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.65 -35.59 4.44 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.546 -179.075 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 31.1 m -100.77 147.79 25.65 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -132.67 155.89 47.96 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.976 0.417 . . . . 0.0 111.623 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -76.48 118.85 19.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.893 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.425 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -109.05 124.66 33.48 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.402 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 22' ' ' LEU . 25.4 Cg_exo -62.68 131.89 35.35 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.797 2.331 . . . . 0.0 112.499 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.22 -21.57 5.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.375 0.607 . . . . 0.0 110.137 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.51 -135.35 3.35 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.477 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.508 HG13 HG12 ' A' ' 27' ' ' VAL . 20.4 pt -77.35 -35.65 22.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.43 0.633 . . . . 0.0 110.911 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 26' ' ' ILE . 6.8 p -141.84 -38.18 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.133 179.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.03 149.11 50.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -160.62 -176.14 32.4 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.952 -0.642 . . . . 0.0 111.972 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 10.5 m -142.68 147.7 20.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.016 0.436 . . . . 0.0 110.501 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 36.2 m -68.5 138.82 55.51 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.751 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.252 179.242 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.589 0 N-CA-C 112.023 -0.431 . . . . 0.0 112.023 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p -79.22 -42.91 24.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.505 0.193 . . . . 0.0 111.143 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.01 135.83 57.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.92 -21.73 44.49 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.649 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 56.8 mttt -58.02 150.21 21.39 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 m -80.87 144.35 32.05 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.603 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.8 p -160.27 178.5 9.56 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.954 0.407 . . . . 0.0 110.794 -178.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.405 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.57 146.5 23.51 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.409 179.527 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HB ' HG23 ' A' ' 27' ' ' VAL . 41.5 mm -59.37 -14.77 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.558 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.0 -28.17 22.76 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.878 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.93 -16.45 60.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.085 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.4 p -69.83 -36.5 75.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.247 0.546 . . . . 0.0 110.527 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.603 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.2 m-20 -126.39 65.7 59.74 Favored Pre-proline 0 N--CA 1.448 -0.53 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.89 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 86.7 Cg_endo -77.22 -134.84 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.566 0 C-N-CA 122.214 1.943 . . . . 0.0 111.645 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.4 m -139.96 158.78 43.52 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.918 -0.488 . . . . 0.0 112.091 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -61.79 151.05 35.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.48 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.75 120.47 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.039 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.22 -39.93 2.32 Favored Glycine 0 N--CA 1.448 -0.541 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.5 m -101.96 145.42 29.28 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.931 0.396 . . . . 0.0 110.865 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -107.16 148.79 28.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -84.51 112.54 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.669 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.9 tp -102.75 123.23 43.16 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.424 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.669 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.8 Cg_endo -67.03 131.14 24.55 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.583 2.189 . . . . 0.0 112.822 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -101.41 -17.97 6.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.482 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.95 -132.5 2.75 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.311 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.3 pt -76.2 -34.7 26.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.234 0.54 . . . . 0.0 111.383 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 9' ' ' ILE . 12.9 p -148.97 -32.5 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.794 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.17 150.48 42.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.214 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.91 -158.61 11.0 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.108 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.6 m -146.18 151.94 14.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.154 0.502 . . . . 0.0 110.893 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 96.1 m -71.91 144.24 49.04 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.169 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 44.9 t . . . . . 0 C--N 1.317 -0.831 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.211 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.448 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.613 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.3 p -80.84 -49.22 11.35 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.625 0.25 . . . . 0.0 110.989 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.95 141.6 57.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.393 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.37 -18.38 57.58 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.395 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.0 mttp -63.32 166.76 5.95 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.345 0.593 . . . . 0.0 111.988 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -93.57 145.94 24.16 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.646 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.66 -177.29 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.686 0.279 . . . . 0.0 110.447 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.13 147.82 26.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.273 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 13.5 tt -61.21 -14.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.354 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.1 mt -57.52 -25.18 59.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.217 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.15 -13.09 64.33 Favored Glycine 0 C--N 1.33 0.199 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.905 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -68.88 -35.63 77.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.327 0.584 . . . . 0.0 110.35 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.646 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 17.9 m-20 -124.82 67.28 51.15 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.75 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.0 Cg_endo -73.72 -138.08 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.344 2.029 . . . . 0.0 112.15 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 69.2 m -138.18 161.98 35.43 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.724 -0.61 . . . . 0.0 112.126 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.613 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 0.4 OUTLIER -59.38 148.89 30.86 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.333 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.55 120.7 5.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.183 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.92 -39.54 2.45 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.383 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 31.4 m -101.53 149.19 24.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.831 0.348 . . . . 0.0 110.972 179.313 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.456 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.6 p90 -109.94 150.8 27.93 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.365 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -85.84 119.71 26.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.405 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.651 HD12 ' HD2' ' A' ' 23' ' ' PRO . 33.6 tp -111.88 122.54 36.78 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-O 120.551 0.215 . . . . 0.0 110.477 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.651 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.92 130.33 25.67 Favored 'Trans proline' 0 CA--C 1.528 0.214 0 C-N-CA 122.625 2.217 . . . . 0.0 112.655 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.414 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 5.3 p -99.79 -20.74 5.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.537 179.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.71 -133.17 3.1 Favored Glycine 0 N--CA 1.445 -0.737 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.978 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.513 HG13 HG22 ' A' ' 27' ' ' VAL . 21.4 pt -78.9 -40.5 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.015 0.436 . . . . 0.0 111.141 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.513 HG22 HG13 ' A' ' 26' ' ' ILE . 16.0 m -136.18 -33.89 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.011 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.5 153.8 37.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.414 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -165.02 -161.74 14.61 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.3 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -144.68 153.76 14.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.148 0.499 . . . . 0.0 110.544 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 89.4 m -74.1 144.64 44.86 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.372 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.456 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 46.4 t . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.276 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.443 0 N-CA-C 111.98 -0.448 . . . . 0.0 111.98 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.59 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 2.9 p -77.95 -47.71 17.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.538 0.209 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.67 137.68 58.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.477 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.18 -21.73 44.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.523 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.59 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 31.0 mtmt -65.14 166.92 8.84 Favored 'General case' 0 C--O 1.216 -0.664 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 m -91.32 151.46 20.86 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.256 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.56 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 15.2 p -163.86 178.71 7.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.323 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.87 147.69 24.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.931 0.396 . . . . 0.0 110.694 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.2 mt -57.51 -19.3 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.445 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -51.72 -28.77 16.05 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 112.028 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.85 -13.42 66.86 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.145 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -70.25 -36.1 74.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.293 0.568 . . . . 0.0 110.432 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.56 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.9 m-20 -126.46 64.93 57.84 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.91 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.1 Cg_endo -77.76 -139.54 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.557 0 C-N-CA 122.087 1.858 . . . . 0.0 111.626 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.6 m -135.97 154.74 51.0 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 121.84 -0.537 . . . . 0.0 111.606 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -62.32 153.43 30.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.06 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.78 123.24 8.62 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.405 0.441 . . . . 0.0 111.148 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.5 -40.67 2.32 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.0 m -102.78 147.05 27.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.928 0.394 . . . . 0.0 110.753 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 37.2 p90 -111.95 149.98 31.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.27 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.2 t -83.97 114.97 22.08 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.506 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -104.86 122.29 43.84 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.451 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.77 131.06 27.96 Favored 'Trans proline' 0 CA--C 1.527 0.165 0 C-N-CA 122.784 2.323 . . . . 0.0 112.555 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -104.71 -18.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.404 0.621 . . . . 0.0 109.788 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.2 -133.25 2.73 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.569 -0.741 . . . . 0.0 112.496 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -76.11 -35.16 28.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.296 0.57 . . . . 0.0 111.411 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.7 p -147.85 -32.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.715 -179.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.87 152.48 40.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.8 -160.01 11.32 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.096 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.71 152.56 16.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.005 0.431 . . . . 0.0 110.835 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 86.5 m -74.39 143.3 44.87 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.746 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.443 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 48.9 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.346 -179.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.769 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 6.1 p -79.99 -38.17 32.69 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.736 0.303 . . . . 0.0 111.07 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.47 126.84 28.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.642 0.258 . . . . 0.0 110.791 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.99 -13.32 52.73 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.734 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 20.3 mmtp -64.05 170.15 3.82 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-O 121.525 0.679 . . . . 0.0 111.038 179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -105.62 148.3 27.49 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.219 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 12.9 p -162.79 178.27 8.59 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.069 0.462 . . . . 0.0 110.862 -178.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.06 147.53 25.04 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.503 HD11 ' HB3' ' A' ' 23' ' ' PRO . 42.5 mt -56.36 -18.62 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.674 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 77.8 mt -52.7 -27.77 18.97 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.99 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 90.14 -14.88 61.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.233 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.6 p -68.75 -35.9 77.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.411 0.624 . . . . 0.0 110.449 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.571 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.3 m-20 -124.74 67.97 52.12 Favored Pre-proline 0 N--CA 1.448 -0.56 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.8 -178.666 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 71.9 Cg_endo -72.87 -133.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 122.423 2.082 . . . . 0.0 111.949 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.432 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 93.0 m -139.09 157.1 46.56 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -178.549 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.769 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.7 m-20 -62.47 149.75 41.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.209 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.29 119.9 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 123.319 0.387 . . . . 0.0 111.206 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 125.72 -38.45 2.26 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 111.434 -0.667 . . . . 0.0 111.434 -179.161 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.469 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 88.2 m -112.3 154.41 25.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.726 0.298 . . . . 0.0 110.583 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -114.69 150.7 34.82 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.724 0.297 . . . . 0.0 110.425 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.7 t -75.23 115.11 14.52 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.44 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.2 tp -109.17 122.02 41.0 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.027 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.4 Cg_endo -64.37 132.17 32.65 Favored 'Trans proline' 0 CA--C 1.528 0.183 0 C-N-CA 122.734 2.289 . . . . 0.0 112.888 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.4 p -104.96 -17.97 7.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.577 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.59 -132.63 2.71 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.524 -0.762 . . . . 0.0 112.436 -179.703 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.412 HG13 HG12 ' A' ' 27' ' ' VAL . 18.4 pt -76.63 -34.72 24.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.197 0.523 . . . . 0.0 111.383 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.412 HG12 HG13 ' A' ' 26' ' ' ILE . 11.8 p -148.28 -32.88 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.818 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.82 153.22 38.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.503 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.33 -162.74 15.87 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.14 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.96 156.14 22.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.442 0.639 . . . . 0.0 110.448 179.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 89.3 m -80.15 128.1 33.11 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.994 -179.537 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.446 HG11 HD22 ' A' ' 22' ' ' LEU . 7.4 p . . . . . 0 C--N 1.323 -0.583 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.101 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 19' ' ' CYS . 2.9 p -77.57 -42.69 34.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.556 0.217 . . . . 0.0 111.011 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.78 136.78 58.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.108 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -19.55 54.14 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.515 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.6 mttt -60.47 157.31 14.31 Favored 'General case' 0 C--O 1.218 -0.596 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 m -86.87 147.31 25.85 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.709 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.49 -175.15 4.05 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.68 150.26 28.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.859 0.361 . . . . 0.0 110.379 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.47 HG22 HG23 ' A' ' 27' ' ' VAL . 10.2 tp -59.58 -17.11 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.014 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.2 mt -57.64 -24.8 58.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.706 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 85.42 -7.86 74.17 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.512 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.0 p -70.04 -33.77 72.38 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.59 0.71 . . . . 0.0 109.961 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.709 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 18.6 m-20 -124.23 67.02 44.33 Favored Pre-proline 0 C--O 1.217 -0.614 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.289 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 72.4 Cg_endo -73.78 -139.4 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.276 1.984 . . . . 0.0 112.058 -179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.417 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 62.3 m -139.04 162.18 35.57 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.762 -0.586 . . . . 0.0 111.993 -178.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.5 m-20 -60.59 150.14 32.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.488 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.67 120.05 4.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.052 0.453 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.08 -39.58 2.42 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 111.307 -0.717 . . . . 0.0 111.307 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.2 m -102.2 146.83 27.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.983 0.42 . . . . 0.0 110.846 179.396 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -110.21 149.26 30.37 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.324 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 t -84.57 118.14 24.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.342 179.274 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.1 tp -111.97 123.65 34.03 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.729 -0.214 . . . . 0.0 110.576 -179.293 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' A' ' 22' ' ' LEU . 26.7 Cg_endo -62.66 130.75 30.75 Favored 'Trans proline' 0 CA--C 1.529 0.228 0 C-N-CA 122.607 2.204 . . . . 0.0 112.388 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.479 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 4.5 p -102.27 -19.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.08 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.51 -133.63 3.05 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.619 -0.719 . . . . 0.0 112.535 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.511 HG13 HG12 ' A' ' 27' ' ' VAL . 18.6 pt -79.77 -34.03 15.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.162 0.506 . . . . 0.0 111.388 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.511 HG12 HG13 ' A' ' 26' ' ' ILE . 7.6 p -143.07 -35.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.813 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.25 154.94 37.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.835 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -161.82 -163.91 15.68 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 121.263 -0.494 . . . . 0.0 111.948 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.4 m -145.92 152.29 14.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.218 0.532 . . . . 0.0 110.788 179.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 85.4 m -72.91 143.95 47.54 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.035 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.442 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 47.5 t . . . . . 0 C--N 1.316 -0.872 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.222 -179.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.408 0 N-CA-C 112.036 -0.425 . . . . 0.0 112.036 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.552 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 1.9 p -79.63 -37.69 35.52 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.66 141.43 57.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.64 -26.5 22.88 Favored Glycine 0 CA--C 1.52 0.37 0 C-N-CA 120.558 -0.829 . . . . 0.0 113.005 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mptm? -53.22 143.41 18.34 Favored 'General case' 0 C--O 1.217 -0.642 0 C-N-CA 122.87 0.468 . . . . 0.0 112.176 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 m -76.82 143.18 39.95 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.632 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.6 p -158.6 179.13 9.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -178.428 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.43 147.78 23.83 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.621 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.524 HD11 ' HB3' ' A' ' 23' ' ' PRO . 33.6 mt -57.7 -16.74 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.653 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.8 mt -52.41 -27.36 15.54 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.07 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.89 -17.33 57.0 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.184 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.8 p -69.81 -36.13 75.39 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.199 0.523 . . . . 0.0 110.455 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.632 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 2.6 m-20 -123.67 66.5 37.0 Favored Pre-proline 0 C--O 1.218 -0.575 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.52 -179.296 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 89.3 Cg_endo -75.8 -130.71 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.166 1.911 . . . . 0.0 111.712 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.2 m -142.02 160.08 40.94 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.713 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.552 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.1 m-20 -61.59 147.75 44.63 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.977 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.65 114.92 1.71 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.973 0.416 . . . . 0.0 111.087 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.82 -37.44 2.23 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.436 -179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 37.3 m -107.82 149.75 27.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.057 0.456 . . . . 0.0 111.135 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.486 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.1 p90 -105.8 149.28 26.62 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.353 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.8 t -84.42 114.41 21.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.667 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.2 tp -105.97 122.59 41.91 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-O 120.629 0.252 . . . . 0.0 110.581 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.667 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.3 Cg_endo -66.07 131.54 27.28 Favored 'Trans proline' 0 N--CA 1.464 -0.211 0 C-N-CA 122.68 2.253 . . . . 0.0 112.77 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -101.21 -18.3 6.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.447 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.38 -132.49 2.79 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.372 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.0 pt -76.72 -34.9 24.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.186 0.517 . . . . 0.0 111.421 -179.665 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.9 -32.83 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.799 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.7 150.71 41.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.393 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.51 -159.56 12.45 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 121.201 -0.523 . . . . 0.0 112.002 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.62 151.44 13.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.297 0.57 . . . . 0.0 110.919 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 75.2 m -69.98 144.86 52.2 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.399 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 45.1 t . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.204 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.402 0 N-CA-C 112.005 -0.438 . . . . 0.0 112.005 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.51 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 30.3 p -81.69 -44.68 16.79 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.667 0.27 . . . . 0.0 110.946 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -55.97 132.5 50.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.425 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.58 -17.36 58.7 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.651 -0.785 . . . . 0.0 113.036 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 9.2 mttp -57.35 144.58 35.5 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 120.653 0.264 . . . . 0.0 111.505 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.9 m -77.0 141.83 40.19 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.59 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 16.7 p -161.32 177.38 10.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.128 0.489 . . . . 0.0 111.073 -178.499 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.41 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.91 146.18 23.86 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.234 179.508 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.411 ' HB ' HG23 ' A' ' 27' ' ' VAL . 39.4 mm -60.0 -13.26 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.52 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.4 mt -53.42 -28.02 27.64 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.757 179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 94.92 -17.85 58.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.116 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -69.53 -37.04 76.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.313 0.577 . . . . 0.0 110.58 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.59 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 13.3 m-20 -126.7 66.14 63.73 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.856 -178.441 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 83.1 Cg_endo -77.09 -128.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.506 0 C-N-CA 122.187 1.925 . . . . 0.0 111.764 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.441 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 80.0 m -141.41 168.19 20.37 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -59.5 145.89 42.37 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.872 178.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.02 122.71 7.04 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.803 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.19 -37.76 3.65 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.823 -0.626 . . . . 0.0 112.211 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -91.79 154.61 18.81 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.576 0.227 . . . . 0.0 110.518 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 47.2 p90 -112.65 151.2 30.43 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -178.078 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 34.6 t -90.73 115.01 27.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.078 -0.965 . . . . 0.0 108.951 178.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.1 tp -101.15 122.21 49.31 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.479 -179.167 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 38.7 Cg_endo -67.47 131.5 24.84 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.575 2.183 . . . . 0.0 112.839 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -100.61 -18.07 6.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.413 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.44 -132.2 2.76 Favored Glycine 0 N--CA 1.445 -0.725 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.395 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 pt -76.23 -34.76 26.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.179 0.514 . . . . 0.0 111.401 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.411 HG23 ' HB ' ' A' ' 9' ' ' ILE . 14.0 p -149.14 -32.35 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.828 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.43 149.79 42.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.119 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -167.43 -158.34 11.61 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.015 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 28.4 m -145.7 151.37 14.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.314 0.578 . . . . 0.0 110.928 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.489 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 99.2 m -71.78 148.03 46.69 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.744 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 40.3 t . . . . . 0 C--N 1.318 -0.796 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.997 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.053 -0.419 . . . . 0.0 112.053 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.536 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.9 p -76.6 -41.43 46.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.687 0.28 . . . . 0.0 110.905 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.3 135.16 55.94 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.21 -15.33 63.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.328 -179.38 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' HE2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -55.41 145.04 23.49 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 120.87 0.367 . . . . 0.0 111.074 179.954 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.552 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 9.5 m -84.24 147.65 27.14 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.48 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.7 p -167.03 -161.07 0.41 Allowed 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.039 0.447 . . . . 0.0 111.008 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -157.92 158.96 36.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.112 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.484 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.9 mt -53.08 -27.18 13.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.841 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.6 mt -54.07 -24.14 16.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.736 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.98 15.75 81.39 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.0 p -79.05 -19.54 51.13 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.733 0.301 . . . . 0.0 110.721 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.48 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 9.3 t0 -127.94 61.88 54.0 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.242 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.61 -154.83 0.04 OUTLIER 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 121.889 1.726 . . . . 0.0 112.208 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 8.1 m -153.84 157.51 39.43 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.585 0.231 . . . . 0.0 111.065 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -57.05 162.52 2.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.722 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.77 124.6 10.04 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.164 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.2 -40.66 2.38 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -178.534 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 58.5 m -104.94 137.77 42.19 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.919 0.39 . . . . 0.0 110.136 178.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.436 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 36.4 p90 -128.76 143.75 51.0 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.585 -178.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 13.3 t -77.98 114.3 16.72 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 178.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -111.9 129.29 24.36 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.653 -178.75 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.484 ' HG3' HG12 ' A' ' 9' ' ' ILE . 32.1 Cg_exo -59.45 130.52 36.07 Favored 'Trans proline' 0 CA--C 1.528 0.209 0 C-N-CA 122.833 2.355 . . . . 0.0 112.26 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.477 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.9 p -105.7 -21.57 5.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.188 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.18 -138.26 3.63 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.44 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 27' ' ' VAL . 23.2 pt -77.0 -38.23 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.985 0.421 . . . . 0.0 111.188 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 26' ' ' ILE . 15.5 m -136.61 -32.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.847 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.58 154.22 38.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.216 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.477 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -159.51 -175.79 30.85 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 121.196 -0.526 . . . . 0.0 111.834 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.9 m -147.28 147.52 17.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.171 0.51 . . . . 0.0 110.829 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 35.0 m -70.64 147.23 49.4 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.556 179.037 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 21.8 t . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.986 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.571 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.8 p -76.78 -37.15 56.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.708 0.289 . . . . 0.0 111.101 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.96 134.11 53.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.719 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.29 -17.65 58.89 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.306 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.7 ttpt -55.61 144.29 27.07 Favored 'General case' 0 C--O 1.217 -0.655 0 C-N-CA 122.563 0.345 . . . . 0.0 111.599 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.6 m -81.67 147.66 29.41 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.067 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.4 p -165.15 -160.86 0.5 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.859 0.362 . . . . 0.0 110.738 -179.32 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -161.26 154.28 21.06 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.231 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.476 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.0 mt -52.69 -26.76 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 O-C-N 124.471 1.107 . . . . 0.0 111.752 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt -53.56 -22.47 8.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.801 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.446 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 78.82 12.53 84.08 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.767 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -72.78 -32.2 65.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.859 0.362 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.89 63.04 46.27 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.963 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.7 Cg_endo -73.58 -154.43 0.04 OUTLIER 'Trans proline' 0 CA--C 1.532 0.38 0 C-N-CA 121.813 1.676 . . . . 0.0 111.946 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 11.9 m -152.18 152.97 32.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.652 0.263 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.63 166.56 3.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.645 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.77 123.75 9.66 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.004 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.29 -37.38 3.18 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 57.0 m -115.88 138.13 51.45 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.966 0.412 . . . . 0.0 110.377 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.418 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.8 p90 -126.46 143.32 51.23 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.324 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.6 t -77.67 112.79 14.87 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.8 tp -106.72 127.17 28.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.681 -178.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.476 ' HG3' HG12 ' A' ' 9' ' ' ILE . 25.6 Cg_exo -62.64 133.08 40.59 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.932 2.421 . . . . 0.0 112.4 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.74 -19.95 6.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.259 0.552 . . . . 0.0 110.301 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.75 -135.46 3.13 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.651 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.451 HG13 HG12 ' A' ' 27' ' ' VAL . 20.0 pt -75.82 -34.85 28.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.375 0.607 . . . . 0.0 111.163 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.451 HG12 HG13 ' A' ' 26' ' ' ILE . 7.2 p -145.34 -36.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.108 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.09 149.67 50.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.87 -171.29 27.77 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.7 m -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.049 0.452 . . . . 0.0 111.029 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.418 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 23.7 m -71.2 145.49 49.65 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.128 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 33.3 t . . . . . 0 C--N 1.315 -0.903 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.153 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.0 p -77.27 -36.59 54.23 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.624 0.25 . . . . 0.0 111.105 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.69 133.19 53.15 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.627 0.251 . . . . 0.0 110.705 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.41 -16.23 61.13 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.46 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.606 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 1.7 ttpp -55.89 139.53 45.65 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 122.434 0.294 . . . . 0.0 111.676 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.7 m -74.6 147.45 41.64 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.1 p -163.84 -168.1 1.54 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.823 0.344 . . . . 0.0 110.936 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.597 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -162.77 156.63 20.56 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.181 179.861 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.678 HD11 ' HB3' ' A' ' 23' ' ' PRO . 47.1 mm -53.19 -26.32 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.782 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.7 mt -52.97 -25.18 11.18 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.768 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 79.11 12.86 83.6 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.186 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 p -78.0 -26.35 48.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.891 0.377 . . . . 0.0 110.655 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.39 60.15 50.49 Favored Pre-proline 0 C--O 1.223 -0.317 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.76 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -79.5 -153.8 0.05 OUTLIER 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 121.777 1.651 . . . . 0.0 112.374 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 22.3 m -152.43 148.1 27.05 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -68.79 -176.73 0.87 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.679 -178.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.03 125.7 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.926 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.33 -34.0 4.46 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 68.9 m -129.28 139.91 51.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.055 0.455 . . . . 0.0 110.764 179.619 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.9 p90 -124.98 142.79 51.25 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.184 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.7 t -76.82 114.24 15.37 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.676 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.4 tp -108.22 126.02 30.62 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.503 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.678 ' HB3' HD11 ' A' ' 9' ' ' ILE . 32.9 Cg_endo -64.77 133.36 36.08 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.678 2.252 . . . . 0.0 112.861 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 p -107.04 -18.94 6.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.614 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.16 -135.09 3.12 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.283 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.434 HG13 HG12 ' A' ' 27' ' ' VAL . 20.9 pt -76.77 -36.13 25.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.373 0.606 . . . . 0.0 111.056 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.597 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.1 p -143.07 -36.37 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.165 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.31 148.13 52.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.45 -167.64 26.37 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -147.31 147.84 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.096 0.475 . . . . 0.0 111.018 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 22.3 m -70.75 146.52 49.78 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.213 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 29.1 t . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.211 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.506 0 N-CA-C 111.995 -0.442 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 25.9 p -69.81 -38.16 76.5 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.782 0.325 . . . . 0.0 110.895 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.7 129.6 42.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.017 -179.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.23 -25.42 27.81 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.52 -0.848 . . . . 0.0 112.789 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.464 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -56.98 150.86 15.98 Favored 'General case' 0 C--O 1.216 -0.684 0 C-N-CA 122.554 0.341 . . . . 0.0 110.525 179.792 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.8 m -75.2 165.99 24.34 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 178.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 6.1 p -178.1 172.83 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.886 0.374 . . . . 0.0 110.571 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.528 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.92 149.33 23.23 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.522 178.965 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.892 HD11 ' HG3' ' A' ' 23' ' ' PRO . 49.7 mm -53.88 -23.21 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 114.334 -1.303 . . . . 0.0 111.756 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.8 mt -51.57 -24.49 5.41 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.194 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.07 -8.42 76.59 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.842 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.7 t -74.29 -21.09 59.9 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.9 t0 -135.88 63.9 53.81 Favored Pre-proline 0 C--O 1.217 -0.611 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.102 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 74.9 Cg_endo -75.89 -142.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.532 0 C-N-CA 121.327 1.351 . . . . 0.0 111.265 179.393 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 61.6 m -139.34 164.34 30.09 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 121.802 -0.561 . . . . 0.0 111.624 -178.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.42 158.28 9.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.239 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.81 122.17 9.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.906 0.384 . . . . 0.0 110.943 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.97 -34.05 6.09 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.557 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 32.1 m -89.1 151.01 22.47 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.1 p90 -124.89 145.88 49.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 10.5 t -83.22 107.22 15.61 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.044 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 34.9 tp -93.82 123.55 59.3 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.557 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.892 ' HG3' HD11 ' A' ' 9' ' ' ILE . 13.7 Cg_exo -68.19 131.15 22.87 Favored 'Trans proline' 0 N--CA 1.464 -0.222 0 C-N-CA 122.662 2.241 . . . . 0.0 112.561 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -105.45 -18.35 7.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.398 0.618 . . . . 0.0 109.551 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.32 -135.11 2.96 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.275 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.427 HG13 HG12 ' A' ' 27' ' ' VAL . 21.0 pt -77.23 -36.41 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.237 0.542 . . . . 0.0 111.262 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.528 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.2 p -142.4 -35.36 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.312 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.49 148.81 47.85 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.886 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.15 -162.42 16.23 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.2 m -146.69 149.4 15.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.235 0.54 . . . . 0.0 111.082 179.289 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.464 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 39.2 m -69.56 142.8 53.54 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.932 179.142 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.432 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 59.7 t . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.059 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 111.939 -0.464 . . . . 0.0 111.939 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.498 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 5.9 p -80.13 -43.77 21.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.699 0.285 . . . . 0.0 110.936 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -60.37 132.79 55.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.36 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.68 -21.43 36.63 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.29 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -61.14 144.07 54.3 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 t -88.52 151.23 22.65 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.443 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.717 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 28.3 p -167.16 -166.23 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 O-C-N 123.23 0.331 . . . . 0.0 110.233 -179.114 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.31 153.22 31.29 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.405 0.622 . . . . 0.0 111.7 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.592 HG22 HG23 ' A' ' 27' ' ' VAL . 7.8 tp -58.33 -11.73 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.148 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -59.09 -20.77 56.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.495 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.69 -20.01 30.08 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.611 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 m -66.34 -26.88 67.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.942 0.401 . . . . 0.0 110.498 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.717 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 25.2 m-20 -118.46 66.28 6.6 Favored Pre-proline 0 C--O 1.221 -0.44 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.445 -179.278 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 56.6 Cg_endo -70.05 -146.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.254 1.969 . . . . 0.0 111.829 179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 70.3 m -143.31 165.29 27.88 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 121.593 -0.692 . . . . 0.0 111.727 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.9 m-20 -62.81 154.34 30.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.691 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.381 0.426 . . . . 0.0 111.197 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.94 -39.56 2.81 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 64.1 m -105.88 148.74 27.25 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.801 0.334 . . . . 0.0 110.595 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -123.54 147.08 47.6 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.222 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.6 t -73.47 109.37 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.016 -179.351 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.638 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.8 tp -105.49 124.7 35.5 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.582 -179.443 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.68 131.29 28.93 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.59 2.193 . . . . 0.0 112.304 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.417 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.0 p -102.89 -20.57 5.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.983 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.66 -134.39 3.24 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.451 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.503 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -77.85 -34.78 20.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.359 0.599 . . . . 0.0 111.021 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.592 HG23 HG22 ' A' ' 9' ' ' ILE . 7.2 p -143.34 -37.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.381 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.73 149.14 50.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.955 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.417 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -158.36 -169.4 21.83 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.079 -0.581 . . . . 0.0 112.057 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.4 m -146.97 151.03 14.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.092 0.472 . . . . 0.0 111.062 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 94.2 m -72.96 124.61 25.79 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.359 179.442 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--N 1.321 -0.666 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.722 179.209 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 29.6 p . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.763 0.316 . . . . 0.0 110.757 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -57.0 130.29 45.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.422 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.53 -16.55 58.75 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.416 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.1 mttt -63.58 142.68 58.31 Favored 'General case' 0 CA--C 1.512 -0.483 0 CA-C-O 120.965 0.412 . . . . 0.0 111.934 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 p -78.48 139.99 38.64 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.673 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.7 p -156.44 179.21 9.47 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.903 0.382 . . . . 0.0 110.794 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.63 146.76 22.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.301 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.8 mm -59.11 -14.41 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 115.483 -0.781 . . . . 0.0 111.663 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.5 mt -53.3 -28.08 26.35 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.751 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.59 -14.45 65.26 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.196 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.6 p -69.98 -35.54 74.49 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.26 0.553 . . . . 0.0 110.585 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.673 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 15.2 m-20 -125.27 65.93 51.21 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.076 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 95.2 Cg_endo -76.04 -137.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.329 2.019 . . . . 0.0 111.932 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -138.83 166.81 23.45 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 121.842 -0.536 . . . . 0.0 112.078 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -60.17 153.92 20.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.743 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.84 125.2 14.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.972 0.415 . . . . 0.0 111.264 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.0 -40.37 2.52 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 29.1 m -90.1 158.58 17.22 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -132.51 149.38 52.34 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.452 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.7 t -75.64 113.47 13.11 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.125 -0.943 . . . . 0.0 109.883 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.599 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.7 tp -100.37 122.18 50.82 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.089 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HD2' HD12 ' A' ' 22' ' ' LEU . 31.5 Cg_endo -64.43 131.71 30.9 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.704 2.27 . . . . 0.0 113.106 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.18 -17.16 7.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.396 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.83 -133.33 2.7 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.351 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -76.5 -35.25 25.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.269 0.557 . . . . 0.0 111.454 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.41 -32.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.74 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.42 152.37 40.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.299 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.16 -160.21 11.7 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.1 -0.572 . . . . 0.0 112.119 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.1 m -144.52 150.46 16.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.228 0.537 . . . . 0.0 110.793 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 63.5 m -71.8 133.14 45.34 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.966 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.322 -0.611 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.345 179.132 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p . . . . . 0 N--CA 1.456 -0.16 0 CA-C-O 120.728 0.299 . . . . 0.0 111.078 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.68 128.14 35.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.072 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.15 -20.74 37.29 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.966 -179.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.72 151.25 39.0 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 122.662 0.385 . . . . 0.0 110.807 -179.973 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.5 m -78.72 168.34 19.88 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.7 p -177.02 174.53 1.69 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.856 0.36 . . . . 0.0 110.547 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.47 143.47 22.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.208 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.564 HD11 ' HB3' ' A' ' 23' ' ' PRO . 51.7 mt -54.86 -22.36 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.595 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.0 mt -52.28 -27.67 15.99 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.824 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.486 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.7 -6.78 74.12 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.952 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.0 p -72.37 -25.54 61.55 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.542 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.4 t0 -132.51 66.07 76.03 Favored Pre-proline 0 C--O 1.219 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.978 179.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 60.2 Cg_endo -71.98 -145.3 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 121.623 1.549 . . . . 0.0 111.645 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.1 m -141.23 154.97 46.07 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.63 -0.669 . . . . 0.0 112.031 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.46 156.55 22.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.17 120.21 5.21 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.08 0.467 . . . . 0.0 111.041 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.84 -39.99 2.33 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.4 m -106.17 151.56 24.59 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.807 0.337 . . . . 0.0 110.279 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -124.89 147.88 48.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.674 0.273 . . . . 0.0 110.36 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.8 t -73.02 109.4 6.53 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.161 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.7 tp -102.61 123.06 43.96 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.389 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.2 Cg_endo -64.22 130.93 28.53 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.654 2.236 . . . . 0.0 112.822 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.98 -17.83 7.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.571 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.77 -132.68 2.7 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.406 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 18.7 pt -76.87 -35.0 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 121.22 0.534 . . . . 0.0 111.417 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 12.1 p -147.6 -32.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.931 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.4 154.37 37.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.38 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.66 -158.86 10.61 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 121.371 -0.443 . . . . 0.0 112.022 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.8 m -147.74 152.52 12.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.189 0.518 . . . . 0.0 110.829 179.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.505 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 88.9 m -73.43 125.79 28.7 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.506 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.532 HG11 HD22 ' A' ' 22' ' ' LEU . 7.2 p . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.643 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.8 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 121.043 0.449 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.23 135.73 56.53 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.738 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.69 -26.16 20.52 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.844 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HD3' ' SG ' ' A' ' 15' ' ' CYS . 1.6 mtpm? -55.43 132.93 49.48 Favored 'General case' 0 CA--C 1.512 -0.5 0 CA-C-O 120.691 0.281 . . . . 0.0 111.547 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' HG12 ' A' ' 30' ' ' VAL . 9.7 m -76.13 154.54 35.39 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.671 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.1 p -174.51 -158.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.031 0.444 . . . . 0.0 110.632 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.56 153.51 31.54 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.932 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 12.6 tt -53.07 -20.92 2.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 114.448 -1.251 . . . . 0.0 112.565 -179.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 26.6 mt -60.63 -17.73 48.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.337 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.38 16.08 80.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.097 -0.573 . . . . 0.0 111.795 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -74.99 -26.44 59.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.825 0.345 . . . . 0.0 110.565 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.671 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 15.5 t0 -126.37 66.06 60.76 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.095 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -71.28 -151.09 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.248 1.965 . . . . 0.0 111.812 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.51 ' SG ' ' HD3' ' A' ' 5' ' ' LYS . 1.5 m -156.08 179.74 8.93 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.011 -0.43 . . . . 0.0 111.984 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -54.46 156.02 3.62 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 124.211 0.944 . . . . 0.0 111.409 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.06 121.37 5.99 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.817 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.51 -40.55 2.51 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.422 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 12.0 m -91.34 142.11 28.05 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -138.06 154.0 49.29 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 120.621 -0.432 . . . . 0.0 111.619 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.56 117.4 18.17 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.768 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.635 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.3 tp -108.41 124.4 34.63 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.414 -179.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.635 ' HD2' HD12 ' A' ' 22' ' ' LEU . 29.0 Cg_endo -63.6 130.91 29.58 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 122.626 2.217 . . . . 0.0 112.391 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -101.66 -21.97 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.107 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.02 -134.44 3.33 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.47 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.493 HG13 HG12 ' A' ' 27' ' ' VAL . 19.7 pt -77.68 -35.23 21.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.311 0.576 . . . . 0.0 110.908 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.493 HG12 HG13 ' A' ' 26' ' ' ILE . 7.7 p -142.76 -37.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.356 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.55 149.91 49.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.069 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.79 -170.99 28.43 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 121.081 -0.581 . . . . 0.0 111.89 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 6' ' ' SER . 13.7 m -148.22 149.9 14.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.933 0.397 . . . . 0.0 110.693 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -67.88 139.41 56.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.593 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 C--N 1.321 -0.648 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.147 178.945 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.8 p . . . . . 0 N--CA 1.455 -0.186 0 CA-C-O 120.536 0.208 . . . . 0.0 111.185 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.44 135.57 56.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.729 0.3 . . . . 0.0 111.511 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 -22.48 39.27 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.86 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 33.6 mtpt -57.7 143.08 42.98 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -74.72 143.22 44.24 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.782 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 17.5 p -163.52 -176.4 4.69 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.546 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.1 OUTLIER -156.67 152.17 26.77 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.617 0.722 . . . . 0.0 112.223 178.449 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.2 tt -61.38 -9.95 3.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 113.854 -1.521 . . . . 0.0 112.876 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -60.25 -18.75 50.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.955 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.41 -22.78 22.05 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.633 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.1 p -69.62 -33.22 72.35 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.045 0.45 . . . . 0.0 110.537 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.782 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 1.9 m-20 -121.6 66.29 18.86 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.794 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.6 Cg_endo -76.05 -138.93 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.576 0 C-N-CA 122.225 1.95 . . . . 0.0 111.117 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.9 m -140.3 159.65 41.72 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 121.778 -0.576 . . . . 0.0 112.081 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -62.86 152.24 36.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.163 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.75 124.83 11.82 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 123.433 0.458 . . . . 0.0 111.28 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.84 2.4 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -178.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -101.47 146.9 27.02 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.034 0.445 . . . . 0.0 110.738 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 36.2 p90 -112.79 146.83 38.13 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.2 t -82.68 109.3 16.74 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 36.9 tp -102.79 122.05 47.22 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.553 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.7 Cg_endo -66.4 129.01 20.41 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.534 2.156 . . . . 0.0 112.543 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.46 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 8.4 p -95.52 -20.95 5.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.549 0.69 . . . . 0.0 109.516 179.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.76 -133.93 3.23 Favored Glycine 0 N--CA 1.444 -0.81 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.981 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.498 HG13 HG22 ' A' ' 27' ' ' VAL . 21.8 pt -79.03 -40.4 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.037 0.446 . . . . 0.0 111.087 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.498 HG22 HG13 ' A' ' 26' ' ' ILE . 15.9 m -135.21 -34.67 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.26 149.44 44.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.153 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.46 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -164.19 -163.59 17.51 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.078 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -149.48 153.14 11.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.033 0.444 . . . . 0.0 110.747 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.429 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 90.4 m -70.13 143.32 52.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.846 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.463 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 53.1 t . . . . . 0 C--N 1.315 -0.894 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.249 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.5 p . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 120.51 0.195 . . . . 0.0 111.36 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.3 131.92 52.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.705 0.288 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 100.17 -19.8 51.44 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.307 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 66.0 mttt -62.2 146.31 51.11 Favored 'General case' 0 C--O 1.219 -0.517 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -82.56 144.74 30.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.685 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.9 p -157.34 -179.31 8.06 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.899 0.381 . . . . 0.0 110.853 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 146.0 21.66 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.279 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 41.3 mm -59.25 -13.15 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.621 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -53.96 -27.17 29.66 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.688 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.48 -16.61 60.28 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.28 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.4 p -69.54 -35.59 75.59 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.27 0.557 . . . . 0.0 110.563 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.685 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.8 m-20 -125.08 66.78 52.26 Favored Pre-proline 0 N--CA 1.449 -0.513 0 CA-C-N 115.069 -0.969 . . . . 0.0 111.023 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 88.1 Cg_endo -74.81 -137.17 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.639 0 C-N-CA 122.358 2.039 . . . . 0.0 111.822 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.407 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.9 m -142.0 157.11 45.32 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 121.709 -0.62 . . . . 0.0 112.527 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 4.7 m-20 -60.67 153.37 24.11 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.6 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.4 127.09 18.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 111.225 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.05 -42.7 1.9 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.423 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 65.4 m -98.74 147.58 24.74 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -118.46 147.79 43.24 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.329 179.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 43.2 t -73.89 111.44 9.04 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.004 -179.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.627 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -102.53 122.92 44.58 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.185 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.627 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.0 Cg_endo -66.36 131.32 26.16 Favored 'Trans proline' 0 N--CA 1.465 -0.195 0 C-N-CA 122.59 2.193 . . . . 0.0 113.045 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.57 -17.13 7.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.403 179.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 -132.48 2.67 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.443 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -76.12 -34.85 27.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.294 0.569 . . . . 0.0 111.44 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 26' ' ' ILE . 12.4 p -149.05 -32.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.728 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.32 151.71 41.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.287 179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.04 -159.57 11.49 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.033 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.79 153.04 13.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.235 0.541 . . . . 0.0 110.674 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 93.6 m -74.3 128.18 34.87 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.934 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.452 HG11 HD22 ' A' ' 22' ' ' LEU . 7.0 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.678 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.7 p . . . . . 0 N--CA 1.456 -0.154 0 CA-C-O 120.831 0.348 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -58.94 125.93 25.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.942 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 110.4 -24.79 17.05 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.951 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.537 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -61.72 148.49 42.7 Favored 'General case' 0 C--O 1.22 -0.494 0 C-N-CA 122.227 0.211 . . . . 0.0 110.518 179.87 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' A' ' 7' ' ' CYS . 11.9 m -79.73 169.78 17.46 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 4.5 p 179.86 179.13 0.54 Allowed 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.72 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.598 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.48 150.83 25.45 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.383 178.677 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.4 mt -54.02 -24.37 10.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.379 -1.282 . . . . 0.0 111.895 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.5 mt -52.15 -25.78 9.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.201 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.62 -4.26 85.94 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.556 -0.83 . . . . 0.0 111.817 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.0 p -72.72 -26.59 61.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.04 0.448 . . . . 0.0 110.486 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.756 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 26.2 t0 -127.58 65.32 66.45 Favored Pre-proline 0 C--O 1.219 -0.51 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.948 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 59.7 Cg_endo -71.3 -145.39 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 121.72 1.614 . . . . 0.0 112.028 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.405 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.7 m -140.93 168.83 18.84 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.654 -0.654 . . . . 0.0 112.141 -178.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.38 155.63 6.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.98 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -54.27 119.68 5.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.926 0.393 . . . . 0.0 110.641 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.78 -37.89 3.59 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 27.5 m -89.49 157.95 17.89 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 30.8 p90 -136.44 149.02 48.05 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.24 -0.584 . . . . 0.0 111.59 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.9 t -73.67 111.85 9.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.76 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 39.0 tp -100.02 119.79 58.55 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.555 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.02 131.9 30.32 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.856 2.37 . . . . 0.0 112.677 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -107.11 -19.2 6.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.962 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.51 -134.3 3.0 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.693 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -75.82 -34.32 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.269 0.556 . . . . 0.0 111.139 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.598 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.8 p -147.1 -35.67 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.316 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.15 150.27 47.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.893 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.23 -163.87 18.19 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.9 m -146.73 152.69 13.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.159 0.504 . . . . 0.0 110.875 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.537 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 40.6 m -71.71 131.97 43.88 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.777 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.321 -0.637 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.191 178.91 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.474 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.9 p . . . . . 0 N--CA 1.456 -0.126 0 CA-C-O 120.634 0.254 . . . . 0.0 111.307 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.66 128.79 38.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.771 0.319 . . . . 0.0 111.272 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.02 -20.45 40.79 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.052 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.82 150.59 41.21 Favored 'General case' 0 C--O 1.219 -0.549 0 C-N-CA 122.611 0.364 . . . . 0.0 110.925 179.999 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.3 m -78.01 167.76 20.95 Favored 'General case' 0 C--N 1.314 -0.942 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 178.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.723 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.8 p -176.83 173.1 1.96 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.024 0.44 . . . . 0.0 110.793 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.34 141.26 20.21 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.925 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.408 ' HB ' HG23 ' A' ' 27' ' ' VAL . 46.7 mm -56.4 -19.32 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.579 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.7 mt -52.82 -28.11 21.21 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.544 179.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 96.93 -9.26 65.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.781 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.8 p -71.94 -26.49 62.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.651 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.723 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 22.8 t0 -134.39 66.36 70.31 Favored Pre-proline 0 C--O 1.219 -0.536 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.131 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 61.6 Cg_endo -72.6 -144.62 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 121.605 1.537 . . . . 0.0 111.53 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.413 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 74.0 m -140.68 155.3 46.53 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 121.485 -0.759 . . . . 0.0 112.297 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -62.84 156.57 23.69 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.285 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.58 123.45 9.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.061 0.458 . . . . 0.0 111.026 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.83 -40.62 2.41 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 73.7 m -103.79 150.57 23.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.895 0.379 . . . . 0.0 110.342 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -123.99 148.11 47.24 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.376 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 t -73.58 107.39 5.82 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.096 -179.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.623 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -99.42 123.29 48.85 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.257 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.623 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.2 Cg_endo -66.17 130.74 24.89 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.583 2.189 . . . . 0.0 112.893 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -102.82 -17.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.516 -0.766 . . . . 0.0 109.36 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.53 -132.26 2.67 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.408 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.0 pt -76.34 -34.78 25.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.168 0.508 . . . . 0.0 111.447 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 9' ' ' ILE . 13.6 p -149.23 -31.98 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.865 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.26 152.9 39.61 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.96 -157.35 9.62 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 121.307 -0.473 . . . . 0.0 112.101 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.1 m -147.38 152.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.163 0.506 . . . . 0.0 110.758 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.494 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 91.7 m -73.27 125.58 28.12 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.548 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 22' ' ' LEU . 7.3 p . . . . . 0 C--N 1.321 -0.663 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.63 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 N--CA 1.451 -0.384 0 CA-C-O 120.878 0.37 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.43 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -62.5 134.53 56.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.968 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.88 -19.19 47.73 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.337 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 73.9 mttt -59.79 137.17 58.13 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.206 0.526 . . . . 0.0 111.621 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 p -80.13 137.73 36.78 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.719 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.1 p -163.26 -160.24 0.59 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.681 0.277 . . . . 0.0 110.698 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.8 156.64 35.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.33 0.586 . . . . 0.0 111.708 179.473 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.438 HG22 HG23 ' A' ' 27' ' ' VAL . 11.7 tt -55.88 -16.48 2.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.298 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.99 -21.03 27.29 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.76 -6.41 65.96 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.442 179.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.9 p -71.91 -24.07 61.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.308 0.575 . . . . 0.0 110.275 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -118.72 63.09 5.6 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.177 -178.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.37 -143.74 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.348 2.032 . . . . 0.0 110.963 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -154.86 -171.08 3.71 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.443 -0.786 . . . . 0.0 113.067 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.01 148.37 26.32 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 113.915 -1.493 . . . . 0.0 109.929 -179.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.85 118.18 2.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.07 0.462 . . . . 0.0 111.325 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.65 -35.59 4.44 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.546 -179.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 31.1 m -100.77 147.79 25.65 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -132.67 155.89 47.96 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.976 0.417 . . . . 0.0 111.623 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -76.48 118.85 19.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.893 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.425 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -109.05 124.66 33.48 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.402 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 22' ' ' LEU . 25.4 Cg_exo -62.68 131.89 35.35 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.797 2.331 . . . . 0.0 112.499 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.22 -21.57 5.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.375 0.607 . . . . 0.0 110.137 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.51 -135.35 3.35 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.477 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.508 HG13 HG12 ' A' ' 27' ' ' VAL . 20.4 pt -77.35 -35.65 22.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.43 0.633 . . . . 0.0 110.911 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 26' ' ' ILE . 6.8 p -141.84 -38.18 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.133 179.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.03 149.11 50.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -160.62 -176.14 32.4 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.952 -0.642 . . . . 0.0 111.972 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 10.5 m -142.68 147.7 20.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.016 0.436 . . . . 0.0 110.501 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 36.2 m -68.5 138.82 55.51 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.751 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.252 179.242 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p . . . . . 0 N--CA 1.454 -0.255 0 CA-C-O 120.505 0.193 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.01 135.83 57.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.92 -21.73 44.49 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.649 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 56.8 mttt -58.02 150.21 21.39 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 m -80.87 144.35 32.05 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.603 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.8 p -160.27 178.5 9.56 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.954 0.407 . . . . 0.0 110.794 -178.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.405 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.57 146.5 23.51 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.409 179.527 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HB ' HG23 ' A' ' 27' ' ' VAL . 41.5 mm -59.37 -14.77 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.558 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.0 -28.17 22.76 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.878 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.93 -16.45 60.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.085 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.4 p -69.83 -36.5 75.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.247 0.546 . . . . 0.0 110.527 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.603 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.2 m-20 -126.39 65.7 59.74 Favored Pre-proline 0 N--CA 1.448 -0.53 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.89 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 86.7 Cg_endo -77.22 -134.84 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.566 0 C-N-CA 122.214 1.943 . . . . 0.0 111.645 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.4 m -139.96 158.78 43.52 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.918 -0.488 . . . . 0.0 112.091 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -61.79 151.05 35.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.48 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.75 120.47 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.039 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.22 -39.93 2.32 Favored Glycine 0 N--CA 1.448 -0.541 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.5 m -101.96 145.42 29.28 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.931 0.396 . . . . 0.0 110.865 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -107.16 148.79 28.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -84.51 112.54 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.669 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.9 tp -102.75 123.23 43.16 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.424 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.669 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.8 Cg_endo -67.03 131.14 24.55 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.583 2.189 . . . . 0.0 112.822 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -101.41 -17.97 6.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.482 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.95 -132.5 2.75 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.311 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.3 pt -76.2 -34.7 26.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.234 0.54 . . . . 0.0 111.383 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 9' ' ' ILE . 12.9 p -148.97 -32.5 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.794 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.17 150.48 42.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.214 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.91 -158.61 11.0 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.108 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.6 m -146.18 151.94 14.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.154 0.502 . . . . 0.0 110.893 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 96.1 m -71.91 144.24 49.04 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.169 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 44.9 t . . . . . 0 C--N 1.317 -0.831 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.211 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.613 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.3 p . . . . . 0 N--CA 1.452 -0.355 0 CA-C-O 120.625 0.25 . . . . 0.0 110.989 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.95 141.6 57.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.393 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.37 -18.38 57.58 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.395 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.0 mttp -63.32 166.76 5.95 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.345 0.593 . . . . 0.0 111.988 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -93.57 145.94 24.16 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.646 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.66 -177.29 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.686 0.279 . . . . 0.0 110.447 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.13 147.82 26.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.273 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 13.5 tt -61.21 -14.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.354 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.1 mt -57.52 -25.18 59.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.217 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.15 -13.09 64.33 Favored Glycine 0 C--N 1.33 0.199 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.905 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -68.88 -35.63 77.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.327 0.584 . . . . 0.0 110.35 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.646 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 17.9 m-20 -124.82 67.28 51.15 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.75 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.0 Cg_endo -73.72 -138.08 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.344 2.029 . . . . 0.0 112.15 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 69.2 m -138.18 161.98 35.43 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.724 -0.61 . . . . 0.0 112.126 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.613 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 0.4 OUTLIER -59.38 148.89 30.86 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.333 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.55 120.7 5.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.183 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.92 -39.54 2.45 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.383 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 31.4 m -101.53 149.19 24.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.831 0.348 . . . . 0.0 110.972 179.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.456 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.6 p90 -109.94 150.8 27.93 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.365 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -85.84 119.71 26.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.405 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.651 HD12 ' HD2' ' A' ' 23' ' ' PRO . 33.6 tp -111.88 122.54 36.78 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-O 120.551 0.215 . . . . 0.0 110.477 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.651 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.92 130.33 25.67 Favored 'Trans proline' 0 CA--C 1.528 0.214 0 C-N-CA 122.625 2.217 . . . . 0.0 112.655 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.414 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 5.3 p -99.79 -20.74 5.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.537 179.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.71 -133.17 3.1 Favored Glycine 0 N--CA 1.445 -0.737 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.978 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.513 HG13 HG22 ' A' ' 27' ' ' VAL . 21.4 pt -78.9 -40.5 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.015 0.436 . . . . 0.0 111.141 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.513 HG22 HG13 ' A' ' 26' ' ' ILE . 16.0 m -136.18 -33.89 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.011 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.5 153.8 37.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.414 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -165.02 -161.74 14.61 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.3 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -144.68 153.76 14.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.148 0.499 . . . . 0.0 110.544 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 89.4 m -74.1 144.64 44.86 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.372 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.456 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 46.4 t . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.276 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.59 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 2.9 p . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 120.538 0.209 . . . . 0.0 110.958 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.67 137.68 58.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.477 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.18 -21.73 44.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.523 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.59 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 31.0 mtmt -65.14 166.92 8.84 Favored 'General case' 0 C--O 1.216 -0.664 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 m -91.32 151.46 20.86 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.256 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.56 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 15.2 p -163.86 178.71 7.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.323 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.87 147.69 24.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.931 0.396 . . . . 0.0 110.694 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.2 mt -57.51 -19.3 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.445 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -51.72 -28.77 16.05 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 112.028 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.85 -13.42 66.86 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.145 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -70.25 -36.1 74.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.293 0.568 . . . . 0.0 110.432 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.56 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.9 m-20 -126.46 64.93 57.84 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.91 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.1 Cg_endo -77.76 -139.54 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.557 0 C-N-CA 122.087 1.858 . . . . 0.0 111.626 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.6 m -135.97 154.74 51.0 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 121.84 -0.537 . . . . 0.0 111.606 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -62.32 153.43 30.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.06 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.78 123.24 8.62 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.405 0.441 . . . . 0.0 111.148 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.5 -40.67 2.32 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.0 m -102.78 147.05 27.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.928 0.394 . . . . 0.0 110.753 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 37.2 p90 -111.95 149.98 31.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.27 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.2 t -83.97 114.97 22.08 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.506 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -104.86 122.29 43.84 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.451 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.77 131.06 27.96 Favored 'Trans proline' 0 CA--C 1.527 0.165 0 C-N-CA 122.784 2.323 . . . . 0.0 112.555 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -104.71 -18.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.404 0.621 . . . . 0.0 109.788 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.2 -133.25 2.73 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.569 -0.741 . . . . 0.0 112.496 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -76.11 -35.16 28.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.296 0.57 . . . . 0.0 111.411 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.7 p -147.85 -32.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.715 -179.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.87 152.48 40.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.8 -160.01 11.32 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.096 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.71 152.56 16.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.005 0.431 . . . . 0.0 110.835 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 86.5 m -74.39 143.3 44.87 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.746 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.443 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 48.9 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.346 -179.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.769 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 6.1 p . . . . . 0 N--CA 1.453 -0.281 0 CA-C-O 120.736 0.303 . . . . 0.0 111.07 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.47 126.84 28.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.642 0.258 . . . . 0.0 110.791 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.99 -13.32 52.73 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.734 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 20.3 mmtp -64.05 170.15 3.82 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-O 121.525 0.679 . . . . 0.0 111.038 179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -105.62 148.3 27.49 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.219 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 12.9 p -162.79 178.27 8.59 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.069 0.462 . . . . 0.0 110.862 -178.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.06 147.53 25.04 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.503 HD11 ' HB3' ' A' ' 23' ' ' PRO . 42.5 mt -56.36 -18.62 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.674 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 77.8 mt -52.7 -27.77 18.97 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.99 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 90.14 -14.88 61.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.233 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.6 p -68.75 -35.9 77.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.411 0.624 . . . . 0.0 110.449 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.571 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.3 m-20 -124.74 67.97 52.12 Favored Pre-proline 0 N--CA 1.448 -0.56 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.8 -178.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 71.9 Cg_endo -72.87 -133.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 122.423 2.082 . . . . 0.0 111.949 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.432 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 93.0 m -139.09 157.1 46.56 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -178.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.769 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.7 m-20 -62.47 149.75 41.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.209 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.29 119.9 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 123.319 0.387 . . . . 0.0 111.206 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 125.72 -38.45 2.26 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 111.434 -0.667 . . . . 0.0 111.434 -179.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.469 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 88.2 m -112.3 154.41 25.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.726 0.298 . . . . 0.0 110.583 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -114.69 150.7 34.82 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.724 0.297 . . . . 0.0 110.425 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.7 t -75.23 115.11 14.52 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.44 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.2 tp -109.17 122.02 41.0 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.027 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.4 Cg_endo -64.37 132.17 32.65 Favored 'Trans proline' 0 CA--C 1.528 0.183 0 C-N-CA 122.734 2.289 . . . . 0.0 112.888 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.4 p -104.96 -17.97 7.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.577 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.59 -132.63 2.71 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.524 -0.762 . . . . 0.0 112.436 -179.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.412 HG13 HG12 ' A' ' 27' ' ' VAL . 18.4 pt -76.63 -34.72 24.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.197 0.523 . . . . 0.0 111.383 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.412 HG12 HG13 ' A' ' 26' ' ' ILE . 11.8 p -148.28 -32.88 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.818 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.82 153.22 38.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.503 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.33 -162.74 15.87 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.14 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.96 156.14 22.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.442 0.639 . . . . 0.0 110.448 179.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 89.3 m -80.15 128.1 33.11 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.994 -179.537 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.446 HG11 HD22 ' A' ' 22' ' ' LEU . 7.4 p . . . . . 0 C--N 1.323 -0.583 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.101 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 19' ' ' CYS . 2.9 p . . . . . 0 N--CA 1.455 -0.204 0 CA-C-O 120.556 0.217 . . . . 0.0 111.011 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.78 136.78 58.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.108 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -19.55 54.14 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.515 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.6 mttt -60.47 157.31 14.31 Favored 'General case' 0 C--O 1.218 -0.596 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 m -86.87 147.31 25.85 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.709 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.49 -175.15 4.05 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.68 150.26 28.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.859 0.361 . . . . 0.0 110.379 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.47 HG22 HG23 ' A' ' 27' ' ' VAL . 10.2 tp -59.58 -17.11 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.014 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.2 mt -57.64 -24.8 58.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.706 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 85.42 -7.86 74.17 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.512 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.0 p -70.04 -33.77 72.38 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.59 0.71 . . . . 0.0 109.961 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.709 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 18.6 m-20 -124.23 67.02 44.33 Favored Pre-proline 0 C--O 1.217 -0.614 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.289 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 72.4 Cg_endo -73.78 -139.4 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.276 1.984 . . . . 0.0 112.058 -179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.417 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 62.3 m -139.04 162.18 35.57 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.762 -0.586 . . . . 0.0 111.993 -178.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.5 m-20 -60.59 150.14 32.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.488 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.67 120.05 4.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.052 0.453 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.08 -39.58 2.42 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 111.307 -0.717 . . . . 0.0 111.307 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.2 m -102.2 146.83 27.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.983 0.42 . . . . 0.0 110.846 179.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -110.21 149.26 30.37 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.324 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 t -84.57 118.14 24.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.342 179.274 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.1 tp -111.97 123.65 34.03 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.729 -0.214 . . . . 0.0 110.576 -179.293 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' A' ' 22' ' ' LEU . 26.7 Cg_endo -62.66 130.75 30.75 Favored 'Trans proline' 0 CA--C 1.529 0.228 0 C-N-CA 122.607 2.204 . . . . 0.0 112.388 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.479 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 4.5 p -102.27 -19.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.08 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.51 -133.63 3.05 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.619 -0.719 . . . . 0.0 112.535 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.511 HG13 HG12 ' A' ' 27' ' ' VAL . 18.6 pt -79.77 -34.03 15.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.162 0.506 . . . . 0.0 111.388 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.511 HG12 HG13 ' A' ' 26' ' ' ILE . 7.6 p -143.07 -35.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.813 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.25 154.94 37.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.835 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -161.82 -163.91 15.68 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 121.263 -0.494 . . . . 0.0 111.948 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.4 m -145.92 152.29 14.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.218 0.532 . . . . 0.0 110.788 179.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 85.4 m -72.91 143.95 47.54 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.035 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.442 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 47.5 t . . . . . 0 C--N 1.316 -0.872 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.222 -179.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.552 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 1.9 p . . . . . 0 N--CA 1.455 -0.197 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.66 141.43 57.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.64 -26.5 22.88 Favored Glycine 0 CA--C 1.52 0.37 0 C-N-CA 120.558 -0.829 . . . . 0.0 113.005 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mptm? -53.22 143.41 18.34 Favored 'General case' 0 C--O 1.217 -0.642 0 C-N-CA 122.87 0.468 . . . . 0.0 112.176 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 m -76.82 143.18 39.95 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.632 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.6 p -158.6 179.13 9.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -178.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.43 147.78 23.83 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.621 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.524 HD11 ' HB3' ' A' ' 23' ' ' PRO . 33.6 mt -57.7 -16.74 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.653 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.8 mt -52.41 -27.36 15.54 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.07 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.89 -17.33 57.0 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.184 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.8 p -69.81 -36.13 75.39 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.199 0.523 . . . . 0.0 110.455 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.632 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 2.6 m-20 -123.67 66.5 37.0 Favored Pre-proline 0 C--O 1.218 -0.575 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.52 -179.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 89.3 Cg_endo -75.8 -130.71 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.166 1.911 . . . . 0.0 111.712 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.2 m -142.02 160.08 40.94 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.552 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.1 m-20 -61.59 147.75 44.63 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.977 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.65 114.92 1.71 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.973 0.416 . . . . 0.0 111.087 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.82 -37.44 2.23 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.436 -179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 37.3 m -107.82 149.75 27.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.057 0.456 . . . . 0.0 111.135 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.486 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.1 p90 -105.8 149.28 26.62 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.353 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.8 t -84.42 114.41 21.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.667 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.2 tp -105.97 122.59 41.91 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-O 120.629 0.252 . . . . 0.0 110.581 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.667 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.3 Cg_endo -66.07 131.54 27.28 Favored 'Trans proline' 0 N--CA 1.464 -0.211 0 C-N-CA 122.68 2.253 . . . . 0.0 112.77 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -101.21 -18.3 6.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.447 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.38 -132.49 2.79 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.372 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.0 pt -76.72 -34.9 24.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.186 0.517 . . . . 0.0 111.421 -179.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.9 -32.83 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.799 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.7 150.71 41.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.393 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.51 -159.56 12.45 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 121.201 -0.523 . . . . 0.0 112.002 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.62 151.44 13.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.297 0.57 . . . . 0.0 110.919 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 75.2 m -69.98 144.86 52.2 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.399 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 45.1 t . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.204 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.51 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 30.3 p . . . . . 0 N--CA 1.451 -0.383 0 CA-C-O 120.667 0.27 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -55.97 132.5 50.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.425 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.58 -17.36 58.7 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.651 -0.785 . . . . 0.0 113.036 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 9.2 mttp -57.35 144.58 35.5 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 120.653 0.264 . . . . 0.0 111.505 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.9 m -77.0 141.83 40.19 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.59 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 16.7 p -161.32 177.38 10.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.128 0.489 . . . . 0.0 111.073 -178.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.41 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.91 146.18 23.86 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.234 179.508 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.411 ' HB ' HG23 ' A' ' 27' ' ' VAL . 39.4 mm -60.0 -13.26 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.52 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.4 mt -53.42 -28.02 27.64 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.757 179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 94.92 -17.85 58.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.116 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -69.53 -37.04 76.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.313 0.577 . . . . 0.0 110.58 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.59 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 13.3 m-20 -126.7 66.14 63.73 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.856 -178.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 83.1 Cg_endo -77.09 -128.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.506 0 C-N-CA 122.187 1.925 . . . . 0.0 111.764 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.441 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 80.0 m -141.41 168.19 20.37 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -59.5 145.89 42.37 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.872 178.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.02 122.71 7.04 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.803 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.19 -37.76 3.65 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.823 -0.626 . . . . 0.0 112.211 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -91.79 154.61 18.81 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.576 0.227 . . . . 0.0 110.518 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 47.2 p90 -112.65 151.2 30.43 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -178.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 34.6 t -90.73 115.01 27.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.078 -0.965 . . . . 0.0 108.951 178.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.1 tp -101.15 122.21 49.31 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.479 -179.167 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 38.7 Cg_endo -67.47 131.5 24.84 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.575 2.183 . . . . 0.0 112.839 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -100.61 -18.07 6.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.413 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.44 -132.2 2.76 Favored Glycine 0 N--CA 1.445 -0.725 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.395 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 pt -76.23 -34.76 26.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.179 0.514 . . . . 0.0 111.401 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.411 HG23 ' HB ' ' A' ' 9' ' ' ILE . 14.0 p -149.14 -32.35 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.828 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.43 149.79 42.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.119 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -167.43 -158.34 11.61 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.015 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 28.4 m -145.7 151.37 14.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.314 0.578 . . . . 0.0 110.928 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.489 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 99.2 m -71.78 148.03 46.69 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.744 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 40.3 t . . . . . 0 C--N 1.318 -0.796 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.997 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.536 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.9 p . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 120.687 0.28 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.3 135.16 55.94 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.21 -15.33 63.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.328 -179.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' HE2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -55.41 145.04 23.49 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 120.87 0.367 . . . . 0.0 111.074 179.954 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.552 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 9.5 m -84.24 147.65 27.14 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.48 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.7 p -167.03 -161.07 0.41 Allowed 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.039 0.447 . . . . 0.0 111.008 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -157.92 158.96 36.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.112 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.484 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.9 mt -53.08 -27.18 13.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.841 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.6 mt -54.07 -24.14 16.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.736 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.98 15.75 81.39 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.0 p -79.05 -19.54 51.13 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.733 0.301 . . . . 0.0 110.721 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.48 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 9.3 t0 -127.94 61.88 54.0 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.242 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.61 -154.83 0.04 OUTLIER 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 121.889 1.726 . . . . 0.0 112.208 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 8.1 m -153.84 157.51 39.43 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.585 0.231 . . . . 0.0 111.065 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -57.05 162.52 2.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.722 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.77 124.6 10.04 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.164 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.2 -40.66 2.38 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -178.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 58.5 m -104.94 137.77 42.19 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.919 0.39 . . . . 0.0 110.136 178.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.436 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 36.4 p90 -128.76 143.75 51.0 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.585 -178.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 13.3 t -77.98 114.3 16.72 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 178.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -111.9 129.29 24.36 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.653 -178.75 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.484 ' HG3' HG12 ' A' ' 9' ' ' ILE . 32.1 Cg_exo -59.45 130.52 36.07 Favored 'Trans proline' 0 CA--C 1.528 0.209 0 C-N-CA 122.833 2.355 . . . . 0.0 112.26 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.477 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.9 p -105.7 -21.57 5.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.188 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.18 -138.26 3.63 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.44 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 27' ' ' VAL . 23.2 pt -77.0 -38.23 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.985 0.421 . . . . 0.0 111.188 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 26' ' ' ILE . 15.5 m -136.61 -32.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.847 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.58 154.22 38.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.216 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.477 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -159.51 -175.79 30.85 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 121.196 -0.526 . . . . 0.0 111.834 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.9 m -147.28 147.52 17.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.171 0.51 . . . . 0.0 110.829 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 35.0 m -70.64 147.23 49.4 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.556 179.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 21.8 t . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.986 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.571 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.8 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.708 0.289 . . . . 0.0 111.101 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.96 134.11 53.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.719 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.29 -17.65 58.89 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.306 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.7 ttpt -55.61 144.29 27.07 Favored 'General case' 0 C--O 1.217 -0.655 0 C-N-CA 122.563 0.345 . . . . 0.0 111.599 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.6 m -81.67 147.66 29.41 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.067 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.4 p -165.15 -160.86 0.5 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.859 0.362 . . . . 0.0 110.738 -179.32 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -161.26 154.28 21.06 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.231 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.476 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.0 mt -52.69 -26.76 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 O-C-N 124.471 1.107 . . . . 0.0 111.752 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt -53.56 -22.47 8.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.801 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.446 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 78.82 12.53 84.08 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.767 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -72.78 -32.2 65.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.859 0.362 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.89 63.04 46.27 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.963 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.7 Cg_endo -73.58 -154.43 0.04 OUTLIER 'Trans proline' 0 CA--C 1.532 0.38 0 C-N-CA 121.813 1.676 . . . . 0.0 111.946 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 11.9 m -152.18 152.97 32.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.652 0.263 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.63 166.56 3.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.645 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.77 123.75 9.66 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.004 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.29 -37.38 3.18 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 57.0 m -115.88 138.13 51.45 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.966 0.412 . . . . 0.0 110.377 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.418 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.8 p90 -126.46 143.32 51.23 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.324 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.6 t -77.67 112.79 14.87 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.8 tp -106.72 127.17 28.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.681 -178.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.476 ' HG3' HG12 ' A' ' 9' ' ' ILE . 25.6 Cg_exo -62.64 133.08 40.59 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.932 2.421 . . . . 0.0 112.4 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.74 -19.95 6.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.259 0.552 . . . . 0.0 110.301 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.75 -135.46 3.13 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.651 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.451 HG13 HG12 ' A' ' 27' ' ' VAL . 20.0 pt -75.82 -34.85 28.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.375 0.607 . . . . 0.0 111.163 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.451 HG12 HG13 ' A' ' 26' ' ' ILE . 7.2 p -145.34 -36.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.108 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.09 149.67 50.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.87 -171.29 27.77 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.7 m -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.049 0.452 . . . . 0.0 111.029 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.418 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 23.7 m -71.2 145.49 49.65 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.128 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 33.3 t . . . . . 0 C--N 1.315 -0.903 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.153 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.0 p . . . . . 0 N--CA 1.455 -0.19 0 CA-C-O 120.624 0.25 . . . . 0.0 111.105 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.69 133.19 53.15 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.627 0.251 . . . . 0.0 110.705 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.41 -16.23 61.13 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.46 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.606 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 1.7 ttpp -55.89 139.53 45.65 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 122.434 0.294 . . . . 0.0 111.676 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.7 m -74.6 147.45 41.64 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.1 p -163.84 -168.1 1.54 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.823 0.344 . . . . 0.0 110.936 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.597 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -162.77 156.63 20.56 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.181 179.861 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.678 HD11 ' HB3' ' A' ' 23' ' ' PRO . 47.1 mm -53.19 -26.32 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.782 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.7 mt -52.97 -25.18 11.18 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.768 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 79.11 12.86 83.6 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.186 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 p -78.0 -26.35 48.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.891 0.377 . . . . 0.0 110.655 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.39 60.15 50.49 Favored Pre-proline 0 C--O 1.223 -0.317 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.76 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -79.5 -153.8 0.05 OUTLIER 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 121.777 1.651 . . . . 0.0 112.374 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 22.3 m -152.43 148.1 27.05 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -68.79 -176.73 0.87 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.679 -178.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.03 125.7 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.926 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.33 -34.0 4.46 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 68.9 m -129.28 139.91 51.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.055 0.455 . . . . 0.0 110.764 179.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.9 p90 -124.98 142.79 51.25 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.184 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.7 t -76.82 114.24 15.37 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.676 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.4 tp -108.22 126.02 30.62 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.503 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.678 ' HB3' HD11 ' A' ' 9' ' ' ILE . 32.9 Cg_endo -64.77 133.36 36.08 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.678 2.252 . . . . 0.0 112.861 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 p -107.04 -18.94 6.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.614 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.16 -135.09 3.12 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.283 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.434 HG13 HG12 ' A' ' 27' ' ' VAL . 20.9 pt -76.77 -36.13 25.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.373 0.606 . . . . 0.0 111.056 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.597 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.1 p -143.07 -36.37 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.165 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.31 148.13 52.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.45 -167.64 26.37 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -147.31 147.84 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.096 0.475 . . . . 0.0 111.018 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 22.3 m -70.75 146.52 49.78 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.213 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 29.1 t . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.211 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 25.9 p . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 120.782 0.325 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.7 129.6 42.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.017 -179.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.23 -25.42 27.81 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.52 -0.848 . . . . 0.0 112.789 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.464 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -56.98 150.86 15.98 Favored 'General case' 0 C--O 1.216 -0.684 0 C-N-CA 122.554 0.341 . . . . 0.0 110.525 179.792 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.8 m -75.2 165.99 24.34 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 178.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 6.1 p -178.1 172.83 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.886 0.374 . . . . 0.0 110.571 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.528 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.92 149.33 23.23 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.522 178.965 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.892 HD11 ' HG3' ' A' ' 23' ' ' PRO . 49.7 mm -53.88 -23.21 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 114.334 -1.303 . . . . 0.0 111.756 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.8 mt -51.57 -24.49 5.41 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.194 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.07 -8.42 76.59 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.842 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.7 t -74.29 -21.09 59.9 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.9 t0 -135.88 63.9 53.81 Favored Pre-proline 0 C--O 1.217 -0.611 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.102 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 74.9 Cg_endo -75.89 -142.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.532 0 C-N-CA 121.327 1.351 . . . . 0.0 111.265 179.393 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 61.6 m -139.34 164.34 30.09 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 121.802 -0.561 . . . . 0.0 111.624 -178.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.42 158.28 9.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.239 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.81 122.17 9.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.906 0.384 . . . . 0.0 110.943 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.97 -34.05 6.09 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.557 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 32.1 m -89.1 151.01 22.47 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.1 p90 -124.89 145.88 49.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 10.5 t -83.22 107.22 15.61 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.044 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 34.9 tp -93.82 123.55 59.3 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.557 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.892 ' HG3' HD11 ' A' ' 9' ' ' ILE . 13.7 Cg_exo -68.19 131.15 22.87 Favored 'Trans proline' 0 N--CA 1.464 -0.222 0 C-N-CA 122.662 2.241 . . . . 0.0 112.561 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -105.45 -18.35 7.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.398 0.618 . . . . 0.0 109.551 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.32 -135.11 2.96 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.275 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.427 HG13 HG12 ' A' ' 27' ' ' VAL . 21.0 pt -77.23 -36.41 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.237 0.542 . . . . 0.0 111.262 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.528 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.2 p -142.4 -35.36 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.312 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.49 148.81 47.85 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.886 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.15 -162.42 16.23 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.2 m -146.69 149.4 15.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.235 0.54 . . . . 0.0 111.082 179.289 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.464 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 39.2 m -69.56 142.8 53.54 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.932 179.142 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.432 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 59.7 t . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.059 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.498 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 5.9 p . . . . . 0 N--CA 1.453 -0.296 0 CA-C-O 120.699 0.285 . . . . 0.0 110.936 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -60.37 132.79 55.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.36 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.68 -21.43 36.63 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.29 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -61.14 144.07 54.3 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 t -88.52 151.23 22.65 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.717 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 28.3 p -167.16 -166.23 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 O-C-N 123.23 0.331 . . . . 0.0 110.233 -179.114 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.31 153.22 31.29 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.405 0.622 . . . . 0.0 111.7 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.592 HG22 HG23 ' A' ' 27' ' ' VAL . 7.8 tp -58.33 -11.73 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.148 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -59.09 -20.77 56.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.495 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.69 -20.01 30.08 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.611 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 m -66.34 -26.88 67.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.942 0.401 . . . . 0.0 110.498 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.717 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 25.2 m-20 -118.46 66.28 6.6 Favored Pre-proline 0 C--O 1.221 -0.44 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.445 -179.278 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 56.6 Cg_endo -70.05 -146.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.254 1.969 . . . . 0.0 111.829 179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 70.3 m -143.31 165.29 27.88 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 121.593 -0.692 . . . . 0.0 111.727 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.9 m-20 -62.81 154.34 30.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.691 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.381 0.426 . . . . 0.0 111.197 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.94 -39.56 2.81 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 64.1 m -105.88 148.74 27.25 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.801 0.334 . . . . 0.0 110.595 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -123.54 147.08 47.6 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.222 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.6 t -73.47 109.37 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.016 -179.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.638 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.8 tp -105.49 124.7 35.5 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.582 -179.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.68 131.29 28.93 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.59 2.193 . . . . 0.0 112.304 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.417 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.0 p -102.89 -20.57 5.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.983 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.66 -134.39 3.24 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.451 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.503 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -77.85 -34.78 20.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.359 0.599 . . . . 0.0 111.021 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.592 HG23 HG22 ' A' ' 9' ' ' ILE . 7.2 p -143.34 -37.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.381 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.73 149.14 50.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.955 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.417 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -158.36 -169.4 21.83 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.079 -0.581 . . . . 0.0 112.057 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.4 m -146.97 151.03 14.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.092 0.472 . . . . 0.0 111.062 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 94.2 m -72.96 124.61 25.79 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.359 179.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--N 1.321 -0.666 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.722 179.209 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.403 0 N-CA-C 111.98 -0.448 . . . . 0.0 111.98 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HA ' ' HD2' ' A' ' 5' ' ' LYS . 29.6 p -80.61 -38.76 28.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.763 0.316 . . . . 0.0 110.757 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -57.0 130.29 45.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.422 -179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.53 -16.55 58.75 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.416 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.1 mttt -63.58 142.68 58.31 Favored 'General case' 0 CA--C 1.512 -0.483 0 CA-C-O 120.965 0.412 . . . . 0.0 111.934 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 p -78.48 139.99 38.64 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.673 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.7 p -156.44 179.21 9.47 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.903 0.382 . . . . 0.0 110.794 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.63 146.76 22.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.301 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 42.8 mm -59.11 -14.41 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 CA-C-N 115.483 -0.781 . . . . 0.0 111.663 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.5 mt -53.3 -28.08 26.35 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.751 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.59 -14.45 65.26 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.196 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.6 p -69.98 -35.54 74.49 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.26 0.553 . . . . 0.0 110.585 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.673 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 15.2 m-20 -125.27 65.93 51.21 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.076 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 95.2 Cg_endo -76.04 -137.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 122.329 2.019 . . . . 0.0 111.932 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 83.5 m -138.83 166.81 23.45 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 121.842 -0.536 . . . . 0.0 112.078 -178.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -60.17 153.92 20.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.743 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.84 125.2 14.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.972 0.415 . . . . 0.0 111.264 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.0 -40.37 2.52 Favored Glycine 0 N--CA 1.449 -0.456 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 29.1 m -90.1 158.58 17.22 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 34.9 p90 -132.51 149.38 52.34 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.452 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.7 t -75.64 113.47 13.11 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.125 -0.943 . . . . 0.0 109.883 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.599 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.7 tp -100.37 122.18 50.82 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.089 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HD2' HD12 ' A' ' 22' ' ' LEU . 31.5 Cg_endo -64.43 131.71 30.9 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.704 2.27 . . . . 0.0 113.106 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -106.18 -17.16 7.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.396 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.83 -133.33 2.7 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.351 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -76.5 -35.25 25.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.269 0.557 . . . . 0.0 111.454 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.41 -32.89 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.74 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.42 152.37 40.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.299 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.16 -160.21 11.7 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.1 -0.572 . . . . 0.0 112.119 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.1 m -144.52 150.46 16.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.228 0.537 . . . . 0.0 110.793 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.595 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 63.5 m -71.8 133.14 45.34 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.966 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--N 1.322 -0.611 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.345 179.132 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 N-CA-C 111.993 -0.443 . . . . 0.0 111.993 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.466 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p -70.65 -37.11 73.7 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.728 0.299 . . . . 0.0 111.078 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.68 128.14 35.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.072 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.15 -20.74 37.29 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.966 -179.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.72 151.25 39.0 Favored 'General case' 0 C--O 1.218 -0.56 0 C-N-CA 122.662 0.385 . . . . 0.0 110.807 -179.973 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.5 m -78.72 168.34 19.88 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.7 p -177.02 174.53 1.69 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.856 0.36 . . . . 0.0 110.547 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.47 143.47 22.11 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.208 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.564 HD11 ' HB3' ' A' ' 23' ' ' PRO . 51.7 mt -54.86 -22.36 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.595 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.0 mt -52.28 -27.67 15.99 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.824 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.486 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.7 -6.78 74.12 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.952 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.0 p -72.37 -25.54 61.55 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.542 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.4 t0 -132.51 66.07 76.03 Favored Pre-proline 0 C--O 1.219 -0.519 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.978 179.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 60.2 Cg_endo -71.98 -145.3 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.64 0 C-N-CA 121.623 1.549 . . . . 0.0 111.645 179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.1 m -141.23 154.97 46.07 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.63 -0.669 . . . . 0.0 112.031 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.46 156.55 22.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.17 120.21 5.21 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.08 0.467 . . . . 0.0 111.041 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.84 -39.99 2.33 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 79.4 m -106.17 151.56 24.59 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.807 0.337 . . . . 0.0 110.279 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -124.89 147.88 48.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.674 0.273 . . . . 0.0 110.36 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.8 t -73.02 109.4 6.53 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.161 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.7 tp -102.61 123.06 43.96 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.389 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.2 Cg_endo -64.22 130.93 28.53 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.654 2.236 . . . . 0.0 112.822 -179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.98 -17.83 7.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.571 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.77 -132.68 2.7 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.406 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 18.7 pt -76.87 -35.0 23.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 121.22 0.534 . . . . 0.0 111.417 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 12.1 p -147.6 -32.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.931 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.4 154.37 37.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.38 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.66 -158.86 10.61 Favored Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 121.371 -0.443 . . . . 0.0 112.022 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.8 m -147.74 152.52 12.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.189 0.518 . . . . 0.0 110.829 179.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.505 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 88.9 m -73.43 125.79 28.7 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.506 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.532 HG11 HD22 ' A' ' 22' ' ' LEU . 7.2 p . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.643 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.38 0 N-CA-C 112.038 -0.425 . . . . 0.0 112.038 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.8 p -70.91 -46.57 62.29 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.043 0.449 . . . . 0.0 110.274 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.23 135.73 56.53 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.738 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.69 -26.16 20.52 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.844 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HD3' ' SG ' ' A' ' 15' ' ' CYS . 1.6 mtpm? -55.43 132.93 49.48 Favored 'General case' 0 CA--C 1.512 -0.5 0 CA-C-O 120.691 0.281 . . . . 0.0 111.547 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.454 ' HA ' HG12 ' A' ' 30' ' ' VAL . 9.7 m -76.13 154.54 35.39 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.671 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.1 p -174.51 -158.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.031 0.444 . . . . 0.0 110.632 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.56 153.51 31.54 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.932 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 12.6 tt -53.07 -20.92 2.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 114.448 -1.251 . . . . 0.0 112.565 -179.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 26.6 mt -60.63 -17.73 48.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.337 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.38 16.08 80.8 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.097 -0.573 . . . . 0.0 111.795 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -74.99 -26.44 59.57 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.825 0.345 . . . . 0.0 110.565 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.671 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 15.5 t0 -126.37 66.06 60.76 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.095 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -71.28 -151.09 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.248 1.965 . . . . 0.0 111.812 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.51 ' SG ' ' HD3' ' A' ' 5' ' ' LYS . 1.5 m -156.08 179.74 8.93 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.011 -0.43 . . . . 0.0 111.984 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -54.46 156.02 3.62 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 124.211 0.944 . . . . 0.0 111.409 -178.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.06 121.37 5.99 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.817 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.51 -40.55 2.51 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -178.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.422 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 12.0 m -91.34 142.11 28.05 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -138.06 154.0 49.29 Favored 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 120.621 -0.432 . . . . 0.0 111.619 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.56 117.4 18.17 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.768 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.635 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.3 tp -108.41 124.4 34.63 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.414 -179.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.635 ' HD2' HD12 ' A' ' 22' ' ' LEU . 29.0 Cg_endo -63.6 130.91 29.58 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 122.626 2.217 . . . . 0.0 112.391 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 p -101.66 -21.97 4.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.107 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.02 -134.44 3.33 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.47 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.493 HG13 HG12 ' A' ' 27' ' ' VAL . 19.7 pt -77.68 -35.23 21.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.311 0.576 . . . . 0.0 110.908 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.493 HG12 HG13 ' A' ' 26' ' ' ILE . 7.7 p -142.76 -37.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.356 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.55 149.91 49.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.069 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.79 -170.99 28.43 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 121.081 -0.581 . . . . 0.0 111.89 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 6' ' ' SER . 13.7 m -148.22 149.9 14.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.933 0.397 . . . . 0.0 110.693 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 22.3 m -67.88 139.41 56.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.593 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 C--N 1.321 -0.648 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.147 178.945 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.461 0 N-CA-C 112.061 -0.415 . . . . 0.0 112.061 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.8 p -75.64 -40.8 55.65 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.536 0.208 . . . . 0.0 111.185 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.44 135.57 56.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.729 0.3 . . . . 0.0 111.511 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.99 -22.48 39.27 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.86 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 33.6 mtpt -57.7 143.08 42.98 Favored 'General case' 0 C--O 1.216 -0.687 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -74.72 143.22 44.24 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.782 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 17.5 p -163.52 -176.4 4.69 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.546 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.1 OUTLIER -156.67 152.17 26.77 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.617 0.722 . . . . 0.0 112.223 178.449 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.2 tt -61.38 -9.95 3.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 113.854 -1.521 . . . . 0.0 112.876 -178.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -60.25 -18.75 50.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.955 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.41 -22.78 22.05 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.633 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.1 p -69.62 -33.22 72.35 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.045 0.45 . . . . 0.0 110.537 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.782 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 1.9 m-20 -121.6 66.29 18.86 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.794 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.6 Cg_endo -76.05 -138.93 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.576 0 C-N-CA 122.225 1.95 . . . . 0.0 111.117 179.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.9 m -140.3 159.65 41.72 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 121.778 -0.576 . . . . 0.0 112.081 -179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -62.86 152.24 36.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.163 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.75 124.83 11.82 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 123.433 0.458 . . . . 0.0 111.28 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.84 2.4 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -178.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 33.2 m -101.47 146.9 27.02 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.034 0.445 . . . . 0.0 110.738 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 36.2 p90 -112.79 146.83 38.13 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.2 t -82.68 109.3 16.74 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 36.9 tp -102.79 122.05 47.22 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.553 -179.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.7 Cg_endo -66.4 129.01 20.41 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.534 2.156 . . . . 0.0 112.543 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.46 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 8.4 p -95.52 -20.95 5.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.549 0.69 . . . . 0.0 109.516 179.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -136.76 -133.93 3.23 Favored Glycine 0 N--CA 1.444 -0.81 0 CA-C-N 115.236 -0.893 . . . . 0.0 111.981 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.498 HG13 HG22 ' A' ' 27' ' ' VAL . 21.8 pt -79.03 -40.4 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.037 0.446 . . . . 0.0 111.087 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.498 HG22 HG13 ' A' ' 26' ' ' ILE . 15.9 m -135.21 -34.67 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.26 149.44 44.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.153 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.46 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -164.19 -163.59 17.51 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 121.102 -0.571 . . . . 0.0 112.078 179.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -149.48 153.14 11.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.033 0.444 . . . . 0.0 110.747 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.429 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 90.4 m -70.13 143.32 52.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.846 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.463 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 53.1 t . . . . . 0 C--N 1.315 -0.894 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.249 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.422 0 N-CA-C 111.941 -0.463 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.5 p -80.26 -44.63 19.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.51 0.195 . . . . 0.0 111.36 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -58.3 131.92 52.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.705 0.288 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 100.17 -19.8 51.44 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.307 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 66.0 mttt -62.2 146.31 51.11 Favored 'General case' 0 C--O 1.219 -0.517 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -82.56 144.74 30.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.685 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 13.9 p -157.34 -179.31 8.06 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.899 0.381 . . . . 0.0 110.853 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 146.0 21.66 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.279 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 41.3 mm -59.25 -13.15 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.621 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -53.96 -27.17 29.66 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.688 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.48 -16.61 60.28 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.28 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.4 p -69.54 -35.59 75.59 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.27 0.557 . . . . 0.0 110.563 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.685 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.8 m-20 -125.08 66.78 52.26 Favored Pre-proline 0 N--CA 1.449 -0.513 0 CA-C-N 115.069 -0.969 . . . . 0.0 111.023 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 88.1 Cg_endo -74.81 -137.17 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.639 0 C-N-CA 122.358 2.039 . . . . 0.0 111.822 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.407 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.9 m -142.0 157.11 45.32 Favored 'General case' 0 C--N 1.327 -0.391 0 O-C-N 121.709 -0.62 . . . . 0.0 112.527 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.774 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 4.7 m-20 -60.67 153.37 24.11 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.6 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.4 127.09 18.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.032 0.444 . . . . 0.0 111.225 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.05 -42.7 1.9 Allowed Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.423 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 65.4 m -98.74 147.58 24.74 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -118.46 147.79 43.24 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.329 179.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 43.2 t -73.89 111.44 9.04 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.004 -179.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.627 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -102.53 122.92 44.58 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.185 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.627 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.0 Cg_endo -66.36 131.32 26.16 Favored 'Trans proline' 0 N--CA 1.465 -0.195 0 C-N-CA 122.59 2.193 . . . . 0.0 113.045 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -103.57 -17.13 7.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.403 179.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 -132.48 2.67 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.281 -0.872 . . . . 0.0 112.443 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.408 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -76.12 -34.85 27.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.294 0.569 . . . . 0.0 111.44 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG12 HG13 ' A' ' 26' ' ' ILE . 12.4 p -149.05 -32.44 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.728 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.32 151.71 41.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.287 179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.04 -159.57 11.49 Favored Glycine 0 N--CA 1.444 -0.768 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.033 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.79 153.04 13.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 121.235 0.541 . . . . 0.0 110.674 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 93.6 m -74.3 128.18 34.87 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.934 -179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.452 HG11 HD22 ' A' ' 22' ' ' LEU . 7.0 p . . . . . 0 C--N 1.322 -0.595 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.678 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.094 -0.402 . . . . 0.0 112.094 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.7 p -68.54 -38.45 80.84 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.831 0.348 . . . . 0.0 110.659 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -58.94 125.93 25.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.942 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 110.4 -24.79 17.05 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.951 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.537 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -61.72 148.49 42.7 Favored 'General case' 0 C--O 1.22 -0.494 0 C-N-CA 122.227 0.211 . . . . 0.0 110.518 179.87 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' A' ' 7' ' ' CYS . 11.9 m -79.73 169.78 17.46 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 4.5 p 179.86 179.13 0.54 Allowed 'General case' 0 N--CA 1.453 -0.303 0 CA-C-O 120.804 0.335 . . . . 0.0 110.72 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.598 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.48 150.83 25.45 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.383 178.677 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.4 mt -54.02 -24.37 10.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.379 -1.282 . . . . 0.0 111.895 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.5 mt -52.15 -25.78 9.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.201 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.461 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.62 -4.26 85.94 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.556 -0.83 . . . . 0.0 111.817 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.0 p -72.72 -26.59 61.64 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.04 0.448 . . . . 0.0 110.486 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.756 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 26.2 t0 -127.58 65.32 66.45 Favored Pre-proline 0 C--O 1.219 -0.51 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.948 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 59.7 Cg_endo -71.3 -145.39 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 121.72 1.614 . . . . 0.0 112.028 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.405 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 67.7 m -140.93 168.83 18.84 Favored 'General case' 0 C--N 1.326 -0.431 0 O-C-N 121.654 -0.654 . . . . 0.0 112.141 -178.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.38 155.63 6.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.98 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -54.27 119.68 5.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.926 0.393 . . . . 0.0 110.641 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.78 -37.89 3.59 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 27.5 m -89.49 157.95 17.89 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 30.8 p90 -136.44 149.02 48.05 Favored 'General case' 0 C--N 1.324 -0.542 0 C-N-CA 120.24 -0.584 . . . . 0.0 111.59 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.9 t -73.67 111.85 9.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.76 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 39.0 tp -100.02 119.79 58.55 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.555 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.02 131.9 30.32 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.856 2.37 . . . . 0.0 112.677 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -107.11 -19.2 6.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.962 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.51 -134.3 3.0 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.693 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 27' ' ' VAL . 19.2 pt -75.82 -34.32 27.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.269 0.556 . . . . 0.0 111.139 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.598 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.8 p -147.1 -35.67 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.316 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.15 150.27 47.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.893 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.23 -163.87 18.19 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.9 m -146.73 152.69 13.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.159 0.504 . . . . 0.0 110.875 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.537 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 40.6 m -71.71 131.97 43.88 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.777 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.321 -0.637 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.191 178.91 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.508 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.474 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 1.9 p -70.02 -36.52 75.14 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.634 0.254 . . . . 0.0 111.307 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.66 128.79 38.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.771 0.319 . . . . 0.0 111.272 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.02 -20.45 40.79 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.052 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.494 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.3 OUTLIER -62.82 150.59 41.21 Favored 'General case' 0 C--O 1.219 -0.549 0 C-N-CA 122.611 0.364 . . . . 0.0 110.925 179.999 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.3 m -78.01 167.76 20.95 Favored 'General case' 0 C--N 1.314 -0.942 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 178.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.723 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 1.8 p -176.83 173.1 1.96 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.024 0.44 . . . . 0.0 110.793 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.34 141.26 20.21 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.925 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.408 ' HB ' HG23 ' A' ' 27' ' ' VAL . 46.7 mm -56.4 -19.32 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.579 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.7 mt -52.82 -28.11 21.21 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.544 179.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 96.93 -9.26 65.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.781 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.8 p -71.94 -26.49 62.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.56 -0.32 . . . . 0.0 110.651 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.723 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 22.8 t0 -134.39 66.36 70.31 Favored Pre-proline 0 C--O 1.219 -0.536 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.131 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 61.6 Cg_endo -72.6 -144.62 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 121.605 1.537 . . . . 0.0 111.53 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.413 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 74.0 m -140.68 155.3 46.53 Favored 'General case' 0 C--N 1.326 -0.428 0 O-C-N 121.485 -0.759 . . . . 0.0 112.297 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -62.84 156.57 23.69 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.285 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.58 123.45 9.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.061 0.458 . . . . 0.0 111.026 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.83 -40.62 2.41 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 73.7 m -103.79 150.57 23.98 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.895 0.379 . . . . 0.0 110.342 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -123.99 148.11 47.24 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.376 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 t -73.58 107.39 5.82 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.096 -179.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.623 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.5 tp -99.42 123.29 48.85 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.257 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.623 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.2 Cg_endo -66.17 130.74 24.89 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.583 2.189 . . . . 0.0 112.893 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 p -102.82 -17.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 115.516 -0.766 . . . . 0.0 109.36 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.53 -132.26 2.67 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.408 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.0 pt -76.34 -34.78 25.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.168 0.508 . . . . 0.0 111.447 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 9' ' ' ILE . 13.6 p -149.23 -31.98 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.865 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.26 152.9 39.61 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.96 -157.35 9.62 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 121.307 -0.473 . . . . 0.0 112.101 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.1 m -147.38 152.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.163 0.506 . . . . 0.0 110.758 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.494 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 91.7 m -73.27 125.58 28.12 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.548 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 22' ' ' LEU . 7.3 p . . . . . 0 C--N 1.321 -0.663 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.63 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 111.954 -0.458 . . . . 0.0 111.954 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 29.6 p -80.35 -43.17 21.61 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.878 0.37 . . . . 0.0 110.673 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.43 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -62.5 134.53 56.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.968 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.88 -19.19 47.73 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.337 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 73.9 mttt -59.79 137.17 58.13 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 121.206 0.526 . . . . 0.0 111.621 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 p -80.13 137.73 36.78 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.719 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 29.1 p -163.26 -160.24 0.59 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.681 0.277 . . . . 0.0 110.698 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.8 156.64 35.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.33 0.586 . . . . 0.0 111.708 179.473 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.438 HG22 HG23 ' A' ' 27' ' ' VAL . 11.7 tt -55.88 -16.48 2.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.298 -178.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.3 mt -56.99 -21.03 27.29 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.76 -6.41 65.96 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.442 179.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.9 p -71.91 -24.07 61.58 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.308 0.575 . . . . 0.0 110.275 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -118.72 63.09 5.6 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.177 -178.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.37 -143.74 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.348 2.032 . . . . 0.0 110.963 178.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -154.86 -171.08 3.71 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.443 -0.786 . . . . 0.0 113.067 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.01 148.37 26.32 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 113.915 -1.493 . . . . 0.0 109.929 -179.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.85 118.18 2.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.07 0.462 . . . . 0.0 111.325 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.65 -35.59 4.44 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.546 -179.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 31.1 m -100.77 147.79 25.65 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -132.67 155.89 47.96 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.976 0.417 . . . . 0.0 111.623 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -76.48 118.85 19.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.893 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.425 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -109.05 124.66 33.48 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.402 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 22' ' ' LEU . 25.4 Cg_exo -62.68 131.89 35.35 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.797 2.331 . . . . 0.0 112.499 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -105.22 -21.57 5.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.375 0.607 . . . . 0.0 110.137 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.51 -135.35 3.35 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.477 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.508 HG13 HG12 ' A' ' 27' ' ' VAL . 20.4 pt -77.35 -35.65 22.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.43 0.633 . . . . 0.0 110.911 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 26' ' ' ILE . 6.8 p -141.84 -38.18 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.133 179.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.03 149.11 50.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -160.62 -176.14 32.4 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.952 -0.642 . . . . 0.0 111.972 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 5' ' ' LYS . 10.5 m -142.68 147.7 20.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.016 0.436 . . . . 0.0 110.501 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.608 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 36.2 m -68.5 138.82 55.51 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.751 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.252 179.242 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.589 0 N-CA-C 112.023 -0.431 . . . . 0.0 112.023 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.45 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.1 p -79.22 -42.91 24.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.505 0.193 . . . . 0.0 111.143 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -59.01 135.83 57.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.687 0.279 . . . . 0.0 111.438 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.92 -21.73 44.49 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.649 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 56.8 mttt -58.02 150.21 21.39 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 m -80.87 144.35 32.05 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.603 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.8 p -160.27 178.5 9.56 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.954 0.407 . . . . 0.0 110.794 -178.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.405 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -154.57 146.5 23.51 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.409 179.527 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HB ' HG23 ' A' ' 27' ' ' VAL . 41.5 mm -59.37 -14.77 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.558 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.0 -28.17 22.76 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.878 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 93.93 -16.45 60.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.085 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.4 p -69.83 -36.5 75.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.247 0.546 . . . . 0.0 110.527 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.603 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.2 m-20 -126.39 65.7 59.74 Favored Pre-proline 0 N--CA 1.448 -0.53 0 CA-C-N 115.122 -0.944 . . . . 0.0 110.89 -178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 86.7 Cg_endo -77.22 -134.84 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.566 0 C-N-CA 122.214 1.943 . . . . 0.0 111.645 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.4 m -139.96 158.78 43.52 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.918 -0.488 . . . . 0.0 112.091 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -61.79 151.05 35.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.48 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.75 120.47 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.039 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.22 -39.93 2.32 Favored Glycine 0 N--CA 1.448 -0.541 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.5 m -101.96 145.42 29.28 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.931 0.396 . . . . 0.0 110.865 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -107.16 148.79 28.41 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.33 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.4 t -84.51 112.54 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.669 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.9 tp -102.75 123.23 43.16 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.424 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.669 ' HD2' HD12 ' A' ' 22' ' ' LEU . 37.8 Cg_endo -67.03 131.14 24.55 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.583 2.189 . . . . 0.0 112.822 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -101.41 -17.97 6.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.482 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.95 -132.5 2.75 Favored Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.311 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.3 pt -76.2 -34.7 26.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.234 0.54 . . . . 0.0 111.383 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 9' ' ' ILE . 12.9 p -148.97 -32.5 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.794 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.17 150.48 42.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.214 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.91 -158.61 11.0 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 121.109 -0.567 . . . . 0.0 112.108 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.6 m -146.18 151.94 14.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.154 0.502 . . . . 0.0 110.893 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 96.1 m -71.91 144.24 49.04 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.169 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 44.9 t . . . . . 0 C--N 1.317 -0.831 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.211 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.448 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.613 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 4.3 p -80.84 -49.22 11.35 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 120.625 0.25 . . . . 0.0 110.989 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.95 141.6 57.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.393 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.37 -18.38 57.58 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.395 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.0 mttp -63.32 166.76 5.95 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.345 0.593 . . . . 0.0 111.988 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.6 m -93.57 145.94 24.16 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 177.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.646 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.66 -177.29 5.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.686 0.279 . . . . 0.0 110.447 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.13 147.82 26.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.273 179.44 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 13.5 tt -61.21 -14.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.354 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.1 mt -57.52 -25.18 59.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.217 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 89.15 -13.09 64.33 Favored Glycine 0 C--N 1.33 0.199 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.905 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -68.88 -35.63 77.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.327 0.584 . . . . 0.0 110.35 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.646 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 17.9 m-20 -124.82 67.28 51.15 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.75 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.0 Cg_endo -73.72 -138.08 0.02 OUTLIER 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 122.344 2.029 . . . . 0.0 112.15 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.415 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 69.2 m -138.18 161.98 35.43 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.724 -0.61 . . . . 0.0 112.126 -178.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.613 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 0.4 OUTLIER -59.38 148.89 30.86 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.333 179.265 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.55 120.7 5.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.183 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.92 -39.54 2.45 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.383 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 31.4 m -101.53 149.19 24.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.831 0.348 . . . . 0.0 110.972 179.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.456 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.6 p90 -109.94 150.8 27.93 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.365 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.6 t -85.84 119.71 26.46 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.405 179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.651 HD12 ' HD2' ' A' ' 23' ' ' PRO . 33.6 tp -111.88 122.54 36.78 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-O 120.551 0.215 . . . . 0.0 110.477 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.651 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.92 130.33 25.67 Favored 'Trans proline' 0 CA--C 1.528 0.214 0 C-N-CA 122.625 2.217 . . . . 0.0 112.655 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.414 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 5.3 p -99.79 -20.74 5.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.537 179.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.71 -133.17 3.1 Favored Glycine 0 N--CA 1.445 -0.737 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.978 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.513 HG13 HG22 ' A' ' 27' ' ' VAL . 21.4 pt -78.9 -40.5 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.015 0.436 . . . . 0.0 111.141 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.513 HG22 HG13 ' A' ' 26' ' ' ILE . 16.0 m -136.18 -33.89 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.011 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.5 153.8 37.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.414 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -165.02 -161.74 14.61 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.3 179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 27.4 m -144.68 153.76 14.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.148 0.499 . . . . 0.0 110.544 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 89.4 m -74.1 144.64 44.86 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.372 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.456 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 46.4 t . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.276 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.443 0 N-CA-C 111.98 -0.448 . . . . 0.0 111.98 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.59 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 2.9 p -77.95 -47.71 17.95 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.538 0.209 . . . . 0.0 110.958 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.67 137.68 58.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.477 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.18 -21.73 44.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.523 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.59 ' HE2' ' HA ' ' A' ' 2' ' ' CYS . 31.0 mtmt -65.14 166.92 8.84 Favored 'General case' 0 C--O 1.216 -0.664 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 m -91.32 151.46 20.86 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.256 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.56 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 15.2 p -163.86 178.71 7.58 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.323 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.87 147.69 24.47 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.931 0.396 . . . . 0.0 110.694 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 38.2 mt -57.51 -19.3 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.445 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.6 mt -51.72 -28.77 16.05 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 112.028 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.85 -13.42 66.86 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.145 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -70.25 -36.1 74.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.293 0.568 . . . . 0.0 110.432 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.56 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.9 m-20 -126.46 64.93 57.84 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.91 -178.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 87.1 Cg_endo -77.76 -139.54 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.557 0 C-N-CA 122.087 1.858 . . . . 0.0 111.626 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 66.6 m -135.97 154.74 51.0 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 121.84 -0.537 . . . . 0.0 111.606 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -62.32 153.43 30.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.06 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.78 123.24 8.62 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 123.405 0.441 . . . . 0.0 111.148 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 116.5 -40.67 2.32 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -178.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.0 m -102.78 147.05 27.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.928 0.394 . . . . 0.0 110.753 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 37.2 p90 -111.95 149.98 31.17 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.27 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.2 t -83.97 114.97 22.08 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.506 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.2 tp -104.86 122.29 43.84 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.451 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.77 131.06 27.96 Favored 'Trans proline' 0 CA--C 1.527 0.165 0 C-N-CA 122.784 2.323 . . . . 0.0 112.555 -179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 p -104.71 -18.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.404 0.621 . . . . 0.0 109.788 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.2 -133.25 2.73 Favored Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.569 -0.741 . . . . 0.0 112.496 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 19.1 pt -76.11 -35.16 28.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.296 0.57 . . . . 0.0 111.411 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.7 p -147.85 -32.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.715 -179.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.87 152.48 40.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -163.8 -160.01 11.32 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.096 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.71 152.56 16.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.005 0.431 . . . . 0.0 110.835 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 86.5 m -74.39 143.3 44.87 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.746 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.443 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 48.9 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.346 -179.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.769 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 6.1 p -79.99 -38.17 32.69 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.736 0.303 . . . . 0.0 111.07 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.47 126.84 28.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.642 0.258 . . . . 0.0 110.791 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.99 -13.32 52.73 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.734 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 20.3 mmtp -64.05 170.15 3.82 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-O 121.525 0.679 . . . . 0.0 111.038 179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -105.62 148.3 27.49 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.219 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 12.9 p -162.79 178.27 8.59 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.069 0.462 . . . . 0.0 110.862 -178.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -154.06 147.53 25.04 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.503 HD11 ' HB3' ' A' ' 23' ' ' PRO . 42.5 mt -56.36 -18.62 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.674 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 77.8 mt -52.7 -27.77 18.97 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.99 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 90.14 -14.88 61.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.233 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.6 p -68.75 -35.9 77.68 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.411 0.624 . . . . 0.0 110.449 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.571 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 14.3 m-20 -124.74 67.97 52.12 Favored Pre-proline 0 N--CA 1.448 -0.56 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.8 -178.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 71.9 Cg_endo -72.87 -133.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 122.423 2.082 . . . . 0.0 111.949 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.432 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 93.0 m -139.09 157.1 46.56 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -178.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.769 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.7 m-20 -62.47 149.75 41.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.797 -1.092 . . . . 0.0 109.209 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.29 119.9 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 O-C-N 123.319 0.387 . . . . 0.0 111.206 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 125.72 -38.45 2.26 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 111.434 -0.667 . . . . 0.0 111.434 -179.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.469 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 88.2 m -112.3 154.41 25.71 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.726 0.298 . . . . 0.0 110.583 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 19.6 p90 -114.69 150.7 34.82 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.724 0.297 . . . . 0.0 110.425 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 41.7 t -75.23 115.11 14.52 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.44 -179.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.2 tp -109.17 122.02 41.0 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.027 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' A' ' 22' ' ' LEU . 30.4 Cg_endo -64.37 132.17 32.65 Favored 'Trans proline' 0 CA--C 1.528 0.183 0 C-N-CA 122.734 2.289 . . . . 0.0 112.888 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.4 p -104.96 -17.97 7.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.577 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.59 -132.63 2.71 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.524 -0.762 . . . . 0.0 112.436 -179.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.412 HG13 HG12 ' A' ' 27' ' ' VAL . 18.4 pt -76.63 -34.72 24.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.197 0.523 . . . . 0.0 111.383 -179.57 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.412 HG12 HG13 ' A' ' 26' ' ' ILE . 11.8 p -148.28 -32.88 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.818 -179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.82 153.22 38.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.503 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.33 -162.74 15.87 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.14 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.96 156.14 22.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.442 0.639 . . . . 0.0 110.448 179.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.589 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 89.3 m -80.15 128.1 33.11 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.994 -179.537 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.446 HG11 HD22 ' A' ' 22' ' ' LEU . 7.4 p . . . . . 0 C--N 1.323 -0.583 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.101 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 19' ' ' CYS . 2.9 p -77.57 -42.69 34.32 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.556 0.217 . . . . 0.0 111.011 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.78 136.78 58.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.108 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -19.55 54.14 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.515 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 31' ' ' CYS . 66.6 mttt -60.47 157.31 14.31 Favored 'General case' 0 C--O 1.218 -0.596 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 m -86.87 147.31 25.85 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 178.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.709 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.3 p -163.49 -175.15 4.05 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -179.099 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -153.68 150.26 28.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.859 0.361 . . . . 0.0 110.379 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.47 HG22 HG23 ' A' ' 27' ' ' VAL . 10.2 tp -59.58 -17.11 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.014 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 61.2 mt -57.64 -24.8 58.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.706 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 85.42 -7.86 74.17 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.512 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 25.0 p -70.04 -33.77 72.38 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.59 0.71 . . . . 0.0 109.961 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.709 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 18.6 m-20 -124.23 67.02 44.33 Favored Pre-proline 0 C--O 1.217 -0.614 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.289 -179.119 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 72.4 Cg_endo -73.78 -139.4 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.276 1.984 . . . . 0.0 112.058 -179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.417 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 62.3 m -139.04 162.18 35.57 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.762 -0.586 . . . . 0.0 111.993 -178.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.414 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 7.5 m-20 -60.59 150.14 32.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.488 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.67 120.05 4.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.052 0.453 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 120.08 -39.58 2.42 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 111.307 -0.717 . . . . 0.0 111.307 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.434 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 29.2 m -102.2 146.83 27.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.983 0.42 . . . . 0.0 110.846 179.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.7 p90 -110.21 149.26 30.37 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.324 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 t -84.57 118.14 24.16 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.342 179.274 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' A' ' 23' ' ' PRO . 32.1 tp -111.97 123.65 34.03 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.729 -0.214 . . . . 0.0 110.576 -179.293 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' A' ' 22' ' ' LEU . 26.7 Cg_endo -62.66 130.75 30.75 Favored 'Trans proline' 0 CA--C 1.529 0.228 0 C-N-CA 122.607 2.204 . . . . 0.0 112.388 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.479 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 4.5 p -102.27 -19.99 5.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.08 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.51 -133.63 3.05 Favored Glycine 0 N--CA 1.444 -0.797 0 CA-C-N 115.619 -0.719 . . . . 0.0 112.535 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.511 HG13 HG12 ' A' ' 27' ' ' VAL . 18.6 pt -79.77 -34.03 15.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 121.162 0.506 . . . . 0.0 111.388 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.511 HG12 HG13 ' A' ' 26' ' ' ILE . 7.6 p -143.07 -35.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.813 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.25 154.94 37.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.835 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -161.82 -163.91 15.68 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 121.263 -0.494 . . . . 0.0 111.948 179.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.4 m -145.92 152.29 14.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.218 0.532 . . . . 0.0 110.788 179.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 85.4 m -72.91 143.95 47.54 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.035 179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.442 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 47.5 t . . . . . 0 C--N 1.316 -0.872 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.222 -179.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.408 0 N-CA-C 112.036 -0.425 . . . . 0.0 112.036 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.552 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 1.9 p -79.63 -37.69 35.52 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -61.66 141.43 57.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.64 -26.5 22.88 Favored Glycine 0 CA--C 1.52 0.37 0 C-N-CA 120.558 -0.829 . . . . 0.0 113.005 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mptm? -53.22 143.41 18.34 Favored 'General case' 0 C--O 1.217 -0.642 0 C-N-CA 122.87 0.468 . . . . 0.0 112.176 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 m -76.82 143.18 39.95 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.632 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 14.6 p -158.6 179.13 9.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.87 0.367 . . . . 0.0 110.886 -178.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -155.43 147.78 23.83 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.621 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.524 HD11 ' HB3' ' A' ' 23' ' ' PRO . 33.6 mt -57.7 -16.74 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.653 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.8 mt -52.41 -27.36 15.54 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.216 -0.447 . . . . 0.0 112.07 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.473 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 91.89 -17.33 57.0 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.184 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.8 p -69.81 -36.13 75.39 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.199 0.523 . . . . 0.0 110.455 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.632 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 2.6 m-20 -123.67 66.5 37.0 Favored Pre-proline 0 C--O 1.218 -0.575 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.52 -179.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 89.3 Cg_endo -75.8 -130.71 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.166 1.911 . . . . 0.0 111.712 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.427 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 71.2 m -142.02 160.08 40.94 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -178.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.552 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.1 m-20 -61.59 147.75 44.63 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.977 178.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.65 114.92 1.71 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.973 0.416 . . . . 0.0 111.087 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.82 -37.44 2.23 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.436 -179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 37.3 m -107.82 149.75 27.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.057 0.456 . . . . 0.0 111.135 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.486 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 38.1 p90 -105.8 149.28 26.62 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.353 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.8 t -84.42 114.41 21.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.667 HD12 ' HD2' ' A' ' 23' ' ' PRO . 34.2 tp -105.97 122.59 41.91 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-O 120.629 0.252 . . . . 0.0 110.581 -179.286 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.667 ' HD2' HD12 ' A' ' 22' ' ' LEU . 36.3 Cg_endo -66.07 131.54 27.28 Favored 'Trans proline' 0 N--CA 1.464 -0.211 0 C-N-CA 122.68 2.253 . . . . 0.0 112.77 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.2 p -101.21 -18.3 6.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.447 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.38 -132.49 2.79 Favored Glycine 0 N--CA 1.446 -0.672 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.372 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG13 HG12 ' A' ' 27' ' ' VAL . 19.0 pt -76.72 -34.9 24.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.186 0.517 . . . . 0.0 111.421 -179.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.404 HG12 HG13 ' A' ' 26' ' ' ILE . 11.9 p -147.9 -32.83 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.799 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.7 150.71 41.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.393 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.51 -159.56 12.45 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 121.201 -0.523 . . . . 0.0 112.002 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.62 151.44 13.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 121.297 0.57 . . . . 0.0 110.919 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 75.2 m -69.98 144.86 52.2 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 115.34 -0.845 . . . . 0.0 111.399 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 45.1 t . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.204 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.402 0 N-CA-C 112.005 -0.438 . . . . 0.0 112.005 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.51 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 30.3 p -81.69 -44.68 16.79 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.667 0.27 . . . . 0.0 110.946 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -55.97 132.5 50.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.425 -179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.58 -17.36 58.7 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.651 -0.785 . . . . 0.0 113.036 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 9.2 mttp -57.35 144.58 35.5 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 120.653 0.264 . . . . 0.0 111.505 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.9 m -77.0 141.83 40.19 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.59 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 16.7 p -161.32 177.38 10.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.128 0.489 . . . . 0.0 111.073 -178.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.41 ' ND2' ' HB2' ' A' ' 13' ' ' ASP . 0.0 OUTLIER -153.91 146.18 23.86 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.234 179.508 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.411 ' HB ' HG23 ' A' ' 27' ' ' VAL . 39.4 mm -60.0 -13.26 5.18 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.52 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.4 mt -53.42 -28.02 27.64 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.757 179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.437 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 94.92 -17.85 58.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.116 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 28.6 p -69.53 -37.04 76.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.313 0.577 . . . . 0.0 110.58 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.59 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 13.3 m-20 -126.7 66.14 63.73 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.856 -178.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' HB2' ' H ' ' A' ' 15' ' ' CYS . 83.1 Cg_endo -77.09 -128.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.506 0 C-N-CA 122.187 1.925 . . . . 0.0 111.764 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.441 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 80.0 m -141.41 168.19 20.37 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -59.5 145.89 42.37 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.872 178.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.02 122.71 7.04 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.803 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.19 -37.76 3.65 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.823 -0.626 . . . . 0.0 112.211 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -91.79 154.61 18.81 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.576 0.227 . . . . 0.0 110.518 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.454 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 47.2 p90 -112.65 151.2 30.43 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -178.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 34.6 t -90.73 115.01 27.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.078 -0.965 . . . . 0.0 108.951 178.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.648 HD12 ' HD2' ' A' ' 23' ' ' PRO . 35.1 tp -101.15 122.21 49.31 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.479 -179.167 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.648 ' HD2' HD12 ' A' ' 22' ' ' LEU . 38.7 Cg_endo -67.47 131.5 24.84 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.575 2.183 . . . . 0.0 112.839 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -100.61 -18.07 6.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.413 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.44 -132.2 2.76 Favored Glycine 0 N--CA 1.445 -0.725 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.395 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 pt -76.23 -34.76 26.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.179 0.514 . . . . 0.0 111.401 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.411 HG23 ' HB ' ' A' ' 9' ' ' ILE . 14.0 p -149.14 -32.35 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.828 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.43 149.79 42.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.119 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -167.43 -158.34 11.61 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.015 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 28.4 m -145.7 151.37 14.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.314 0.578 . . . . 0.0 110.928 179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.489 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 99.2 m -71.78 148.03 46.69 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.744 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 40.3 t . . . . . 0 C--N 1.318 -0.796 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.997 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.053 -0.419 . . . . 0.0 112.053 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.536 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.9 p -76.6 -41.43 46.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.687 0.28 . . . . 0.0 110.905 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.3 135.16 55.94 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.21 -15.33 63.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.328 -179.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' HE2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER -55.41 145.04 23.49 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 120.87 0.367 . . . . 0.0 111.074 179.954 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.552 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 9.5 m -84.24 147.65 27.14 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.48 ' CB ' ' HB3' ' A' ' 13' ' ' ASP . 29.7 p -167.03 -161.07 0.41 Allowed 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.039 0.447 . . . . 0.0 111.008 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -157.92 158.96 36.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.112 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.484 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.9 mt -53.08 -27.18 13.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.841 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.6 mt -54.07 -24.14 16.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.736 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.98 15.75 81.39 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.0 p -79.05 -19.54 51.13 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.733 0.301 . . . . 0.0 110.721 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.48 ' HB3' ' CB ' ' A' ' 7' ' ' CYS . 9.3 t0 -127.94 61.88 54.0 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.242 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -73.61 -154.83 0.04 OUTLIER 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 121.889 1.726 . . . . 0.0 112.208 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 8.1 m -153.84 157.51 39.43 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.585 0.231 . . . . 0.0 111.065 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -57.05 162.52 2.48 Favored 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.722 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.77 124.6 10.04 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.164 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.2 -40.66 2.38 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -178.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 58.5 m -104.94 137.77 42.19 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.919 0.39 . . . . 0.0 110.136 178.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.436 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 36.4 p90 -128.76 143.75 51.0 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.585 -178.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 13.3 t -77.98 114.3 16.72 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 178.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 28.0 tp -111.9 129.29 24.36 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.653 -178.75 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.484 ' HG3' HG12 ' A' ' 9' ' ' ILE . 32.1 Cg_exo -59.45 130.52 36.07 Favored 'Trans proline' 0 CA--C 1.528 0.209 0 C-N-CA 122.833 2.355 . . . . 0.0 112.26 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.477 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.9 p -105.7 -21.57 5.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.188 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.18 -138.26 3.63 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.44 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 27' ' ' VAL . 23.2 pt -77.0 -38.23 27.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.985 0.421 . . . . 0.0 111.188 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 26' ' ' ILE . 15.5 m -136.61 -32.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.847 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.58 154.22 38.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.216 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.477 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -159.51 -175.79 30.85 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 121.196 -0.526 . . . . 0.0 111.834 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.9 m -147.28 147.52 17.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.171 0.51 . . . . 0.0 110.829 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 35.0 m -70.64 147.23 49.4 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.556 179.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 21.8 t . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.986 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.571 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 2.8 p -76.78 -37.15 56.35 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 120.708 0.289 . . . . 0.0 111.101 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -64.96 134.11 53.2 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.719 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 95.29 -17.65 58.89 Favored Glycine 0 N--CA 1.453 -0.167 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.306 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 4.7 ttpt -55.61 144.29 27.07 Favored 'General case' 0 C--O 1.217 -0.655 0 C-N-CA 122.563 0.345 . . . . 0.0 111.599 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.6 m -81.67 147.66 29.41 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.067 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.4 p -165.15 -160.86 0.5 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.859 0.362 . . . . 0.0 110.738 -179.32 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -161.26 154.28 21.06 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.231 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.476 HG12 ' HG3' ' A' ' 23' ' ' PRO . 60.0 mt -52.69 -26.76 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 O-C-N 124.471 1.107 . . . . 0.0 111.752 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt -53.56 -22.47 8.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.801 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.446 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 78.82 12.53 84.08 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.767 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.2 m -72.78 -32.2 65.43 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.859 0.362 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.89 63.04 46.27 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.963 -179.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 73.7 Cg_endo -73.58 -154.43 0.04 OUTLIER 'Trans proline' 0 CA--C 1.532 0.38 0 C-N-CA 121.813 1.676 . . . . 0.0 111.946 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 11.9 m -152.18 152.97 32.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.652 0.263 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.63 166.56 3.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.645 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.77 123.75 9.66 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.004 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.29 -37.38 3.18 Favored Glycine 0 N--CA 1.445 -0.704 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 57.0 m -115.88 138.13 51.45 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.966 0.412 . . . . 0.0 110.377 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.418 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.8 p90 -126.46 143.32 51.23 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.324 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.6 t -77.67 112.79 14.87 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.8 tp -106.72 127.17 28.62 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.681 -178.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.476 ' HG3' HG12 ' A' ' 9' ' ' ILE . 25.6 Cg_exo -62.64 133.08 40.59 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.932 2.421 . . . . 0.0 112.4 179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.74 -19.95 6.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.259 0.552 . . . . 0.0 110.301 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.75 -135.46 3.13 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.651 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.451 HG13 HG12 ' A' ' 27' ' ' VAL . 20.0 pt -75.82 -34.85 28.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.375 0.607 . . . . 0.0 111.163 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.451 HG12 HG13 ' A' ' 26' ' ' ILE . 7.2 p -145.34 -36.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.108 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.09 149.67 50.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.87 -171.29 27.77 Favored Glycine 0 N--CA 1.443 -0.843 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 15.7 m -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.049 0.452 . . . . 0.0 111.029 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.418 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 23.7 m -71.2 145.49 49.65 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.128 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 33.3 t . . . . . 0 C--N 1.315 -0.903 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.153 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.606 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 3.0 p -77.27 -36.59 54.23 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.624 0.25 . . . . 0.0 111.105 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -63.69 133.19 53.15 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.627 0.251 . . . . 0.0 110.705 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.41 -16.23 61.13 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.46 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.606 ' HB2' ' O ' ' A' ' 2' ' ' CYS . 1.7 ttpp -55.89 139.53 45.65 Favored 'General case' 0 C--O 1.217 -0.646 0 C-N-CA 122.434 0.294 . . . . 0.0 111.676 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.7 m -74.6 147.45 41.64 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 24.1 p -163.84 -168.1 1.54 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.823 0.344 . . . . 0.0 110.936 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.597 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -162.77 156.63 20.56 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.181 179.861 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.678 HD11 ' HB3' ' A' ' 23' ' ' PRO . 47.1 mm -53.19 -26.32 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.782 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.7 mt -52.97 -25.18 11.18 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.768 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 79.11 12.86 83.6 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.186 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 p -78.0 -26.35 48.52 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.891 0.377 . . . . 0.0 110.655 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.39 60.15 50.49 Favored Pre-proline 0 C--O 1.223 -0.317 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.76 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -79.5 -153.8 0.05 OUTLIER 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 121.777 1.651 . . . . 0.0 112.374 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 22.3 m -152.43 148.1 27.05 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -68.79 -176.73 0.87 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.679 -178.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.03 125.7 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.926 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.33 -34.0 4.46 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 68.9 m -129.28 139.91 51.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.055 0.455 . . . . 0.0 110.764 179.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 31' ' ' CYS . 35.9 p90 -124.98 142.79 51.25 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.184 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.7 t -76.82 114.24 15.37 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.676 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.4 tp -108.22 126.02 30.62 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.572 -0.286 . . . . 0.0 110.503 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.678 ' HB3' HD11 ' A' ' 9' ' ' ILE . 32.9 Cg_endo -64.77 133.36 36.08 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.678 2.252 . . . . 0.0 112.861 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 p -107.04 -18.94 6.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.614 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -141.16 -135.09 3.12 Favored Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.283 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.434 HG13 HG12 ' A' ' 27' ' ' VAL . 20.9 pt -76.77 -36.13 25.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.373 0.606 . . . . 0.0 111.056 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.597 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.1 p -143.07 -36.37 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.165 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.31 148.13 52.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.45 -167.64 26.37 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 111.63 -0.588 . . . . 0.0 111.63 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 m -147.31 147.84 17.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.096 0.475 . . . . 0.0 111.018 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 22.3 m -70.75 146.52 49.78 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.213 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 19' ' ' CYS . 29.1 t . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.211 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.506 0 N-CA-C 111.995 -0.442 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 25.9 p -69.81 -38.16 76.5 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.782 0.325 . . . . 0.0 110.895 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.7 129.6 42.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.017 -179.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.23 -25.42 27.81 Favored Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.52 -0.848 . . . . 0.0 112.789 -179.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.464 ' HE3' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -56.98 150.86 15.98 Favored 'General case' 0 C--O 1.216 -0.684 0 C-N-CA 122.554 0.341 . . . . 0.0 110.525 179.792 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.8 m -75.2 165.99 24.34 Favored 'General case' 0 C--N 1.312 -1.026 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 178.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.735 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 6.1 p -178.1 172.83 1.55 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.886 0.374 . . . . 0.0 110.571 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.528 ' HB2' HG22 ' A' ' 27' ' ' VAL . 0.1 OUTLIER -156.92 149.33 23.23 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.522 178.965 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.892 HD11 ' HG3' ' A' ' 23' ' ' PRO . 49.7 mm -53.88 -23.21 8.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 114.334 -1.303 . . . . 0.0 111.756 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.8 mt -51.57 -24.49 5.41 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.194 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.487 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.07 -8.42 76.59 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.842 -179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.7 t -74.29 -21.09 59.9 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.735 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 24.9 t0 -135.88 63.9 53.81 Favored Pre-proline 0 C--O 1.217 -0.611 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.102 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 74.9 Cg_endo -75.89 -142.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.532 0 C-N-CA 121.327 1.351 . . . . 0.0 111.265 179.393 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 61.6 m -139.34 164.34 30.09 Favored 'General case' 0 C--N 1.324 -0.537 0 O-C-N 121.802 -0.561 . . . . 0.0 111.624 -178.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.42 158.28 9.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.239 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -53.81 122.17 9.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.906 0.384 . . . . 0.0 110.943 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.97 -34.05 6.09 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.557 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 32.1 m -89.1 151.01 22.47 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.432 ' CE1' ' HB ' ' A' ' 32' ' ' VAL . 40.1 p90 -124.89 145.88 49.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 10.5 t -83.22 107.22 15.61 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.044 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.439 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 34.9 tp -93.82 123.55 59.3 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.557 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.892 ' HG3' HD11 ' A' ' 9' ' ' ILE . 13.7 Cg_exo -68.19 131.15 22.87 Favored 'Trans proline' 0 N--CA 1.464 -0.222 0 C-N-CA 122.662 2.241 . . . . 0.0 112.561 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -105.45 -18.35 7.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.398 0.618 . . . . 0.0 109.551 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.32 -135.11 2.96 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.275 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.427 HG13 HG12 ' A' ' 27' ' ' VAL . 21.0 pt -77.23 -36.41 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.237 0.542 . . . . 0.0 111.262 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.528 HG22 ' HB2' ' A' ' 8' ' ' ASN . 7.2 p -142.4 -35.36 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.312 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.49 148.81 47.85 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.886 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -165.15 -162.42 16.23 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.2 m -146.69 149.4 15.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.235 0.54 . . . . 0.0 111.082 179.289 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.464 ' SG ' ' HE3' ' A' ' 5' ' ' LYS . 39.2 m -69.56 142.8 53.54 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.932 179.142 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.432 ' HB ' ' CE1' ' A' ' 20' ' ' PHE . 59.7 t . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.059 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.374 0 N-CA-C 111.939 -0.464 . . . . 0.0 111.939 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.498 ' HB3' ' HB2' ' A' ' 16' ' ' ASP . 5.9 p -80.13 -43.77 21.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.699 0.285 . . . . 0.0 110.936 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 31' ' ' CYS . . . -60.37 132.79 55.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.36 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 104.68 -21.43 36.63 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.29 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -61.14 144.07 54.3 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.4 t -88.52 151.23 22.65 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.717 ' HB2' ' O ' ' A' ' 13' ' ' ASP . 28.3 p -167.16 -166.23 0.78 Allowed 'General case' 0 C--N 1.321 -0.633 0 O-C-N 123.23 0.331 . . . . 0.0 110.233 -179.114 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -154.31 153.22 31.29 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.405 0.622 . . . . 0.0 111.7 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.592 HG22 HG23 ' A' ' 27' ' ' VAL . 7.8 tp -58.33 -11.73 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.23 -1.35 . . . . 0.0 113.148 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 66.0 mt -59.09 -20.77 56.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.495 ' O ' ' HD3' ' A' ' 14' ' ' PRO . . . 87.69 -20.01 30.08 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.611 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 m -66.34 -26.88 67.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.942 0.401 . . . . 0.0 110.498 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.717 ' O ' ' HB2' ' A' ' 7' ' ' CYS . 25.2 m-20 -118.46 66.28 6.6 Favored Pre-proline 0 C--O 1.221 -0.44 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.445 -179.278 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 11' ' ' GLY . 56.6 Cg_endo -70.05 -146.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.254 1.969 . . . . 0.0 111.829 179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.437 ' H ' ' HB2' ' A' ' 14' ' ' PRO . 70.3 m -143.31 165.29 27.88 Favored 'General case' 0 C--N 1.328 -0.355 0 O-C-N 121.593 -0.692 . . . . 0.0 111.727 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 5.9 m-20 -62.81 154.34 30.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.691 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.381 0.426 . . . . 0.0 111.197 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 112.94 -39.56 2.81 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.42 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 64.1 m -105.88 148.74 27.25 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.801 0.334 . . . . 0.0 110.595 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -123.54 147.08 47.6 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.222 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 42.6 t -73.47 109.37 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.016 -179.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.638 HD12 ' HD2' ' A' ' 23' ' ' PRO . 31.8 tp -105.49 124.7 35.5 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.582 -179.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 22' ' ' LEU . 33.1 Cg_endo -64.68 131.29 28.93 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.59 2.193 . . . . 0.0 112.304 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.417 ' H ' ' HA2' ' A' ' 29' ' ' GLY . 6.0 p -102.89 -20.57 5.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.983 179.724 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.66 -134.39 3.24 Favored Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.451 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.503 HG13 HG12 ' A' ' 27' ' ' VAL . 19.1 pt -77.85 -34.78 20.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.359 0.599 . . . . 0.0 111.021 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.592 HG23 HG22 ' A' ' 9' ' ' ILE . 7.2 p -143.34 -37.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.381 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.73 149.14 50.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.955 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.417 ' HA2' ' H ' ' A' ' 24' ' ' VAL . . . -158.36 -169.4 21.83 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 121.079 -0.581 . . . . 0.0 112.057 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.4 m -146.97 151.03 14.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.092 0.472 . . . . 0.0 111.062 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 3' ' ' ALA . 94.2 m -72.96 124.61 25.79 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.359 179.442 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--N 1.321 -0.666 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.722 179.209 . . . . . . . . 0 0 . 1 stop_ save_